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Abstract
The ideal outcome for medical research is the ability to provide personalised treatment
for the population. Genetics studies are necessary to achieve this, since a person’s genetic
code does not change over time. Alzheimer’s disease (AD) is a neurodegenerative disorder
with a significant genetic component. Clinical trials in AD are difficult to design due
to advanced neuropathological changes before development of symptoms, consequently, it
would be beneficial to determine an individual’s risk of AD.
Genome-wide association studies (GWAS) have unearthed over 20 variants associated with
AD. It is expected there are more variants associated with disease which may explain dis-
ease aetiology, however, GWAS is not able to detect additional variants without increasing
sample size. Set-based analysis is an attractive alternative to determining the association
of one single nucleotide polymorphism (SNP), since the combined effect of all SNPs in the
set may be captured. A gene-based analysis using the MAGMA approach in the AD data
shows this by finding additional independent gene associations using identical data.
Polygenic Risk Scores (PRSs) are used for a variety of purposes in assessing the genetic
liability to disorders. To further improve the power of set-based analyses, PRS as a set-
based analysis is considered; this approach incorporates external data to improve power.
This power increase is shown compared with other set-based methods using simulation
studies and identifies two novel genes in imputed AD data; CSMD1 and MACROD2.
The downside to the PRS approach is that it assumes independence between SNPs and
thus data must be pruned for Linkage Disequilibrium (LD). Therefore, a novel approach
which extends PRS and adjusts for LD is presented. This method is termed POLARIS
and is shown to have better power compared to MAGMA in simulation studies and has
determined three novel genes; PPARGC1A, RORA and ZNF423, in imputed AD data.
v
Nomenclature
p P-value
Nsnps Number of SNPs
pFisher Fisher’s set-based p-value
P Probability
M Number of SNPs∑M
i=1 Sum of all values between 1 and M
ln() Natural logarithm loge()
χ22N Chi-squared distribution with 2N degrees of freedom
Unif(0, 1) Uniform distribution with mean 0 and variance 1
pone−sided One sided p-value
ptwo−sided Two sided p-value
pSimes Simes set-based p-value
minj=1,...,M Minimum of all values between 1 and M
p MAGMA MAGMA’s set-based p-value
β, BETA Natural log of the SNP effect size (loge(OR))
g SNP genotypes
pi Risk of disease
p PRS PRS set-based p-value
λ Genomic control parameter
Ngenes Number of genes
N Number of individuals
Psc Self-contained p-value
Pc Competitive p-value
SE Standard error
r2 Measure of LD/correlation between 0 and 1
N(a, b) Normal distribution with mean a and variance b
SD Standard deviation
r Correlation coefficient
g˜ SNP LD-adjusted dosages
C Correlation matrix between SNPs
λk Eigenvalues from spectral decomposition of the correlation matrix C
xk Orthonormal eigenvectors from spectral decomposition of the correlation matrix C
S Covariance matrix between SNPs
x Mean zero data
λ0 Ridge parameter for POLARIS
(√
1
N
)
I Identity matrix
D Correlation matrix between SNPs estimated from the test set
β˜ LD-adjusted βs
E[ ] Expectation
vi
Contents
Contents vii
List of Figures xiii
List of Tables xviii
1 Introduction 2
1.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Alzheimer’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2.1 What is Alzheimer’s Disease (AD)? . . . . . . . . . . . . . . . . . . . 2
1.2.2 Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.3 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.4 Neuropathology of Alzheimer’s Disease . . . . . . . . . . . . . . . . . 4
1.2.5 Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.6 Genetic Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.7 Environmental Risk Factors . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Methodological Approaches to Genetic Data . . . . . . . . . . . . . . . . . . 7
1.3.1 Genome-Wide Association Study (GWAS) . . . . . . . . . . . . . . . 7
1.3.2 Polygenic Risk Score (PRS) . . . . . . . . . . . . . . . . . . . . . . . 10
1.3.3 Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.3.4 Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.5 Rare Variant Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.4 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.5 Thesis Outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2 Methods 19
2.1 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.1.1 Genetic and Environmental Risk for Alzheimers Disease (GERAD)
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.1.2 International Genomics of Alzheimer’s Project (IGAP) Data . . . . 20
vii
2.2 Methodological Approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2.1 Fisher’s method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2.2 Simes method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.2.3 MAGMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.2.4 Polygenic Risk Score (PRS) . . . . . . . . . . . . . . . . . . . . . . . 23
2.3 Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3.1 R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3.2 PLINK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3.3 Python . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3.4 MAGMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3 MAGMA Gene-Based Analysis in AD Data 25
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.1 Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.2 Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.3.1 Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.3.1.1 GERAD Results . . . . . . . . . . . . . . . . . . . . . . . . 29
3.3.1.2 IGAP (GERAD SNPs only) Results . . . . . . . . . . . . . 31
3.3.1.3 IGAP Stage 1 (All SNPs) Results . . . . . . . . . . . . . . 32
3.3.1.4 Conserved Regions . . . . . . . . . . . . . . . . . . . . . . . 35
3.3.2 Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.3.3 Comparison of MAGMA Settings . . . . . . . . . . . . . . . . . . . . 39
3.3.3.1 Type I error . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.3.3.2 Power . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
4 Polygenic Risk Score Set-Based Approach 51
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2.1 Polygenic Risk Scores . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2.2 MAGMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.2.3 Fisher’s Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.2.4 Simes’ Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
viii
4.2.5 Power Comparison Between Methods . . . . . . . . . . . . . . . . . . 55
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.3.1 Type I error . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.3.1.1 100 SNP Simulation . . . . . . . . . . . . . . . . . . . . . . 60
4.3.1.2 Simple LD Block . . . . . . . . . . . . . . . . . . . . . . . . 61
4.3.1.3 Complex LD Structure . . . . . . . . . . . . . . . . . . . . 64
4.3.1.4 Different LD structure of Discovery and Test Datasets . . . 64
4.3.1.5 Effect Sizes with Varying Direction . . . . . . . . . . . . . 65
4.3.1.6 Real Data Simulation . . . . . . . . . . . . . . . . . . . . . 66
4.3.2 Power Comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.3.2.1 100 SNP Simulation . . . . . . . . . . . . . . . . . . . . . . 67
4.3.2.2 Simple LD Block . . . . . . . . . . . . . . . . . . . . . . . . 70
4.3.2.3 Complex LD Structure . . . . . . . . . . . . . . . . . . . . 73
4.3.2.4 Different LD Structure of Discovery and Test Datasets . . 74
4.3.2.5 Effect Sizes with Varying Direction . . . . . . . . . . . . . 75
4.3.2.6 Real Data Simulation . . . . . . . . . . . . . . . . . . . . . 76
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5 PRS Approach: Gene-Based and Pathway Analyses in AD Data 80
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
5.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
5.2.1 Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.2.2 Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.3.1 Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.3.1.1 Correlation Between P-values and the Number of SNPs in
a Gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.3.1.2 Conserved Regions . . . . . . . . . . . . . . . . . . . . . . . 92
5.3.2 Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
6 POLARIS: Polygenic LD-Adjusted Risk Score Set-Based Approach 101
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
6.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
6.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
6.2.1 POLARIS Rationale and Derivation . . . . . . . . . . . . . . . . . . 103
ix
6.2.2 POLARIS Set-Based Analysis Comparison Applied to Simulated Data106
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6.3.1 Type I error . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6.3.1.1 Simple LD Block . . . . . . . . . . . . . . . . . . . . . . . . 112
6.3.1.2 Complex LD Structure . . . . . . . . . . . . . . . . . . . . 114
6.3.1.3 Different LD Structure of Discovery and Test Datasets . . 116
6.3.1.4 Effect Sizes with Varying Direction . . . . . . . . . . . . . 118
6.3.1.5 Real Data Simulation . . . . . . . . . . . . . . . . . . . . . 119
6.3.1.6 Power . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
6.3.1.7 Simple LD Structure . . . . . . . . . . . . . . . . . . . . . . 121
6.3.1.8 Complex LD Structure . . . . . . . . . . . . . . . . . . . . 124
6.3.1.9 Different LD Structure of Discovery and Test Datasets . . 126
6.3.1.10 Effect Sizes with Varying Direction . . . . . . . . . . . . . 128
6.3.1.11 Real Data Simulation . . . . . . . . . . . . . . . . . . . . . 129
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
7 POLARIS: Gene-Based and Pathway Analyses in AD Data 135
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
7.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
7.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
7.2.1 POLARIS Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . 139
7.2.2 POLARIS Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . 140
7.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
7.3.1 POLARIS Gene-Based Analysis . . . . . . . . . . . . . . . . . . . . . 141
7.3.1.1 Correlation Between P-values and the Number of SNPs in
a Gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
7.3.1.2 Conserved Regions . . . . . . . . . . . . . . . . . . . . . . . 150
7.3.2 POLARIS Pathway Analysis . . . . . . . . . . . . . . . . . . . . . . 153
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
8 POLARIS: Polygenic LD-Adjusted Risk Score Whole Genome Based Approach159
8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
8.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
8.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
8.2.1 POLARIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
8.2.2 LDpred . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
8.2.3 Comparison between POLARIS, PRS and LDpred . . . . . . . . . . 163
x
8.2.4 Prediction Modelling Using POLARIS . . . . . . . . . . . . . . . . . 166
8.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
8.3.1 Comparison Between POLARIS, PRS and LDpred . . . . . . . . . . 167
8.3.1.1 Simulation Results . . . . . . . . . . . . . . . . . . . . . . . 167
8.3.1.2 Real AD Data Results . . . . . . . . . . . . . . . . . . . . . 172
8.3.2 Extensions to POLARIS . . . . . . . . . . . . . . . . . . . . . . . . . 174
8.3.2.1 POLARIS software . . . . . . . . . . . . . . . . . . . . . . 174
8.3.3 Prediction Modelling Using POLARIS . . . . . . . . . . . . . . . . . 175
8.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
9 Application of POLARIS as Cross Disorder Analysis 183
9.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
9.1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
9.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
9.2.1 Genetic Correlation . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
9.2.2 Cross Disorder POLARIS . . . . . . . . . . . . . . . . . . . . . . . . 186
9.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
9.3.1 Genetic Correlation . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
9.3.2 Cross Disorder POLARIS . . . . . . . . . . . . . . . . . . . . . . . . 189
9.3.2.1 Attention Deficit Hyperactivity Disorder (ADHD) . . . . . 189
9.3.2.2 Anxiety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
9.3.2.3 Autism Spectrum Disorder (ASD) . . . . . . . . . . . . . . 190
9.3.2.4 Bipolar Disorder (BIP) . . . . . . . . . . . . . . . . . . . . 191
9.3.2.5 Coronary Artery Disease (CAD) . . . . . . . . . . . . . . . 191
9.3.2.6 Major Depressive Disorder (MDD) . . . . . . . . . . . . . . 191
9.3.2.7 Neuroticism . . . . . . . . . . . . . . . . . . . . . . . . . . 191
9.3.2.8 Parkinson’s Disease (PD) . . . . . . . . . . . . . . . . . . . 192
9.3.2.9 Schizophrenia (SZ) . . . . . . . . . . . . . . . . . . . . . . . 192
9.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
10 Discussion and Implications 196
10.1 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
10.2 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
10.3 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
10.4 Further Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
10.5 Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
xi
11 Supplementary Material 204
11.1 129 SNPs in Real Data Simulations . . . . . . . . . . . . . . . . . . . . . . . 204
11.2 21 GWAS Index SNPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
11.3 POLARIS Python Script . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
11.3.1 POLARIS master.py . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
11.3.2 POLARIS function.py . . . . . . . . . . . . . . . . . . . . . . . . . . 217
References 231
xii
List of Figures
1.1 AD Pathology Progression . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2 Manhattan Plot From Harold et al. 2009 . . . . . . . . . . . . . . . . . . . 8
1.3 Manhattan Plot From Lambert et al. 2013 . . . . . . . . . . . . . . . . . . . 9
1.4 Manhattan Plot From Escott-Price et al. 2014 . . . . . . . . . . . . . . . . 13
3.1 MAGMA-PCA Analysis in GERAD Data . . . . . . . . . . . . . . . . . . . 30
3.2 MAGMA-PCA Analysis in GERAD Data with a Gene Window . . . . . . . 31
3.3 MAGMA-SUMMARY Analysis in IGAP Data, GERAD SNPs only . . . . . 32
3.4 MAGMA-SUMMARY Analysis in IGAP Data with a Gene Window, GERAD
SNPs only . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.5 MAGMA-SUMMARY Analysis in IGAP Stage 1 Data . . . . . . . . . . . . 33
3.6 MAGMA-SUMMARY Analysis in IGAP Stage 1 Data with a Gene Window 34
3.7 LD Plots for Two Simulated Scenarios . . . . . . . . . . . . . . . . . . . . . 41
3.8 Scatter plots of −log10(p-values) generated with (PCA), (SUMMARY),
(PART) and (Mult Regression) settings for 500 simulated sets of 100 SNPs,
of which 10 SNPs were in LD. All SNPs association OR=1 (Null Hypothesis). 44
3.9 Scatter plots of −log10(p-values) generated with (PCA), (SUMMARY),
(PART) and (Mult Regression) settings for 500 simulated sets of 100 SNPs,
of which 10 SNPs were in LD. SNPs association ORs=1.1 for SNPs in the
LD block, OR=1 otherwise. . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.10 Comparison of MAGMA Settings in Real Data (Simulation of 115 SNPs
from Real Data, with a Proportion of Phenotypes Permuted to Maintain
Effect Sizes, Test and Discovery Set N=13,164.) Varying the Position of
the Associated SNP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.11 Comparison of classification by isotropic combined statistic (circle) with
classification according to ellipsoidal distribution of correlated test statistics
(ellipse). corr = cos φ. Data points in regions A will be misclassified as
negative, data points in regions B as positive when the isotropic statistic is
used. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
xiii
4.1 LD Plot for 100 SNPs in Simple LD Simulations . . . . . . . . . . . . . . . 57
4.2 LD Plot for 100 SNPs in Complex LD Simulations . . . . . . . . . . . . . . 57
4.3 LD Plot for 100 SNPs in Discovery and Test with Different LD Structure
Simulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.4 LD Plot for 100 SNPs with Varying Effect Sizes Simulation . . . . . . . . . 58
4.5 LD Plot for Real LD Structure . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.6 Type I Error Comparison of Set-Based Methods; Simulation of 100 inde-
pendent SNPs where none are associated with disease with OR=1 and Test
N=10,000. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.7 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD and 90 independent SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.8 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs
in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with
r2 = 0.6, 10 SNPs in LD with r2 = 0.8 and 60 independent, unassociated
SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.9 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD with OR∼ N(1, 0.22) and 90 independent, unassociated SNPs where
Test LD is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8). . . . . 65
4.10 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs
with Varying LD with ORs with Randomly Varying Direction and 90 inde-
pendent, unassociated SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.11 Type I Error Comparison of Set-Based Methods; Simulation 129 SNPs from
Real Data, with Permuted Phenotypes to Remove Effect Sizes, N=13,164. . 67
4.12 Power Comparison of Set-Based Methods; Simulation of 100 independent
SNPs where 10% are associated with disease with OR=1.1 and Test N=10,000.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.13 Power Comparison of Set-Based Methods; Simulation of 100 independent
SNPs where 5% are associated with disease with OR=1.1 and Test N=10,000.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.14 Power Comparison of Set-Based Methods; Simulation of 100 independent
SNPs where 1% are associated with disease with OR=1.1 and Test N=10,000.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.15 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
and 90 independent SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
xiv
4.16 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 =
0.6, 10 SNPs in LD with r2 = 0.8, all 40 SNPs in LD Blocks have OR∼
N(1.02, 0.36), and 60 independent, unassociated SNPs. . . . . . . . . . . . . 73
4.17 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with OR∼ N(1.1, 0.22) and 90 independent, unassociated SNPs where Test
LD is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8). . . . . . . . 75
4.18 Power Comparison of Set-Based Methods; Simulation of 10 SNPs with Vary-
ing LD with ORs with Randomly Varying Direction and 90 independent,
unassociated SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.19 Power Comparison of Set-Based Methods; Simulation 129 SNPs from Real
Data, with Permuted Phenotypes to Maintain Effect Sizes, N=13,164. . . . 77
5.1 Plot of Gene-Based −log10(p-values) Using Genotype and Imputed GERAD
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
5.2 Plot of Number of Gene SNPs in Genotype and Imputed GERAD Data . . 90
6.1 LD Plot for 100 SNPs in Simple LD Simulations . . . . . . . . . . . . . . . 108
6.2 LD Plot for 100 SNPs in Complex LD Simulations . . . . . . . . . . . . . . 108
6.3 LD Plot for 100 SNPs in Discovery and Test with Different LD Structure
Simulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.4 LD Plot for 100 SNPs with Varying Effect Sizes Simulation . . . . . . . . . 109
6.5 LD Plot for Real LD Structure with 115 SNPs . . . . . . . . . . . . . . . . 110
6.6 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD and 90 independent SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.7 Type I Error Comparison of POLARIS and an Adjustment using the Inverse
of the Correlation Matrix; Simulation of 10 SNPs in LD and 90 independent
SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
6.8 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs
in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with
r2 = 0.6, 10 SNPs in LD with r2 = 0.8 and 60 independent, unassociated
SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
6.9 Type I Error Comparison of POLARIS and an Adjustment using the Inverse
of the Correlation Matrix; Simulation of 10 SNPs in LD with r2 = 0.2, 10
SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6, 10 SNPs in LD
with r2 = 0.8 and 60 independent, unassociated SNPs. . . . . . . . . . . . . 116
xv
6.10 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD with OR∼ N(1, 0.22) and 90 independent, unassociated SNPs where
Test LD is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8). . . . . 117
6.11 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD with OR∼ N(1, 0.22) and 90 independent, unassociated SNPs where
Test LD is high (r2 = 0.8) and Discovery LD is moderate (r2 = 0.6). . . . . 118
6.12 Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs
with Varying LD with ORs with Randomly Varying Direction and 90 inde-
pendent, unassociated SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . 119
6.13 Type I Error Comparison of Set-Based Methods; Simulation of 115 SNPs
from Real Data, with Permuted Phenotypes to Remove Effect Sizes. . . . . 120
6.14 Type I Error Comparison of POLARIS and an Adjustment using the Inverse
of the Correlation Matrix; Simulation of 115 SNPs from Real Data, with
Permuted Phenotypes to Remove Effect Sizes. . . . . . . . . . . . . . . . . . 121
6.15 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
and 90 independent SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
6.16 Power Comparison of POLARIS and an Adjustment using the Inverse of
the Correlation Matrix; Simulation of 10 SNPs in LD and 90 independent
SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
6.17 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6,
10 SNPs in LD with r2 = 0.8 and 60 independent, unassociated SNPs. . . 125
6.18 Power Comparison of POLARIS and an Adjustment using the Inverse of
the Correlation Matrix; Simulation of 10 SNPs in LD with r2 = 0.2, 10
SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6, 10 SNPs in LD
with r2 = 0.8 and 60 independent, unassociated SNPs. . . . . . . . . . . . . 126
6.19 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with OR∼ N(1.02, 0.22) and 90 independent, unassociated SNPs where
Test LD is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8). . . . . 127
6.20 Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with OR∼ N(1.02, 0.22) and 90 independent, unassociated SNPs where
Test LD is high (r2 = 0.8) and Discovery LD is moderate (r2 = 0.6). . . . . 128
6.21 Power Comparison of Set-Based Methods; Simulation of 10 SNPs with Vary-
ing LD with ORs with Randomly Varying Direction and 90 independent,
unassociated SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
xvi
6.22 Power Comparison of Set-Based Methods; Simulation of 115 SNPs from
Real Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
6.23 Power Comparison of POLARIS and an Adjustment using the Inverse of
the Correlation Matrix; Simulation of 115 SNPs from Real Data . . . . . . 131
7.1 Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed GERAD
data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
7.2 Venn Diagram Displaying the Overlap of Gene-Wide Significant Hits from
POLARIS, MAGMA-PCA and MAGMA-SUMMARY . . . . . . . . . . . . 147
7.3 Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed GERAD
data Using a Gene Window 35kb Upstream and 10kb Downstream . . . . . 149
8.1 LD Plot for 100 SNPs in Complex LD Simulations . . . . . . . . . . . . . . 164
8.2 Type I Error Comparison Between POLARIS and LDpred: Simulation of
10 SNPs in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs
in LD with r2 = 0.6, 10 SNPs in LD with r2 = 0.8 and 60 independent,
unassociated SNPs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
8.3 Power Comparison Between POLARIS and LDpred: Simulation of 10 SNPs
in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with
r2 = 0.6, 10 SNPs in LD with r2 = 0.8, all 40 SNPs in LD Blocks have
OR∼ N(1.02, 0.36), and 60 independent, unassociated SNPs. . . . . . . . . 168
8.4 Power Comparison Between POLARIS and LDpred with a closeup of y-axis:
Simulation of 10 SNPs in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4,
10 SNPs in LD with r2 = 0.6, 10 SNPs in LD with r2 = 0.8, all 40 SNPs in
LD Blocks have OR∼ N(1.02, 0.36), and 60 independent, unassociated SNPs.169
8.5 Comparison Between β Adjustment in POLARIS and LDpred . . . . . . . . 171
8.6 Plot of the −log10(p-value) at different p-value inclusion thresholds for PO-
LARIS, LDpred and PRS, in unpruned, intelligently pruned and clumped
data. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
8.7 Plot of Correlation Coefficient, r, for Varying ORs. In All Data (Black)
and Cases (Red) and Controls (Green) Separately for MAF=0.2 (solid) and
MAF=0.3 (dashed) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
9.1 Plot of the Genetic Correlation Between All Disorders . . . . . . . . . . . . 188
9.2 LD Plot for CLU SNPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
xvii
List of Tables
3.1 Number of LoF Genes from the Exome Aggregation Consortium . . . . . . 35
3.2 Number of Genes in Conserved Noncoding Sequences . . . . . . . . . . . . . 36
3.3 MAGMA Pathway Results in GERAD data . . . . . . . . . . . . . . . . . . 37
3.4 MAGMA and ALIGATOR Pathway Results in IGAP stage 1 data . . . . . 38
3.5 Number of Genes in Each Pathway from the MAGMA and ALIGATOR
Approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
5.1 PRS Gene-based Analysis in AD Genotype Data . . . . . . . . . . . . . . . 86
5.2 Gene-based Analysis Comparison for PRS, MAGMA, Simes’ and Fisher’s
Methods in AD Genotype Data . . . . . . . . . . . . . . . . . . . . . . . . . 87
5.3 Gene-Wide Significant Genes from PRS Gene-based Analysis in AD Im-
puted Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.4 Correlation Between −log10(p-values) of Each Gene-Based Method and the
Number of SNPs in the Gene . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.5 Correlation Between Power (p ≤ 0.05) of Each Gene-Based Method and the
Number of SNPs in the Gene . . . . . . . . . . . . . . . . . . . . . . . . . . 92
5.6 Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
5.7 Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data, No Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.8 Number of LoF Genes from the Exome Aggregation Consortium, Imputed
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.9 Number of LoF Genes from the Exome Aggregation Consortium, Imputed
Data, No Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.10 Number of Genes in Conserved Noncoding Sequences, Genotype Data . . . 94
5.11 Number of Genes in Conserved Noncoding Sequences, Genotype Data, No
Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.12 Number of Genes in Conserved Noncoding Sequences, Imputed Data . . . . 94
xviii
5.13 Number of Genes in Conserved Noncoding Sequences, Imputed Data, No
Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.14 AD Associated Pathways Calculated Using PRS in GERAD data . . . . . . 96
5.15 AD Associated Pathways Calculated Using PRS in GERAD data Excluding
APOE Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.16 Correlations Between AD Associated Pathways, where Correlations were
Calculated Using Individual PRS, where PRS is adjusted for population
stratification (Pathway Numbers Correspond to those in Table 5.14) . . . . 98
7.1 Comparison of the Number and Proportion of All Genes Below a P-value
Threshold for POLARIS, MAGMA-PCA in GERAD data and MAGMA-
SUMMARY in IGAP data . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
7.2 Comparison of the Number and Proportion of Independent Genes Below
a P-value Threshold for POLARIS, MAGMA-PCA in GERAD data and
MAGMA-SUMMARY in IGAP data . . . . . . . . . . . . . . . . . . . . . . 142
7.3 Comparison of the Number and Proportion of All Genes Below a P-value
Threshold for POLARIS, MAGMA-PCA in GERAD imputed data and
MAGMA-SUMMARY in IGAP data . . . . . . . . . . . . . . . . . . . . . . 143
7.4 Comparison of the Number and Proportion of Independent Genes Below
a P-value Threshold for POLARIS, MAGMA-PCA in GERAD imputed
data and MAGMA-SUMMARY in IGAP data . . . . . . . . . . . . . . . . . 144
7.5 Gene-Wide Significant Genes from POLARIS Gene-based Analysis in AD
Imputed Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
7.6 Gene-Wide Significant Genes from MAGMA-PCA Gene-based Analysis in
AD Imputed Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
7.7 Gene-Wide Significant Genes from MAGMA-SUMMARY Gene-based Anal-
ysis in IGAP Data (GERAD SNPs only) . . . . . . . . . . . . . . . . . . . . 146
7.8 Gene-Wide Significant Genes from POLARIS Gene-based Analysis in AD
Imputed Data Using a Gene Window (35kb upstream and 10kb downstream)148
7.9 Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
7.10 Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data, No Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . 151
7.11 Number of LoF Genes from the Exome Aggregation Consortium, Imputed
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
7.12 Number of LoF Genes from the Exome Aggregation Consortium, Imputed
Data, No Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . 151
xix
7.13 Number of Genes in Conserved Noncoding Sequences, Genotype Data . . . 152
7.14 Number of Genes in Conserved Noncoding Sequences, Genotype Data, No
Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
7.15 Number of Genes in Conserved Noncoding Sequences, Imputed Data . . . . 153
7.16 Number of Genes in Conserved Noncoding Sequences, Imputed Data, No
Overlapping Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
7.17 AD Associated Pathways Calculated Using POLARIS in GERAD data . . . 154
7.18 Correlations Between AD Associated Pathways, where Correlations were
Calculated Using Individual PRS Estimated With POLARIS, where PO-
LARIS is adjusted for population stratification (Pathway Numbers Corre-
spond to those in Table 7.17) . . . . . . . . . . . . . . . . . . . . . . . . . . 155
8.1 POLARIS Prediction Modelling, Excluding 20 GWAS hits and APOE region177
8.2 POLARIS Prediction Modelling, Including 20 GWAS hits and APOE region177
8.3 POLARIS Prediction Modelling, Excluding 20 GWAS hits, APOE region
and 10,697 heterogeneous IGAP SNPs . . . . . . . . . . . . . . . . . . . . . 178
8.4 POLARIS Prediction Modelling, Including 20 GWAS hits and APOE region
and Excluding 10,697 heterogeneous IGAP SNPs . . . . . . . . . . . . . . . 178
8.5 Prediction Comparison Between POLARIS, PRS and LDpred; Excluding
20 GWAS hits, APOE region and 10,697 heterogeneous IGAP SNPs . . . . 179
9.1 Information on Disorders with Data Downloaded . . . . . . . . . . . . . . . 185
9.2 Results for AD Gene-Based Analysis Using ADHD Summary Statistics as
Weights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
9.3 Results for AD Gene-Based Analysis Using ASD Summary Statistics as
Weights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
9.4 Results for AD Gene-Based Analysis Using BIP Summary Statistics as
Weights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
9.5 Results for AD Gene-Based Analysis Using Neuroticism Summary Statistics
as Weights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
9.6 Results for AD Gene-Based Analysis Using PD Summary Statistics as Weights192
9.7 Results for AD Gene-Based Analysis Using SZ Summary Statistics as Weights193
11.1 Details of 129 SNPs Used in Real Data Simulations . . . . . . . . . . . . . . 204
11.2 21 GWAS Index SNPs with Summary Stats from IGAP Stage 1 . . . . . . . 209
1
1 Introduction
1.1 Introduction
The gold standard endpoint for medical research is to develop personalised treatment
for all individuals; whether this is through the use of prevention strategies and lifestyle
modifications or personalised medicines. Genetics studies are crucial to achieving this goal,
with research extending from single gene disorders to complex disorders and genomics [1].
Major advances in genetic research have been influenced by the completion of the Human
Genome Project [2], the development of Genome-Wide Association Studies (GWASs) [3]
and the reduced cost of genome sequencing [4]; and the rate of discovery in this field is
still accelerating [5].
1.2 Alzheimer’s Disease
1.2.1 What is Alzheimer’s Disease (AD)?
Late Onset (LO) Alzheimer’s Disease (AD) is a devastating neurodegenerative condition
with a significant genetic heritability [6]. AD is the most common form of dementia first
described by Alois Alzheimer in 1907 [7]. LOAD is defined when the disease onset occurs
after the age of 65. It is possible for the disease to develop at a younger age, this is termed
Early Onset (EO) AD, and is a much rarer form of the disease [8].
AD is a growing public health concern, with the prevalence expected to increase in coming
years. It currently affects more than 520,000 people in the UK [8] and 1 in 3 people in the
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UK today will develop dementia in their lifetime. Globally there is expected to be a 204%
increase in the number of people living with dementia by 2050 [9]. With growing disease
prevalence comes growing economic impact; the cost in the UK is expected to more than
double by 2040, and the impact of dementia on the economy is larger than the combined
cost of cancer and heart disease [9]. In the US, 7.9 trillion dollars of medical costs could
be saved by early diagnosis [10].
1.2.2 Symptoms
AD begins as memory loss and develops into severe dementia and death. The disease may
present differently in each person but can encompass a number of varied symptoms. The
disease may progress differently as well, and the life expectancy after initial symptoms is
on average 8-10 years, although again this varies a lot, particularly with the age of onset
[8].
Usually, memory loss begins as memory lapses where people with AD struggle to learn
new information or remember recent events [8]. Sometimes memory loss which is due to
dementia can be confused with forgetfulness due to normal aging [9]. This memory loss
impacts daily life because people with AD may forget medication, appointments, conver-
sations or events and can forget their local area and become confused with directions. In
early stages, Alzheimer’s patients tend to have less trouble remembering events which hap-
pened a long time in the past. This memory loss is caused by damage to the hippocampus
[8].
Alzheimer’s patients may also experience difficulties with thinking, communication, rea-
soning and perception [8]. For example, they can have issues with problem solving, judging
distances, changes in sleep pattern or may have mood changes such as becoming irritable
and anxious [8][9].
The symptoms become more severe as the disease progresses, resulting in the person with
AD requiring much more support and care and eventually leading to them needing help
with all daily activities.
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1.2.3 Diagnosis
There is no easy test to determine whether a person has AD, particularly because the
symptoms are common to a number of other diseases. AD is predominantly assessed by
interviewing the person, and if possible a close relative or friend. The symptom devel-
opment is thoroughly investigated to determine if memory has got worse gradually over
time. Pen-and-paper tests are used to assess the individuals mental ability and sometimes
a brain scan is used, usually in order to exclude other conditions [8].
Overall, these different assessments made by GPs, psychiatrists or neurologists can be
collated to make a decision about whether the person has AD or not [8][9]. Although it
is not possible to be certain about a diagnosis without determining if the neuropathology
of AD is present by autopsy [11].
1.2.4 Neuropathology of Alzheimer’s Disease
Pathologically, AD is distinct and recognizable [11]. AD is defined by the presence of
intracellular neurofibrillary tangles and extracellular amyloid plaques [12]. The neurofib-
rillary tangles are made up of an unusual build up of phosphorylated tau in the neurons.
The amyloid plaques have a beta-amyloid core encased by neurites [11].
One of the major challenges in identifying treatments for AD is the amount of pathological
change in the brain prior to an individual developing symptoms, this is shown in Figure
1.1. Therefore, by the time AD is diagnosable, substantial neurodegeneration has already
occurred. Additionally, when determining control subjects for studies (those without
AD), it is possible that these subjects may go on to later develop AD, or may already
have some of the pathological changes which characterise the disease- thus reducing the
power of these studies. Genetics is therefore hugely beneficial in this case, since a person’s
genetics could be assessed at birth. If it is possible to accurately predict individuals who
are most likely to develop AD, treatments can be targeted at these individuals prior to
symptom development.
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Figure 1.1: AD Pathology Progression [13]
1.2.5 Treatments
The cause of sporadic LOAD is unknown and as such there are no treatments specifically
for AD, but current treatments are targeted at specific AD symptoms or to slow disease
progression [14]. The benefits of medicines for AD are small, and a number of non-drug
therapies can also be used to help care for a person with AD [8].
There are two main drug treatments used in AD; these are Acetylcholinesterase inhibitors
and NMDA receptor antagonists. AD patients have reduced levels of acetylcholine which
passes messages between nerve cells. Acetylcholinesterase inhibitors prevent an enzyme
from breaking down acetylcholine in the brain. NMDA receptor antagonists stop the
effects of glutamate. Glutamate also passes messages between nerve cells, this is released
in excess in AD brains leading to additional brain damage [8].
Non-drug treatments such as maintaining activity and brain stimulation in the person
with AD can be beneficial. This involves finding activities suited to each person’s abilities,
including arts, crafts, physical exercise and music. In addition, maintaining good social
interactions can help to reduce symptoms [8].
5
1.2.6 Genetic Risk Factors
Firstly, the genes related to EOAD were determined, using gene-mapping [12]. These
genes were APP [15], PSEN1 [16] and PSEN2 [17].
However, the most common form of AD is LOAD which is often defined as having an onset
after the age of 65, LOAD is also the primary focus of this thesis. LOAD is a complex
genetic disorder, meaning that the disease does not follow Mendelian inheritance. The
apolipoprotein E (APOE ) gene is the strongest genetic risk factor for LOAD [18]. APOE
has three different isoforms: 4, 3 and 2. The number of 4 isoforms is much higher in
cases compared to controls [12].
GWAS, gene-based analyses and whole-exome sequencing studies have identified a large
number of genes which are associated with LOAD, these are discussed in more detail in
Section 1.3. There are over 20 genes which have been found to have an association with AD
[19][20][21][22]. In addition, eight biological pathways have been found to be associated
with AD, including immune response and cholesterol transport [23][24].
1.2.7 Environmental Risk Factors
This thesis focuses on the genetic risk in AD, but a number of environmental risk factors
have also been found to be associated with AD [25].
The largest risk factor for AD is age; it mainly affects people over the age of 65. Over
65, the risk of AD doubles every 5 years. It is found that AD is more common in females
compared to males, although the reason for this difference is unclear, but is hypothesised
to be related to the lack of oestrogen after menopause [8].
Risk factors for dementia are also risk factors for cardiovascular disease, so maintaining a
healthy lifestyle and exercising regularly may reduce the risk of dementia. A person can
maintain a healthy lifestyle by not smoking, taking regular exercise, eating healthily and
maintaining healthy blood pressure [9].
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Additional environmental factors strongly associated with AD are air pollution, for exam-
ple, increases in nitrogen oxide, particulate matter and ozone levels increase the risk of
AD, being in the presence of pesticides or solvents at work, and increased levels of vitamin
D also lead to the increase in AD risk [25].
1.3 Methodological Approaches to Genetic Data
Methodologies in genetic research have advanced in recent years. This has been aided by
improved computational resources, advanced laboratory methods and increased sample
sizes in genetics studies.
These methods are discussed in AD and also Type II Diabetes and Schizophrenia (SZ).
The findings in these complex traits are also discussed since Type II Diabetes is a risk
factor for AD [26] and psychosis is presented in some people with AD [27]. Genetic results
from these two disorders may aid in the biological understanding of AD.
1.3.1 Genome-Wide Association Study (GWAS)
Genetic discoveries reached a plateau due to studies being underpowered for the effect size
of each individual genetic variant [3]. Therefore, GWASs which assess whether genome-
wide variants are associated with disease in a number of individuals, were developed to find
associations between complex traits and genomic loci; specifically to determine associations
between common diseases and Single Nucleotide Polymorphisms (SNPs) [3]. The aim was
to use detected variants to better understand the biology of disease, however, translating
GWAS results to informing disease biology is not straightforward [28]. In order to have
power to detect such small associations with disease, a large number of subjects were
required and a large number of SNPs across the genome would be analysed.
The Genetic and Environmental Risk in Alzheimer’s Disease Consortium (GERAD) pub-
lished a Genome-Wide Association Study (GWAS) that identified novel variants in CLU
and PICALM which were associated with AD [19], see Figure 1.2. Concurrently, the
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The European Alzheimer’s Disease Initiative (EADI) identified the CR1 and CLU loci
to associate with AD [20]. Subsequent publications by Genetic and Environmental Risk
in Alzheimer’s Disease Consortium (GERAD), the Alzheimer Disease Genetics Consor-
tium (ADGC) and The Cohorts for Heart and Aging Research in Genomic Epidemiology
Consortium (CHARGE) Consortium identified a further 5 novel loci [29][30][31].
Figure 1.2: Manhattan Plot From Harold et al. 2009 [19]
Due to the large sample sizes required to detect such small individual SNP effects, a
number of different consortia collaborated to form one large consortium for many different
complex traits. This involved the meta-analysis of SNP effects from each group in order
to increase power and detect a larger number of variants.
The International Genomics of Alzheimer’s Project (IGAP) [20] consortium is an amal-
gamation of the four different genetic groups (GERAD, EADI, ADGC and CHARGE)
previously discussed. Meta-analysis of the 4 GWAS datasets determined 11 novel variants
associated with AD, these results are shown in the Manhattan plot in Figure 1.3 [20].
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Figure 1.3: Manhattan Plot From Lambert et al. 2013 [20]
SZ is another disorder where a large number of variants have been identified using GWAS
and this has led to a much greater understanding of disease aetiology. A GWAS of 3,416
subjects (479 cases, 2,937 controls) and a replication set of 16,726 subjects determined a
strong independent association with ZNF804A, which has a potential role regulating gene
expression [32]. Five novel loci associated with SZ were determined using a GWAS with a
much larger number of 21,856 subjects and an additional independent replication sample
with 29,839 subjects, where subjects were of European ancestry. The most associated
loci was a neuronal development regulatory gene; MIR137 [33]. The identification of an
additional 13 loci was possible using a multi-stage GWAS where a Swedish sample was
used and meta-analysed with another SZ GWAS [34]. Finally, an extremely large GWAS
including 36,989 SZ cases and 113,075 controls found 108 novel loci, and thus demonstrated
the ability for large GWAS to detect a huge number of associations [35].
GWAS has also been particularly successful in studies of Type II Diabetes [28]. The use
of GWAS has enabled the identification of 38 SNPs associated with Type II Diabetes;
these associations were determined against a dichotomous variable, but when considering
continuous glycemic traits, an additional 24 variants were discovered [36].
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Initially, researchers were sceptical about the validity of the experimental design of GWAS,
but it is much more widely accepted more recently due to the number of robust findings
[28].
The GWAS design has led to the discovery of a huge number of associated variants across
a range of disorders, GWAS are not hypothesis driven, all genotyped SNPs are tested for
their association with a particular disease. However, there are some potential issues with
the GWAS approach. The first being that GWAS studies have been unable to explain the
total genetic variation estimated by linkage studies. This ‘missing heritability’ could be
due to interactions between SNPs, rare variants or variants which have not been genotyped
or are imputed with poor accuracy. Additionally, annotations of identified variants are
characterised using the most proximal gene, but the variant may be acting upon an entirely
different gene [36]. Another issue with GWAS is whether the associated variants are
biologically relevant, although the number of biological pathways implicated in diseases,
based on GWAS results, is substantial [3]. Linking GWAS results to the underlying disease
biology has been successful by using new analytical techniques, molecular technology and
additional data [28].
Meta-analysing the results of different GWAS is very beneficial in terms of increasing the
power to determine SNPs associated with disease, although, issues may arise where the
GWASs have heterogeneity between populations; differing Linkage Disequilibrium (LD)
structure between SNPs may lead to different SNPs being statistically significant in each
GWAS. Meta-analysing these SNPs together may cancel their individual effects into a null
overall effect.
1.3.2 Polygenic Risk Score (PRS)
GWAS unearthed a large number of genetic associations with complex disorders, all of
which have a small individual effect. However, there were still potentially vast numbers of
variants which did not reach genome-wide significance, but may still collectively contribute
to disease risk.
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In order to determine the polygenic effect of a particular disease, Polygenic Risk Score
(PRS) was developed. Polygenic Risk Score (PRS) involves the combination of all SNPs
across the genome into one risk score for each individual. It is then possible to assess the
genetic burden of a particular disorder and determine whether the risk score is able to
predict whether an individual will have the disease [37].
The effectiveness of PRS was first shown in SZ, where the polygenic component was highly
associated with SZ (p = 1.9× 10−19) and explains at least one-third of liability variation
[37]. PRS was then calculated using the largest Schizophrenia (SZ) GWAS and was able
to confirm that PRS is associated with SZ and is able to predict case/control status. In
this data, 7% of variation on the liability scale is explained using PRS [35].
AD was also shown to be a complex polygenic disorder, with the polygenic component
strongly associated with AD (p = 4.9 × 10−26) [38]. Additionally, the best reported
accuracy to predict whether or not a subject has AD based on PRSs is 78.2%. This
accounts for 90% of the maximum prediction accuracy possible for AD [39].
PRS computed in 18 genetic loci associated with Type II Diabetes were successfully able
to predict diabetes cases, but this provided only a slight improvement compared to using
known risk factors only [40]. However, this prediction was further improved upon by
the inclusion of a large number of SNPs (Nsnps=1,000), this was found in the Estonian
Biobank cohort [41].
PRS has the main advantage that it is able to produce a risk score per subject, which
can be used in further analyses. PRS is also able to increase power from a standard
GWAS by incorporating the SNP effect sizes from an independent study. It improves
power by accounting for a number of SNPs which individually have a small effect size, but
collectively contribute to disease risk. In addition, it is desirable to predict a person’s risk
of disease using PRS, as this can be used in clinical trials or to prioritise subjects to follow
up. It may also enable subjects to be treated for a particular disease in a precautionary
manner before they are actually diagnosed with the disease (particularly relevant to adult-
onset disorders). Disease prediction has the potential to be used as a tool for personal
health management [42].
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PRS assumes independence between SNPs and therefore, data must be pruned for Linkage
Disequilibrium (LD) before analysis. LD is a correlation between SNPs, or the non-random
association of alleles at different loci [3]. This likely removes a large number of SNPs
from the data, and some (albeit small) LD between SNPs may remain. PRS requires
the use of two independent datasets, one of which must have individual genotype data.
Unfortunately, individual genotype data is rarely freely available to download, so this may
limit researchers able to use this approach. The use of PRS in precision medicine has
a number a challenges; firstly, the lack of genetic research in non-European populations
mean that results are not widely applicable, which is a necessity for clinical applications,
and secondly, education for the public and clinicians to use the new concept of a continuous
genetic risk component, rather than the presence/absense of a particular variant [43].
1.3.3 Gene-Based Analysis
Gene-based analysis offers an attractive alternative to single SNP analyses, since the com-
bined effect of SNPs within the gene may be captured, whereas single SNP analyses are
often underpowered due to the small effect sizes of individual SNPs. In addition, gene-
based analysis specifically identifies the gene associated with disease rather than a single
SNP as a proxy for the gene.
Genes are found to be fairly consistently associated with disease across different popula-
tions using a gene-based analysis. In contrast, different SNPs in a set in LD may be found
to be associated with a disease in different samples. Gene-based analyses also directly
provide information for functional analysis [44].
There are a number of methods to assess the gene-based effect by combining the effects of
all SNPs within the gene. Fisher’s method [45] combines p-values of all SNPs in the gene
to generate an overall gene p-value, but assumes independence between SNPs. Simes [46]
is similar to Fisher’s method, except it adjusts the SNP p-values for the number of SNPs in
the gene and tests whether at least one of these SNPs is associated with disease. GATES
extended Simes [44] is an addition to Simes method which also incorporates functional in-
formation. Rank/threshold truncated products of p methods [47][48][49] forms the product
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of the most significant SNPs in the gene. Set-based analysis as implemented in PLINK
[50][51] where a permutation procedure is used to adjust SNPs for LD. Brown’s method
[52][53] is an extension to Fisher’s method but which adjusts for the LD structure be-
tween SNPs. A logistic kernel-machine based test is available which accounts for epistatic
and non-linear SNP effects for all SNPs within the gene [54]. Multi-marker Analysis of
GenoMic Annotation (MAGMA) [55] uses a regression based approach which computes
principal components from all SNPs to adjust for LD. Finally, Pascal [56] utilises the sum
and maximum of chi-squared statistics to generate a gene score.
A gene-based analysis has been undertaken in the International Genomics of Alzheimer’s
Project (IGAP) AD data using Brown’s method [52]. This approach determined two
additional novel genes; TP53INP1 and IGHV1-67 [21]. These results are shown in the
Manhattan plot in Figure 1.4.
Figure 1.4: Manhattan Plot From Escott-Price et al. 2014 [21]
Gene-based analyses in Frontotemporal Dementia (FTD) have aided in identifying gene as-
sociations which were undetermined using GWAS only, thus demonstrating the increased
power of gene-based approaches. In 3,348 FTD cases and 9,390 controls, APOE and
TOMM40 were associated with behavioural variant FTD and SERPINA1 and ARHGAP35
were found to be associated with progressive non-fluent aphasia [57].
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The power of gene-based analyses is further demonstrated in Rheumatoid Arthritis (RA),
where a gene-based analysis in publically available RA datasets (14,361 cases, 43,923 con-
trols of European ancestry and 4,873 cases, 17,642 controls of Asian ancestry) determined
221 novel genes associated with RA, 71 of which overlapped both ancestries [58].
Gene-based analyses combine the information of all SNPs in a gene, so are more likely
to find novel associations and more informative results [59]. Genes are more robustly
determined across different populations compared to single SNP analysis, since due to LD,
associated SNPs may be representing different causal SNPs [44]. Restricting the analysis
to genes makes biological sense, since a gene is a defined functional unit of the genome
[44]. Gene-based analyses require a less stringent multiple testing corrected significance
threshold compared to single SNP analyses, due to fewer genes being assessed compared
to SNPs.
There are a huge number of potential gene-based approaches, so there may be difficulty in
choosing the appropriate method based on the data available to the researcher. It could
also be difficult to annotate SNPs to genes, for example, should only SNPs within the
gene be included, or is it more appropriate to include a window of SNPs around the gene
which may contain additional transcriptional regulatory elements.
1.3.4 Pathway Analysis
Despite the findings of a large number of SNPs and genes which are associated with disease,
the biology underlying the aetiology of disease remains difficult to determine. Therefore,
a large number of methods have become available in order to link genetic associations to
a relevant biological process, these are known as gene-set or pathway analyses [60].
Pathway analysis is another set-based approach where a group of genes which all have a
similar biological function are used, it is then investigated whether this group of genes is
associated with disease. A pathway analysis is beneficial because it gives specific biological
information about the potential mechanisms involved in disease.
A pathway analysis has been undertaken in IGAP AD data. This used the Association
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LIst Go AnnoTatOR (ALIGATOR) algorithm [61] which defines genes to be significant if
they contain a single SNP with a p-value less than a set threshold. The significant gene
set is then compared to randomly generated gene sets to determine if there is an excess
of association with AD in the gene set. Eight pathways were found to be associated with
AD [23][24]; these pathways are immune response, regulation of endocytosis, cholesterol
transport, hematopoietic cell lineage, proteasome-ubiquitin activity, reactome hemostasis,
clathrin and protein folding.
Five pathways have been found to be associated with schizophrenia; serotonergic synpase,
ubiquitin mediated proteolysis, hedgehog signalling, adipocytokine signalling and renin
secretion. These pathways were consistent across three different populations of European-
American, African-American and Han Chinese ancestry [62].
In addition, the presense of pathways associated with Type II Diabetes have also been
determined. These pathways are tight junction, cell cycle, melanogenesis, vibrio cholerae
infection, gastric acid secretion, phagosome, ubiquitin mediated proteolysis and protein
processing in endoplasmic reticulum [63].
Pathway analyses allow the connection of genetic associations with their relevant biological
processes in order to better understand disease mechanisms. Pathway analysis can, like
gene-based analyses, further improve power by assessing the collective effect of SNPs
or genes with small individual effects. Pathway analyses may also account for genetic
heterogeneity within populations [60].
There are a large number of pathway approaches available and no particular consensus
within the field regarding the optimal approach to take. Pathway analyses are hugely
dependent on these methods, and how the gene-sets are defined, and thus results should
be interpreted with care [60].
1.3.5 Rare Variant Analysis
It was thought that one reason for the ‘missing heritability’ from GWAS could be due
to the presense of rare variants which are associated with disease, but are too rare to be
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determined from a GWAS.
In AD, low frequency risk variants have been identified through next generation sequencing
(TREM2 ) [64] and an whole-exome association study (PLCG2, TREM2 and ABI3 [22]).
These three genes are highly expressed in microglia, which further implicates the immune
response pathway, which was identified from pathway analyses.
Whole exome sequencing studies have determined novel genes associated with a number of
different disorders. PLA2G4E has been identified as a potential gene associated with panic
disorder in a Japanese population, although it did not reach gene-wide significance [65].
In SZ cases, rare variants found from a whole exome sequencing study show enrichment
in loss of function intolerant genes (p < 3.6× 10−10) [66].
The study of rare variants is advantageous since it is possible to explain additional disease
risk and heritability. The importance of rare variants in disease is well known, with
highly penetrant rare variants causing rare subtypes of common diseases. Advances in
genetic technologies has allowed the successful sequencing of low frequency variants for a
reasonable cost [67].
Cost is, however, still somewhat prohibitive, and rare variant studies tend to focus on
exome regions, although whole genome sequencing is likely to become more widely used
as costs continue to decrease [67]. It will be a challenge to develop appropriate statistical
methods which can differentiate functional variants from rare neutral variants [68].
1.4 Aims
The main aim of this thesis is to identify novel genes which are associated with AD in
order to better understand the aetiology of AD. This will be done by researching recent,
powerful methods which are better able to identify novel variants than GWAS alone. If
current methods are limited, then the development of a novel approach which improves
power will be investigated. The implication and credibility of any novel variants found
to be associated with AD will be assessed and any potential biological mechanisms which
16
may explain the development of AD will be discussed.
1.5 Thesis Outline
The second chapter in this thesis discusses the two main datasets used throughout the
thesis and the different versions of this data. In addition, the main methodological ap-
proaches which are predominantly used in the thesis are outlined and the software which
is used for the analyses is highlighted.
Next, a gene-based analysis in the AD data is carried out, using a widely used methodology,
MAGMA, which has greater power than other gene-based approaches. This is to determine
whether gene-based approaches have more power compared to single-SNP analyses and
are thus able to find novel associations in the same data.
A new approach to gene-based analysis was then investigated which incorporates additional
data to further improve power using the Polygenic Risk Score (PRS) methodology. This
was tested against current methods; MAGMA, Fisher’s and Simes. The PRS gene-based
approach was then used in AD data to determine whether any novel genes are identified.
This PRS gene-based method is extended to adjust for correlation or LD between SNPs,
this novel method is called POlygenic Ld-Adjusted Risk Score (POLARIS). Again, this
novel method was compared to MAGMA in simulated data and then applied to real AD
data to identify potential novel genes.
POLARIS was then extended to compute a risk score across the whole genome, more
similarly to standard PRS and was compared to another LD adjustment approach, LDpred.
The ability of the POLARIS score to predict AD case/control status was assessed and
compared to the prediction ability of PRS.
All risk score methods so far have been weighted using effect sizes from the same disorder;
the final chapter investigates the use of weights from different disorders in a POLARIS
gene-based analysis. This will enable the determination of genes in common between AD
and other disorders, which may lead to a better understanding of the underlying biological
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mechanism of AD.
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2 Methods
2.1 Data
2.1.1 Genetic and Environmental Risk for Alzheimers Disease (GERAD) Data
The AD data used in this thesis was obtained from the Genetic and Environmental Risk in
Alzheimer’s Disease Consortium (GERAD) [19]. The GERAD stage 1 sample comprised
up to 3,941 AD cases and 7,848 controls. These samples were recruited by the Medical
Research Council (MRC) Genetic Resource for AD (Cardiff University; Kings College
London; Cambridge University; Trinity College Dublin), the Alzheimers Research UK
(ARUK) Collaboration (University of Nottingham; University of Manchester; University
of Southampton; University of Bristol; Queens University Belfast; the Oxford Project to
Investigate Memory and Ageing (OPTIMA), Oxford University); Washington University,
St Louis, United States; MRC PRION Unit, University College London; London and the
South East Region AD project (LASER-AD), University College London; Competence
Network of Dementia (CND) and Department of Psychiatry, University of Bonn, Germany
and the National Institute of Mental Health (NIMH) AD Genetics Initiative. All AD
cases met criteria for either probable (NINCDS-ADRDA, DSM-IV) or definite (CERAD)
AD. All elderly controls were screened for dementia using the MMSE or ADAS-cog, were
determined to be free from dementia at neuropathological examination or had a Braak
score of 2.5 or lower. For this GERAD data, the full individual genotypes for all individuals
are available. Publically available control data from the Wellcome Trust Case Control
Consortium (WTCCC) were also included in the data. After Quality Check (QC), the
GERAD data used in this thesis has 13,164 subjects; 3,332 AD cases and 9,832 controls.
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This GERAD data contains a total of 419,048 genotyped SNPs. This is termed the
GERAD genotype data throughout this thesis.
The Haplotype Reference Consortium (HRC), version r1.1 2016, was used to impute
GERAD genotype data on the Michigan Imputation Server [69], which to date, allows the
most accurate imputation of genetic variants. Imputed genotype probabilities (also known
as dosages) were converted to the most probable genotype with a probability threshold
of 0.9 or greater. SNPs were removed if: their imputation INFO-score< 0.4, minor al-
lele frequency (Minor Allele Frequency (MAF))< 0.01, missingness of genotypes≥ 0.05 or
Hardy Weinberg Equilibrium (HWE)< 10−6. A total of 6,119,694 variants were retained.
To correct for population structure and genotyping differences, all analyses were adjusted
for gender and the top 15 principal components. This data is hereafter referred to as the
GERAD imputed data.
2.1.2 International Genomics of Alzheimer’s Project (IGAP) Data
Additionally, summary statistics from the International Genomics of Alzheimer’s Project
(IGAP) study [20] were used. IGAP is a large two-stage study based upon GWAS on
individuals of European ancestry. In stage 1, IGAP used genotyped and imputed data on
7,055,881 SNPs to meta-analyse four previously-published GWAS datasets consisting of
17,008 Alzheimer’s disease cases and 37,154 controls (The Genetic and Environmental Risk
in AD consortium - GERAD, The European Alzheimer’s disease Initiative - EADI, the
Alzheimer Disease Genetics Consortium - ADGC and The Cohorts for Heart and Aging
Research in Genomic Epidemiology consortium - CHARGE). In stage 2, 11,632 SNPs were
genotyped and tested for association in an independent set of 8,572 AD cases and 11,312
controls. Finally, a meta-analysis was performed combining results from stages 1 and 2.
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2.2 Methodological Approaches
2.2.1 Fisher’s method
Fisher’s method [45][53] is a method of combining the p-values of SNPs within a set to
determine the evidence against a common null hypothesis [70]. It obtains an overall p-value
for each set from a group of p-values which are independent tests of the same hypothesis.
Fisher’s set-based p-value is calculated using Equation 2.1.
p Fisher = P
(
− 2
M∑
i=1
ln(pi) ≥ χ22M
)
(2.1)
where p Fisher is Fisher’s set-based p-value, P is the probability, M is the number of SNPs
in the set and pi is the p-value for SNP i.
If the summary statistics used to calculate the Fisher’s statistic have been calculated
adjusting for population covariates, then the overall set p-value will also be adjusted for
population covariates.
Fisher’s method assumes independence between SNPs, and therefore, in the presense of
LD between SNPs, it is expected that the set-based p-value produced by Fisher will be
biased since the type I error rate is likely inflated [44]. Fisher’s method also assumes that
under the null hypothesis the p-values follow a Uniform distribution, pi ∼ Unif(0, 1).
Provided that these assumptions hold, Fisher’s method is asymptotically optimal.
Fisher’s method has one disadvantage in that it treats large and small p-values asym-
metrically, and therefore the method is asymmetrically sensitive to small p-values when
compared to large p-values, for example if you combine two studies, one with p=0.001 and
one with p=0.999, the combined Fisher’s p-value would be p=0.008, therefore, the small
p-values have a greater influence on the combined p-value. This asymmetry can result in
bias when combining studies on the same null hypothesis [70].
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2.2.2 Simes method
Simes’ [46], like Fisher’s, is a set-based method accounting for the number of SNPs within
the set, however, it also attempts to correct for LD between SNPs in the set. The null
hypothesis of this method is that no SNP within the set is associated with disease, and the
alternative hypothesis is that at least one SNP within the set is associated with disease
[44]. The Simes’ set-based p-value is calculated using Equation 2.2. Simes removes the
issue of LD by considering whether at least one SNP in the set is associated with disease,
rather than combining the effect of all SNPs.
p Simes = min
j=1,...,M
(
Mp(j)
j
)
(2.2)
where p Simes is the Simes’ set-based p-value, M is the number of SNPs in the set,
p(1), ..., p(M) are the SNP p-values arranged in ascending order, j is the rank and p(j)
is the jth p-value.
As with Fisher’s method, p Simes will be adjusted for population covariates if the summary
statistics have been calculated with population covariate adjustment.
In essence, the Simes method corrects for multiple testing in such a way that is less
conservative than the Bonferroni correction [71]. Like Fisher’s method, Simes assumes
that, under the null hypothesis, the set of p-values comes from a Uniform distribution,
pi ∼ Unif(0, 1) [46]. If the SNPs are independent, then the Simes set-based p-values are
expected to also follow a Uniform distribution between 0 and 1, however, if SNPs are
positively correlated, the estimate of the set-based p-value is likely to be conservative [44].
2.2.3 MAGMA
MAGMA [55] is a regression based approach which fully accounts for LD between SNPs.
The matrix of SNPs within the set is transposed into Principal Components (PCs), and
PCs with small eigenvalues are removed. The remaining PCs are then regressed against
the phenotype of interest and an F-test is used to determine the strength of the associ-
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ation between the set and the phenotype and thus gives the MAGMA set-based p-value,
p MAGMA. MAGMA also has the functionality to calculate set-based p-values using sum-
mary statistics (MAGMA-SUMMARY).
2.2.4 Polygenic Risk Score (PRS)
For M SNPs in a set, PRS [37] combines single-SNP genotypes gi (i = 1, . . . ,M) into
a single regression predictor using single-SNP effect sizes (log(Odds Ratio (OR)i) = βi)
taken from a previous study as coefficients,
PRS =
M∑
i=1
βigi = β
T g. (2.3)
The PRS method implements a 2-stage approach, where independent discovery and test
sets are available. The effect sizes β are determined from the discovery set and a vector
of the number of risk alleles g is obtained from the test set. The underlying assumption
is that individual genotypes are available for the test set, but only summary data (effect
sizes β) for the discovery set are available.
The PRS method assumes that SNPs are independent and does not adjust for LD between
markers and thus requires LD pruning [72].
Once the PRSs have been generated, a p-value is calculated using logistic regression,
adjusting for population covariates. The logistic regression model can be seen in Equation
2.4.
log
(
pi
1− pi
)
= β0 + β1PRS + population covariates (2.4)
where pi is the risk of disease, β0 is the intercept and β1 is the effect size for the association
of the PRS with disease, often interpreted as the log(OR).
The strength of association between the PRS and disease is given by p PRS , which is the
p-value for the β1 coefficient in the logistic regression model.
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2.3 Software
2.3.1 R
R [73] is a free software which is widely used for statistical computing and graphics. R is
the software used for all analyses in this thesis, unless stated otherwise.
2.3.2 PLINK
PLINK [50][51] is an open source whole genome association toolset which is used for a
number of different genotype analyses throughout this thesis. In all cases, PLINK v1.9
was used.
2.3.3 Python
Python [74] is another programming language which is freely available. This is not specif-
ically aimed at statistical programming, but it does have this functionality. It was used
when parallel processing was required, since this language is easier to program parallel jobs
compared to R. The Anaconda distribution (https://www.anaconda.com) of Python was
used, since this optimises the processing of large datasets; this is a necessary requirement
in genetics studies.
2.3.4 MAGMA
The MAGMA [55] approach comes with a corresponding software written in C. This is
operated from the command line and enables the user to use either the MAGMA-Principal
Component Analysis (PCA) or MAGMA-SUMMARY approach, depending on the data.
MAGMA v1.06 was used throughout this thesis.
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3 MAGMA Gene-Based Analysis in AD Data
3.1 Introduction
Set-based analysis offers an attractive alternative to single SNP analyses, since the com-
bined effect of SNPs within the set may be captured. Single SNP analyses are often
underpowered due to the small effect sizes of individual SNPs, set-based analysis consid-
ers the combined effect of all SNPs within the set, which may have a larger combined
effect size and hence higher power to detect association than any individual SNP. In addi-
tion, gene-based analysis, a gene centred equivalent of set-based analysis, identifies genes
associated with disease rather than a single SNP as a proxy for the gene. In gene-based
analyses, genes are found to be fairly consistently associated with disease across different
populations. In contrast, different SNPs in a set in LD may be found to be associated with
a disease in different samples. Gene-based analyses also directly provide information for
functional analysis [44]. Set-based analysis can also be employed as a pathway analysis,
and applied to sets of SNPs defined by epigenomics for different tissue/cell types.
MAGMA v1.06 [55] is a recent approach which has emerged as a widely used and com-
putationally efficient set-based method. It is a regression based approach which accounts
for LD between SNPs when individual genotype data are available. The matrix of SNPs
within the set is decomposed into PCs, and PCs with small eigenvalues are removed. The
remaining PCs are then used as uncorrelated predictors in regression against the pheno-
type of interest and an F-test is used to determine the strength of the association between
the set and the phenotype, providing the MAGMA gene-based p-value. The MAGMA
program can be used on individual genotypes using the PCA method and also on sum-
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mary statistics using Brown’s method [52]. It often happens that summary statistics are
available from a large consortium, while in-house studies with individual genotypes have
smaller sample sizes. In such situations, the options for using MAGMA are either apply-
ing the PCA method to the in-house genotype dataset, or applying the summary statistic
approach to a meta-analysis of summary statistics of both datasets. It has been shown
as being more powerful than other gene-based softwares [55] such as PLINK [50][51] and
VEGAS [75].
3.1.1 Objectives
The aims of this chapter are to:
• Investigate whether gene-based analysis has more power than single SNP analyses
by combining the effect of all SNPs in the gene. MAGMA software is used to carry
out these gene-based analyses.
• Determine whether it is possible to find equivalent signals using a gene-based analysis
in smaller data compared to a single SNP analysis in larger data.
• Consider whether we can enhance our analysis using flanking regions around the
gene, since transcriptional regulatory elements are likely to be contained within
these intervals and there may be some merit in capturing the variation within these
regions [76].
• Demonstrate whether genes from the gene-based analysis are represented in con-
served regions. Conserved regions are genes which are evolutionary constrained, it
is expected that no enrichment will be observed in the AD GWAS data since AD is
a post-reproductive onset disorder [77].
• Extend this analysis to consider pathways, which have previously been found to be
associated with AD [23][24], and assess whether a similar association is shown using
MAGMA software compared to ALIGATOR [61].
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3.2 Materials and Methods
The MAGMA gene-based and pathway analysis was run in both the GERAD [19] and
IGAP stage 1 [20] data, discussed in Section 2.1. The GERAD data contains raw genotype
data, and as such, MAGMA using the PCA approach was used on this data (MAGMA-
PCA). The IGAP data consists of summary statistics only, MAGMA has the option to
carry out set-based analysis on summary statistics using Brown’s method [52] (MAGMA-
SUMMARY), and therefore, this approach was used in this data. MAGMA-SUMMARY
utilises a mean χ2 approach for the summary statistics. The mean χ2 statistic is calculated
for the SNPs within a gene and is compared to a known approximation of the sampling
distribution. The use of a known sampling distribution is what enables the method to be
computationally efficient.
Two separate analyses are considered on the IGAP data, the first using summary statistics
for the SNPs in GERAD only and the second using all stage 1 SNPs. Prior to the gene-
based analysis, SNP summary statistics for the whole IGAP data were adjusted for the
genomic control parameter, λ=1.087, as reported in [21].
3.2.1 Gene-Based Analysis
SNPs were assigned to genes using GENCODE (v19) gene models [78]. Only genes with
known gene status and those marked as protein coding were used. SNPs that belong to
multiple genes were assigned to all possible genes, where SNPs were within genes only.
SNPs were assigned to 14,607 unique genes.
Since only summary statistics were available in the IGAP data, the LD between SNPs
cannot be estimated directly from the data. Therefore, the LD was estimated using the
1000 Genomes Project (1000G) data [79]. The 1000G data is a haplotype reference set
which can be used by genetic researchers.
MAGMA provides a gene-based p-value for the annotated genes. The number of genes
which are gene-wide significant (p < 2.5 × 10−6) were determined. Of these significant
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genes, the number of genes which were not identified by SNP regions in the IGAP data
were determined. The SNP region is defined as ± 500kilobases (kb) of a single genome-
wide significant SNP (p < 5× 10−8).
The gene-based results using GERAD and IGAP considering only SNPs in GERAD data
are directly comparable since the analyses have the same number of SNPs, but IGAP
includes a larger number of subjects. The gene-based analysis from the IGAP stage
1 data includes a larger number of SNPs so is not directly comparable with the other
results. A gene-based analysis in the combined IGAP stage 1 and 2 data has previously
been published and therefore is not repeated here [21].
The MAGMA analysis was repeated where SNPs within a window of a gene were assigned
to the gene. A window was used which is 35kb upstream and 10kb downstream of the
gene, since transcriptional regulatory elements are likely to be contained within these
intervals and there may be merit in capturing the variation within these regions [76]. The
annotation and MAGMA analysis was repeated using genes with this window.
The final aim was to determine whether genes identified were in conserved regions. Both
for genes that are evolutionary constrained, i.e, that are less likely to harbour variants of
strong effect, probably due to functional importance, and for genes in Conserved Noncod-
ing Sequences (CNS) which are less prone to variation and thus thought to play a role in
the regulation of their neighbouring genes [80]. Genes which are subject to strong selec-
tion against various mutations were determined using the Exome Aggregation Consortium
(ExAC) which contains high quality exome sequence data for 60,706 subjects [81]. This
database contains a list of genes, so the number of genes from our analysis which reside
in this list were determined. The CNS were defined from [82], this data contains genomic
locations for these regions. Of the genes from the gene-based analysis, the number which
were in conserved regions and the number of significant genes using a gene-wide significant
p-value threshold of 2.5 × 10−6 [83] and a nominal threshold of 0.05 were determined. A
chi-squared test was then used to determine whether an association between gene signif-
icance and whether the genes are in conserved regions exists. This was then extended to
investigate SNPs; again a chi-squared test was used to assess whether an association exists
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between the number of SNPs in a conserved region and whether SNPs were significant,
using a genome-wide significant p-value threshold of 5× 10−8 and a nominal threshold of
0.05. A nominal threshold was used in the case where small numbers were observed in
conserved regions. When cell counts were small, a more robust Fisher’s exact test was
used instead of a chi-squared test. A chi-squared test assumes that genes are independent,
of course, this is not, in general, the case, and therefore results should be interpreted with
caution.
3.2.2 Pathway Analysis
The eight pathways discovered as being associated with AD [23][24] were used to determine
whether the same pathways are found to be associated with disease using the MAGMA
pathway approach.
The pathway analysis in MAGMA builds upon the gene-based analysis. It uses the p-values
for the association of a gene to AD and converts them to Z-values. The self-contained test
uses the Z-values for the genes in the pathway as the dependent variable in an intercept
only regression model. If the intercept is non-zero, this suggests the pathway is associated
with disease. The competitive test uses the Z-values for all genes as the dependent variable
in a regression model, whilst using a binary indicator, which is equal to one if the gene
is in the pathway and zero otherwise, as an independent variable. The pathway tests in
MAGMA correct for the effects of gene size and gene density [84].
3.3 Results
3.3.1 Gene-Based Analysis
3.3.1.1 GERAD Results
The results of the gene-based analyses are summarised in Figures 3.1-3.6.
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Figure 3.1 shows the results from the MAGMA-PCA gene-based analysis in the GERAD
data. The top box shows the total number of genes in the analysis (Ngenes=14,606), the
middle-left box shows the number of genes which are not gene-wide significant (Ngenes=14,603)
and the middle-right shows the number of genes which reach gene-wide significance (Ngenes=3).
The bottom boxes show which of these gene-wide significant genes are identified by
genome-wide significant SNPs. The bottom-left box shows the number of gene-wide sig-
nificant genes which are identified by genome-wide significant SNPs (Ngenes=3) and the
bottom-right box shows the number of gene-wide significant genes which are not identified
by genome-wide significant SNPs (Ngenes=0). All flow diagrams are organised in the same
way.
There are three genes which are gene-wide significant, however, these are all close to a
genome-wide significant SNP and are explained by the large effect of APOE. The results
for the MAGMA-PCA gene-based analysis in GERAD data with a window 35kb upstream
and 10kb downstream of the gene are shown in Figure 3.2. The use of the window enables
a larger number of gene-wide significant genes to be determined, therefore, suggesting
a benefit of using a flanking region. However, again, all these genes are explained by
genome-wide significant SNPs.
Number of Genes
in GERAD data:
Ngenes=14,606
Number of Genes
with p > 2.5 × 10−6:
Ngenes=14,603
Number of Genes
with p ≤ 2.5 ×
10−6: Ngenes=3
Number of Genes
Identified by SNP
regions in GERAD
data: Ngenes=3
Number of Genes
NOT Identi-
fied by SNP re-
gions in GERAD
data: Ngenes=0
Figure 3.1: MAGMA-PCA Analysis in GERAD Data
Since, no genes are found using the single SNP analysis in GERAD data, it is also true
that no additional genes are determined when comparing the GERAD gene-based analysis
to the single SNP analysis in the IGAP data (considering only GERAD SNPs). Therefore,
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from this analysis, it cannot be concluded that gene-based analyses in smaller data have
greater power than single SNP analyses in larger data based on AD genotype data with
N=13164.
Number of Genes
in GERAD data:
Ngenes=14,607
Number of Genes
with p > 2.5 × 10−6:
Ngenes=14,602
Number of Genes
with p ≤ 2.5 ×
10−6: Ngenes=5
Number of Genes
Identified by SNP
regions in GERAD
data: Ngenes=5
Number of Genes
NOT Identi-
fied by SNP re-
gions in GERAD
data: Ngenes=0
Figure 3.2: MAGMA-PCA Analysis in GERAD Data with a Gene Window
3.3.1.2 IGAP (GERAD SNPs only) Results
The results for the gene-based analysis in IGAP data considering only GERAD SNPs are
seen in Figures 3.3 and 3.4, the flow diagrams are organised as in Section 3.3.1.1. The
MAGMA-SUMMARY [55] gene-based analysis in IGAP data considering GERAD SNPs
only, using the 1000G data to estimate LD between SNPs, seen in Figure 3.3, produced
14,541 genes, 17 of which were significant at the gene-wide level (p < 2.5 × 10−6). All of
these 17 genes were identified by significant SNP regions in the IGAP data, where SNP
regions are defined as ±500kb of a single significant SNP (p < 5× 10−8).
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Figure 3.3: MAGMA-SUMMARY Analysis in IGAP Data, GERAD SNPs only
Again, the use of flanking regions results in a larger number of genes reaching gene-wide
significance, see Figure 3.4. Although, all of these 24 gene-wide significant SNPs were
identified by single SNP analyses.
The conclusions based on this analysis in IGAP using GERAD SNPs only are the same
as those based on GERAD data.
Number of Genes in
IGAP combined data:
Ngenes=14,561
Number of Genes
with p > 2.5 × 10−6:
Ngenes=14,534
Number of Genes
with p ≤ 2.5 ×
10−6: Ngenes=24
Number of Genes
Identified by SNP
regions in IGAP
data: Ngenes=24
Number of Genes
NOT Identified by
SNP regions in IGAP
data: Ngenes=0
Figure 3.4: MAGMA-SUMMARY Analysis in IGAP Data with a Gene Window, GERAD
SNPs only
3.3.1.3 IGAP Stage 1 (All SNPs) Results
The MAGMA-SUMMARY analysis was rerun using all SNPs in the stage 1 IGAP data.
The 1000G was used to estimate LD between SNPs. The results can be seen in Figure
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3.5. For this analysis, 28 gene-wide significant genes (p < 2.5 × 10−6) were determined,
3 of which were not identified by genome-wide significant SNP (p < 5 × 10−8) regions in
IGAP data. These genes were HBEGF, SLC39A13, and FLJ00418.
Number of Genes
in IGAP data:
Ngenes=14,563
Number of Genes
with p > 2.5 × 10−6:
Ngenes=14,535
Number of Genes
with p ≤ 2.5 ×
10−6: Ngenes=28
Number of Genes
Identified by SNP
regions in IGAP
data: Ngenes=25
Number of Genes
NOT Identified by
SNP regions in IGAP
data: Ngenes=3
HBEGF,
SLC39A13,
FLJ00418
Figure 3.5: MAGMA-SUMMARY Analysis in IGAP Stage 1 Data
The MAGMA-SUMMARY analysis with a gene window of 35kb upstream and 10kb down-
stream finds a larger number of gene-wide significant SNPs, 2 of which are not identified
by single SNP analyses; these genes are HBEGF and SLC39A13. The SLC39A13 gene
was previously determined by a gene-based analysis in the combined IGAP stage 1 and 2
data [21]. Additionally, the HBEGF gene was identified in [21] study using IGAP stage 1
data but this was not replicated in IGAP stage 2 data.
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Figure 3.6: MAGMA-SUMMARY Analysis in IGAP Stage 1 Data with a Gene Window
Two genes were determined in this analysis in the IGAP stage 1 data with all SNPs
using a gene window which have not previously been determined; HBEGF and FLJ00418.
Although, in the analysis by [21], the effect of these genes were cancelled out when the
stage 1 and 2 IGAP results were meta-analysed together.
From these gene-based analyses, it is seen that by combining the effect of SNPs in the
IGAP stage 1 data including all SNPs it is possible to attain more power than single
SNP analyses. In the smaller sets, GERAD and IGAP only including GERAD SNPs, no
improvement in power over single SNP analyses is observed by using gene-based analyses.
Since there was no power gained by gene-based analysis in GERAD data compared to
single SNP analysis for AD data, there is no evidence that the gene-based analysis would
increase power even in a smaller dataset.
All analyses show that using flanking regions for the gene-based analysis improves power,
since the number of gene-wide significant genes increases when the flanking region is used,
indicating the potential variation captured by using these regions.
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3.3.1.4 Conserved Regions
Loss of Function (LoF) genes from The Exome Aggregation Consortium (ExAC)
The GWAS data were interrogated for genes that are evolutionary constrained, i.e, that
are less likely to harbour variants of strong effect, probably due to functional importance.
The Exome Aggregation Consortium (ExAC) defines constrained genes using a pLI metric
[81]. In effect, Loss of Function (LoF) intolerant genes (pLI ≥ 0.9) harbour considerably
less protein-truncated variants than expected. Interestingly, the ExAC study shows that
the most highly constrained genes are enriched in GWAS loci. As LoF genes are expected
to carry essential functions, however, the common variants within these genes are not
expected to have a strong effect, as observed with the relatively low OR associated with
GWAS loci.
Of the 14,563 genes identified from the IGAP stage 1 data, Table 3.1 show the number
of genes in and out of LoF regions and which of these are above or below the p-value
threshold.
Table 3.1: Number of LoF Genes from the Exome Aggregation Consortium
p ≤ 0.05 p > 0.05
in LoF 251 2496
out LoF 1004 10812
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 7 2740
out LoF 29 11787
(ii) p ≤ 2.5× 10−6
No enrichment is observed for LoF intolerant genes in our AD GWAS dataset for either
the nominal p-value threshold or gene-wide p-value threshold (p=0.2986 and p=0.834
(Fisher’s exact) respectively). This is perhaps not surprising as AD is a post-reproductive
onset disorder and would therefore not be strongly selected against [77]. One possible
explanation is “antagonistic pleiotropy” in which genes that exert a beneficial effect (early
in life, up to the age of reproduction) become detrimental later in life [77][85]. The immune
response system is one such example [85].
Conserved Noncoding Sequences (CNS)
CNS are regions of the genome that are evolutionary constrained, less prone to variation
and thus thought to play a role in the regulation of their neighbouring genes [80].
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Table 3.2 shows the number of genes in the CNS at each p-value threshold, 0.05 and
2.5× 10−6 respectively. Since the cell counts are low for both tables, a Fisher’s exact test
is used rather than a chi-squared test.
Table 3.2: Number of Genes in Conserved Noncoding Sequences
p ≤ 0.05 p > 0.05
in LoF 3 24
out LoF 1252 13284
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 27
out LoF 36 14500
(ii) p ≤ 2.5× 10−6
Again, no enrichment of CNS in the IGAP dataset is observed for either the nominal
or gene-wide p-value threshold (p=0.5025 and p=1 respectively, both determined using
Fisher’s exact test).
3.3.2 Pathway Analysis
A pathway analysis using the MAGMA software was undertaken in both the GERAD
and IGAP data, the eight pathways analysed are those which were previously determined
as being associated with AD [23]. MAGMA produces both a self-contained (Psc) and a
competitive (Pc) test of association. A self-contained test determines whether the pathway
is associated with disease, whereas a competitive test determines whether the association
of the pathway is in addition to the baseline level of association [84]. Other gene-set
approaches, such as ALIGATOR define a competitive test somewhat differently, by as-
sessing whether a gene-set is more strongly associated compared to a permutation set of
pathways containing randomly selected genes. Pathways are classed as being associated
if the p-value is less than 1.56× 10−3; this was determined using a Bonferroni correction
(0.05÷ (8 pathways× 4)) [71].
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Table 3.3: MAGMA Pathway Results in GERAD data
Pathway
Number
of Genes
MAGMA-PCA
in GERAD
MAGMA-SUMMARY
in GERAD
Beta SE Pc Psc Beta SE Pc Psc
Immune
response
728 0.00447 0.0304 0.2497 0.0073 0.00143 0.0295 0.4119 0.6431
Regulation of
endocytosis
186 0.00666 0.0557 0.1431 0.1354 0.00383 0.0581 0.2782 0.7480
Cholesterol
transport
41 0.00311 0.124 0.3179 0.0473 0.00491 0.125 0.2283 0.0749
Hematopoietic
cell lineage
64 -0.0111 0.103 0.5646 0.1177 0.00636 0.1 0.1691 0.0627
Proteasome-
ubiquitin activity
269 0.00895 0.0449 0.0688 0.0471 0.00646 0.0452 0.1439 0.5256
Reactome
hemostasis
385 -0.0107 0.04 0.9516 0.1685 -0.00811 0.0397 0.8992 0.7828
Clathrin 381 -0.00842 0.0411 0.9006 0.5128 -0.00412 0.04 0.7409 0.8852
Protein
folding
146 -0.00851 0.0611 0.9192 0.8540 -0.00738 0.062 0.8844 0.9702
Table 3.3 shows the pathway analysis results in the GERAD data. The pathway results
using the gene p-values from both MAGMA-PCA and MAGMA-SUMMARY approaches
in the GERAD data are presented. It is seen that for both the self-contained and com-
petitive tests, no pathways have evidence of an association. As expected, the majority of
the competitive p-values are higher than the self-contained p-values, although this pattern
is less consistent when the MAGMA-SUMMARY approach was used. For some of the
pathways, the p-values vary between those using the MAGMA-PCA approach and the
MAGMA-SUMMARY approach.
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Table 3.4: MAGMA and ALIGATOR Pathway Results in IGAP stage 1 data
Pathway
Number
of Genes
Beta SE Pc Psc
ALIGATOR
p-value
Immune
response
722 0.0071 0.0326 0.1575 0.0133 0.00266
Regulation of
endocytosis
186 0.00527 0.0653 0.2353 0.1876 0.0002
Cholesterol
transport
41 0.0128 0.13 0.0320 0.0004 0.00024
Hematopoietic
cell lineage
64 0.00967 0.108 0.0870 0.0054 0.00007
Proteasome-
ubiquitin activity
269 -0.00565 0.0512 0.7938 0.0934 0.00929
Reactome
hemostasis
384 0.00187 0.0451 0.3978 0.2569 0.00785
Clathrin 378 0.0189 0.0459 0.0049 0.0368 0.00038
Protein
folding
146 0.00859 0.0694 0.1069 0.0202 0.00634
Table 3.4 shows the same analysis in the IGAP stage 1 data, with the additional ALIGA-
TOR [61] p-value [23][24] presented for comparison. IGAP gains power by having a larger
number of subjects, despite this, no pathways reach significance based on the competitive
test, but the cholesterol transport pathway now reaches significance for a self contained
association with AD. The p-values found from the ALIGATOR analysis are consistently
lower than those found using the MAGMA approach.
The results differ between MAGMA and ALIGATOR, this is likely due to the difference
between the two approaches. Table 3.5 shows the differences in the number of genes
included in each pathway between the MAGMA and ALIGATOR approaches; ALIGATOR
has a much smaller number of genes in each pathway compared to MAGMA. ALIGATOR
only selects genes which contain at least one SNP with a p-value below a set p-value
threshold and the number of significant genes in a GO category are compared to 5000
replicate gene lists [61]. MAGMA pathways will contain more noise due to the inclusion of
all SNPs in a pathway, including those which may have no evidence of an association with
disease. Due to the difference in approaches, the alternative hypothesis being tested differs
between ALIGATOR and MAGMA; ALIGATOR is testing whether the gene-set contains
a larger than expected number of significant genes, whereas MAGMA tests whether the
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combined effect of genes in a pathway is associated with disease.
Table 3.5: Number of Genes in Each Pathway from the MAGMA and ALIGATOR Ap-
proaches
Pathway
Number of Genes
in MAGMA
Number of Significant
Genes in ALIGATOR
Immune
response
722 5
Regulation of
endocytosis
186 14
Cholesterol
transport
41 8
Hematopoietic
cell lineage
64 11
Proteasome-
ubiquitin activity
269 5
Reactome
hemostasis
384 25
Clathrin 378 7
Protein
folding
146 12
3.3.3 Comparison of MAGMA Settings
A slight difference in pathway results is observed depending on whether MAGMA-PCA or
MAGMA-SUMMARY is used. Therefore, the difference between results from these two
different approaches is investigated.
The purpose of this section is to report findings showing issues with the power of set-based
analysis using summary statistics, and to provide a theoretical explanation for them. In
particular, the power of the set-based analysis using MAGMA on summary statistics
can appear to be substantially larger than the power of MAGMA-PCA or Multivariate
Regression on the exact same genotype data. The PCA approach was reported to give
a clear advantage in power [55] over other methods implemented in MAGMA, including
the mean of the χ2 statistic for the SNPs in a gene [52], and the top χ2 statistic among
the SNPs in a gene. In the latter approach, an adaptive permutation procedure is used
to obtain an empirical gene p-value. The authors emphasize “...that although MAGMA
can perform analysis of summary statistics, raw data analysis should always be preferred
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if possible” [55]. The findings reported below indicate that analysis of summary statistics
does not provide a reliable reference for comparisons of test power in the presence of
correlation.
A data set of 100 SNPs is simulated with MAF=0.2. Of 100 SNPs, ten were in LD with
r2 = 0.2 and 0.8, and the remaining SNPs were independent (see LD plot in Figure 3.7a
for r2 = 0.2). All SNPs were in HWE. The data were simulated for 10,000 cases and
10,000 controls (20,000 subjects in total). Simulations are repeated 500 times. To test the
type I error, effect sizes are fixed at OR=1 for all SNPs. For the power estimation, effect
sizes are defined as OR=1.1 for SNPs in the LD block.
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(a) Simple LD Structure
(b) Real LD Structure
Figure 3.7: LD Plots for Two Simulated Scenarios
MAGMA is run on these scenarios using different settings, in particular:
• (PCA) - using all available genotypes
MAGMA syntax: magma --bfile all.data --gene-annot gene.loc.annot
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• (SUMMARY) - using summary statistics generated by PLINK [50][51] with logistic
regression
MAGMA syntax: magma --bfile all.data --pval all.data.assoc.logistic N=20000
--gene-annot gene.loc.annot
• (PART) - using summary statistics of one part of the split data (5,000 cases and
5,000 controls), and deriving LD from the other part of the data.
MAGMA syntax: magma --bfile part2 --pval part1.assoc.logistic N=10000 --
gene-annot gene.loc.annot
Multivariate regression analysis (Mult Regression) was used on the exact same data using
all available genotypes with glm(CasCon.status ∼ SNP1+SNP2+...+SNP99+SNP100, fam-
ily=binomial) function in R-statistical software. The SNP-set association p-value was cal-
culated using the Log-Likelihood ratio test p= 1-pchisq(model$null.deviance-model$deviance,
df=model$df.null-model$df.residual)
Real LD structure was also investigated, simulating null associations and OR=1.1 in the
correlation block (for LD structure see Figure 3.7b).
3.3.3.1 Type I error
The type I error was around 5% at 0.05 significance level for all settings: (0.051, 0.051,
0.067, 0.051) when r2 = 0.2 between 10 SNPs in a block, and (0.043, 0.045, 0.036, 0.043)
when r2 = 0.8 between 10 SNPs in a block, for (PCA), (SUMMARY), (PART) and (Mult
Regression) settings, respectively. The correspondence between p-values under the null
hypothesis for all SNPs was quite good (see Figures 3.8a, 3.8b). Reassuringly, the highest
correlations between −log10(p-values) (0.96 and 0.91, for r2 in the LD block 0.2 and
0.8, respectively) were observed for PCA and Multiple regression settings. The weakest
correlation (0.4, 0.3) was between −log10(p-values) generated by (PCA/Mult regression)
and (PART) settings. This makes sense as in the (PART) setting only half of the data was
used to estimate SNP p-values and the other half was used to determine LD between SNPs.
The correlation between (PCA) and summary statistic based settings (SUMMARY) was
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0.902 and 0.574, for r2 in the LD block 0.2 and 0.8, respectively.
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(a) Simple LD Structure
(b) Real LD Structure
Figure 3.8: Scatter plots of −log10(p-values) generated with (PCA), (SUMMARY),
(PART) and (Mult Regression) settings for 500 simulated sets of 100 SNPs, of
which 10 SNPs were in LD. All SNPs association OR=1 (Null Hypothesis).
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3.3.3.2 Power
Figures 3.9a, 3.9b show scatterplots comparing −log10(p-values) of the different analyses,
with LD block r2 = 0.2 and r2 = 0.8, respectively. The power for the PCA setting of
MAGMA and Mult Regression in R, give similar power estimates with a slight advantage
of Mult Regression (compare power 0.119 vs 0.251 and 0.226 vs 0.242 in the right plots in
Figures 3.8a, 3.8b, respectively). This is expected as the PCA-setting of MAGMA projects
the SNP matrix for a gene onto its PCs, pruning away PCs with very small eigenvalues,
and then uses those PCs as predictors for the phenotype in the regression model.
However, Figures 3.9a, 3.9b show consistently higher power for summary stats based
analyses over PCA and Multiple regression settings. The weakest correlation (0.4, 0.3)
was between −log10(p-values) generated by (PCA/Mult regression) and (PART) settings.
Note that in the (PART) setting only half of the data were used to estimate SNP p-values
and the other half were used to determine LD between SNPs. The correlation between
(PCA) and summary statistics based settings (SUMMARY) was 0.902 and 0.574, for r2
in the LD block 0.2 and 0.8, respectively. These findings show that even when the type
I error rate remains correct, the p-value for an individual sample found from summary
statistics can differ widely from that found using PCA or Mult Regression in the presence
of LD.
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(a) Simple LD Structure
(b) Real LD Structure
Figure 3.9: Scatter plots of −log10(p-values) generated with (PCA), (SUMMARY),
(PART) and (Mult Regression) settings for 500 simulated sets of 100 SNPs,
of which 10 SNPs were in LD. SNPs association ORs=1.1 for SNPs in the LD
block, OR=1 otherwise.
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These simulated scenarios have a very simple LD structure and effect sizes as compared
to real data, and may overemphasise the type I and II errors. Therefore, a real LD struc-
ture was also considered, simulating OR=1.1 in the correlation block (for LD structure
see Figure 3.7b). Similar patterns of discrepancies were observed between the p-values
generated by (PCA) and (SUMMARY) settings of MAGMA (see Figure 3.10).
Figure 3.10: Comparison of MAGMA Settings in Real Data (Simulation of 115 SNPs from
Real Data, with a Proportion of Phenotypes Permuted to Maintain Effect
Sizes, Test and Discovery Set N=13,164.) Varying the Position of the Asso-
ciated SNP.
Test power calculated for Brown’s method (MAGMA-SUMMARY) may overestimate or
underestimate the actual joint power of the tests, as defined in terms of the overlap of the
sampling distributions under the alternate and null hypotheses, depending on the rela-
tionship between the mean vector of the alternate hypothesis and the correlation matrix.
A situation where the effects are roughly aligned with the correlation, as is commonly the
case in genetic data, will lead to an overestimation of the actual test power, which would
be found correctly from multivariate regression or Hotelling’s T 2 test. This is shown in
Figure 3.11 where the isotropic statistic given by Brown’s method (circle) is compared
to the correct ellipsoidal distribution given by correlated test statistics. Region A in the
figure shows points which would be misclassified as not associated with disease and region
B shows those which would be classed as associated with disease when in fact they are
not.
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Figure 3.11: Comparison of classification by isotropic combined statistic (circle) with clas-
sification according to ellipsoidal distribution of correlated test statistics (el-
lipse). corr = cos φ. Data points in regions A will be misclassified as negative,
data points in regions B as positive when the isotropic statistic is used.
In practice, there might be a situation when only summary data are available. In this
case it is sensible to prune SNPs for LD before using MAGMA-SUMMARY on summary
statistics. MAGMA authors recommend using MAGMA-PCA on individual genotype data
where available rather than summary statistic data. When individual genotype data is
available, there is no need to LD prune the data when using MAGMA-PCA.
There is no consensus in the field as to whether the inflation seen using a summary statistic
approach (such as MAGMA-SUMMARY or Brown’s method) in the presense of strong LD
gives an advantage in that it is possible to identify significant sets or whether this is a
power inflation, as type I error is well controlled using this approach. Brown’s method
is useful when only summary statistics are available and it may be possible to find a
larger number of significant sets in the presence of strong LD. It is a personal opinion
that raw genotypes should always be preferable, where available. Although, it is matter
of preference and therefore for each researcher to decide which method they prefer.
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3.4 Discussion
The first aim of this chapter was to investigate whether gene-based analysis has more
power than single SNP analyses by combining the effect of all SNPs in the gene. It
was shown in the IGAP stage 1 data including all SNPs, that additional genes may be
determined using a gene-based analysis compared to a single SNP analysis. Two genes
were identified which have not been found to be previously associated with AD, HBEGF
and FLJ00418, however, these genes were not found in a previous gene-based analysis
which meta-analysed stage 1 and 2 of IGAP [21] suggesting a spurious association of some
SNPs, which correctly did not pass the genome-wide significance threshold in IGAP stage
2 data.
It was also determined whether it is possible to find equivalent signals using a gene-based
analysis in smaller data compared to a single SNP analysis in larger data. In the data used
here, the gene-based analysis in GERAD was not powerful enough to find more associated
genes than a single SNP analysis in the larger IGAP set.
It was considered whether the analysis could be enhanced by using flanking regions around
the gene, since transcriptional regulatory elements are likely to be contained within these
intervals and there may be some merit in capturing the variation within these regions
[76]. In all analyses considered, the use of a flanking region; 35kb upstream and 10kb
downstream, always resulted in a larger number of gene-wide significant genes being found.
It was demonstrated that genes from the gene-based analysis are not represented in con-
served regions. There was no enrichment observed for LoF intolerant genes or CNS. As
suggested, this is not surprising as AD is a post-reproductive onset disorder and would
therefore not be strongly selected against [77]. One possible explanation is “antagonis-
tic pleiotropy” in which genes that exert a beneficial effect become detrimental later in
life [77][85]. The immune response system is an example of this [85] and was a pathway
previously found to be associated with AD [23][24].
This analysis was extended to consider eight pathways which have previously been found to
be associated with AD [23][24], and it was assessed whether a similar association is shown
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using MAGMA software compared to ALIGATOR [61]. There is little association for the
eight pathways shown in the GERAD data only, and only the cholesterol transport pathway
is significant in the IGAP stage 1 data based on a self-contained test. A larger number
of pathways reach significance in the self-contained test of association, but this does not
withstand the correction for the baseline level of association. The MAGMA pathway
analysis results showed a weaker association for all pathways compared to ALIGATOR
results. For the pathway analysis in the GERAD data, it was seen that the pathway
results vary slightly depending on whether the MAGMA-PCA or MAGMA-SUMMARY
approach was used for the gene-based analysis. This is unexpected, since both approaches
were applied to the same data.
The differences between the MAGMA-PCA and MAGMA-SUMMARY approaches were
compared to each other and to multiple regression using simulated data, both with a
simple constructed and real LD structure. In all examples, the type I error is similar
for all methods, however, when the associated SNPs reside in the LD block, the power
is often higher when using the MAGMA-SUMMARY method compared to the MAGMA-
PCA method. This seems strange, since one would expect the raw data to always be the
optimal data to use, in fact, the MAGMA authors recommend using the MAGMA-PCA
approach where possible. Of course, it may be the case that only summary statistic data
are available (i.e. IGAP summary statistics), in which case, it may be sensible to LD
prune the data prior to using MAGMA-SUMMARY to avoid potentially spurious results.
Although it has been shown that it is possible to increase power over single SNP analyses
by using a gene-based approach, the power increase is minimal and has not determined
any novel genes associated with AD. It would be interesting to consider other approaches
to gene-based analyses, which may further increase power.
50
4 Polygenic Risk Score Set-Based Approach
4.1 Introduction
Polygenic Risk Scores (PRSs) are now widely used for a variety of purposes in assess-
ing the genetic liability to disorders or more general phenotypes. These include sample
stratification, risk prediction, and the detection of relationships between different subphe-
notypes (see e.g. [86], [38], and [87], respectively). The PRS method can also be adapted
to partition the polygenic risk based on meaningful SNP sets, such as genes or biological
pathways, and to determine whether a set of SNPs, weighted with their individual genetic
risk effects, is associated at the whole-genome or set-specific level. In contrast to set anal-
ysis which aims to analyse the joint association of SNPs with a single phenotype, PRS
aims to assess the genetic liability to some phenotype on the basis of the polygenic risk
for the same or a different phenotype estimated from independent data.
As discussed in Chapter 3, set-based analysis is an attractive alternative to single SNP
analyses since the combined effect of SNPs within a set may be captured. Single SNP
analyses are often underpowered due to the small effect sizes of individual SNPs. Set-
based analysis considers the combined effect of all SNPs within the set, which would
be expected to have a larger effect size and thus be easier to detect. The results in
Chapter 3 did not show very large power increases between set-based analysis and single
SNP analyses, therefore, this chapter aims to further increase the power of the set-based
analysis.
PRS analysis can be considered as set-based analysis when a set includes all SNPs in the
whole genome. PRSs provide a method for combining information from individual SNPs
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into a single measure of risk allele burden. In their most widely used form, PRSs have
been applied to genome-wide SNP data where they can capture a useful fraction of genetic
liability to polygenic traits. PRSs can also be used as genome-wide predictors of affected
status [35][37][38]. It seems reasonable that the basic principles of polygenic score anal-
ysis can also be applied to individual genes, or to gene-set analyses. The motivation for
doing so is somewhat different than PRS analyses of genome-wide data; which is to detect
associations with potentially biologically informative features rather than predict case-
control status or trait liability captured. As for genome-wide analyses, genes or gene-set
PRS could be used to predict affected status, or to estimate the gene-specific or pathway-
specific SNP liability captured by GWAS. However, for polygenic disorders where risk is
dispersed across hundreds of genes and multiple gene-sets, self-evidently, gene-specific or
pathway-specific SNP liability to a phenotype will be lower than the liability captured by
genome-wide data, and accordingly, such tests will afford less case-control discriminatory
power. However, if the disease is homogeneous and is caused by different biological pro-
cesses, then the biologically relevant pathway may potentially predict a subphenotype of
disease better than the whole genome PRS. Risk scores for each individual per set can be
used to stratify individuals for follow-up studies and prioritise genes for further functional
studies.
Other set-based methods, discussed in Section 1.3.3, have advantages and limitations,
however, these methods do not incorporate the effect sizes from external data whilst
maintaining a self-contained test of association in the individual genotype data. Set-based
methods using individual SNP p-values are also able to improve power by incorporating
external data available from previous studies using meta-analysis, although evidence of an
association in this case could result solely from the external data.
The application of PRSs to a set-based framework which informs the analysis with pre-
viously reported effect sizes of a SNPs association to disease is suggested. The PRS is
calculated per person per set, and the overall set effect is computed using logistic regres-
sion.
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4.1.1 Objectives
The aims of this chapter are to:
• Propose the use of PRS as a set-based approach.
• Evaluate the PRSset−based method in simulated data, both with constructed and real
LD structure.
• Compare the type I error and power for the PRSset−based method to other set-based
approaches, namely; MAGMA[55], Fisher’s method [45] for combining p-values and
Simes’ method [46] which finds the smallest adjusted p-value.
4.2 Materials and Methods
4.2.1 Polygenic Risk Scores
In order to apply the use of PRSs [37] for set-based analysis, PRSs were calculated for
each set of SNPs and each individual using the SNP effect size (β = loge(OR)) from a
discovery dataset and the number of risk alleles from an independent test dataset.
PRS is a weighted score, where the number of risk alleles an individual has for a SNP
is multiplied by the SNP effect size from an external discovery set, and this is summed
across all SNPs in the set, see Section 2.2.4 for more details. This approach assumes
independence between the SNPs included in the score.
For all analyses below, missing genotypes in real data were processed by estimating the
missing genotypes using MAF. The SNP genotype was estimated as 2× MAF, this is the
same approach used in the PLINK software [50].
Once the PRSs have been generated, a set-based p-value is calculated using logistic re-
gression, adjusting for population covariates. The logistic regression model can be seen in
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Equation 4.1.
log
(
pi
1− pi
)
= β0 + β1PRS + population covariates (4.1)
where pi is the risk of disease, β0 is the intercept and β1 is the effect size for the associ-
ation of PRS with disease, often interpreted as the log(OR). Similarly, for a continuous
phenotype, linear regression can be used to determine the set-based p-value.
The strength of association between the set-based PRS and disease is given by p PRS ,
which is the p-value for the β1 coefficient in the logistic regression model.
The application of PRSs as a set-based method was compared to MAGMA [55] gene
analysis, Fisher’s method [45][53] of combining p-values and Sime’s set-based method [46].
4.2.2 MAGMA
MAGMA [55] is a regression based approach (see Chapter 3) which fully accounts for LD
between SNPs, using the PCs of the SNP correlation matrix, see Section 2.2.3 for further
details. This MAGMA-PCA method is implemented in both the test set only and the
discovery and test set combined, since this utilises all data which is used to calculate the
PRS, although this method requires the raw genotypes for both datasets.
MAGMA also has the functionality to calculate set-based p-values using summary statis-
tics (MAGMA-SUMMARY). In order to allow for the fairest comparison between this and
the PRS method, by utilising all available data, the discovery set summary statistics are
used for the gene-based analysis and the test set is used to estimate LD between SNPs
and also on the summary statistics for the combined test and discovery sets.
4.2.3 Fisher’s Method
Fisher’s method [45][53] is a method of combining the p-values of SNPs within a set to
determine the evidence against a common null hypothesis [70]. It obtains an overall p-value
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for each set from a group of p-values which are independent tests of the same hypothesis,
see Section 2.2.1 for the equation to compute Fisher’s method.
Since this method is calculated in the test set summary statistics only, no information re-
garding the direction of the effect of associated SNPs is utilised, however, the PRSset−based
method is able to use this information. Therefore, to allow for a fairer comparison, a one-
sided p-value is calculated for SNPs associated with disease (pone-sided =
ptwo-sided
2 ). These
adjusted p-values are then used to calculate Fisher’s set-based p-value.
4.2.4 Simes’ Method
Simes’ [46], like Fisher’s, is a set-based method accounting for the number of SNPs within
the set, however, it also attempts to correct for LD between SNPs in the set. The null
hypothesis of this method is that no SNP within the set is associated with disease, and the
alternative hypothesis is that at least one SNP within the set is associated with disease
[44]. The Simes’ set-based p-value is calculated using Equation 2.2. Simes removes the
issue of LD by considering whether at least one SNP in the set is associated with disease,
rather than combining the effect of all SNPs. Details of Simes’ method are presented in
Section 2.2.2.
When compared to the PRS approach, Simes is also informed by the discovery set by
using a one-sided p-value for those SNPs which are associated with disease to ensure this
method utilises all data available to the PRS method.
4.2.5 Power Comparison Between Methods
Genotype data for both the test and discovery sets were simulated in order to compare
the power between a number of set-based methods. A number of different scenarios were
simulated;
• 100 SNPs: 100 independent SNPs, a percentage of which are associated with dis-
ease.
55
• Simple LD Block: 10 SNPs in LD with i) r2 = 0.2 and ii) r2 = 0.8 which are
associated with disease, OR=1.1, and 90 independent unassociated SNPs, see Figure
4.1 for LD structure.
• Complex LD: 4 LD Blocks of 10 SNPs each, and 60 independent unassociated
SNPs. Block 1 has pairwise r2 = 0.2, Block 2 has pairwise r2 = 0.4, Block 3 has
pairwise r2 = 0.6, and Block 4 has pairwise r2 = 0.8, all 40 SNPs in LD with OR ∼
N(1.02, 0.36) (OR from a Normal Distribution with mean 1.02 and variance 0.36),
see Figure 4.2 for LD plot. The mean and variance for the sampled effect sizes are
calculated from all SNPs in the IGAP data [20].
• Discovery and Test with Different LD Structure: 10 SNPs in LD with OR∼
N(1.02, 0.36) and 90 independent, unassociated SNPs where test set LD is moderate
(r2 = 0.6) and discovery set LD is high (r2 = 0.8), see Figure 4.3 for LD plot.
• Effect Sizes of Varying Direction: It is possible that for certain MAFs, SNPs
in LD have effects in opposite directions [88]. 10 SNPs with varying LD with ORs
with randomly varying direction and 90 independent unassociated SNPs, LD plot
shown in Figure 4.4.
• Real Data Simulations: 129 SNPs from real AD data, with case control status
permuted, while maintaining effect sizes. The real LD structure is shown in Figure
4.5.
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(a) r2 = 0.2
(b) r2 = 0.8
Figure 4.1: LD Plot for 100 SNPs in Simple LD Simulations
Figure 4.2: LD Plot for 100 SNPs in Complex LD Simulations
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(a) Test Set r2 = 0.6
(b) Discovery Set r2 = 0.8
Figure 4.3: LD Plot for 100 SNPs in Discovery and Test with Different LD Structure
Simulations
Figure 4.4: LD Plot for 100 SNPs with Varying Effect Sizes Simulation
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Figure 4.5: LD Plot for Real LD Structure
A total of 1,000 simulations were used for each scenario. The power to detect the asso-
ciation between the set and disease is calculated as the proportion of p-values from the
1,000 simulations which were below a p-value threshold; the p-value thresholds used were
p=0.05, 0.01 and 0.001. The power of the PRSset−based method was compared to the
power of MAGMA-PCA (calculated in both the test set only and the combined discovery
and test set), MAGMA-SUMMARY in the discovery set with LD estimated from the test
set, MAGMA-SUMMARY in test and discovery data combined, and Simes’ and Fisher’s
methods calculated in the test set only.
In all cases, the sample size of the discovery dataset was varied, in order to determine the
influence of the discovery set sample size on the PRSset−based method. Simulations were
run with N=10,000, 30,000 and 50,000 for the discovery set. The test dataset contained
10,000 or 30,000 subjects. In both the discovery and test datasets, 30% of the sample size
were cases. The case/control ratio was defined to have fewer cases than controls since this
is usual in real data, i.e. in AD data (17,008 cases, 37,154 controls) [20] and in SZ data
(36,989 cases, 113,075 controls) [35].
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4.3 Results
4.3.1 Type I error
Initial simulations were used to determine the type I error for all set-based methods in
all possible scenarios to ensure that the methods are comparable in terms of power. The
expected type I error for a p-value threshold of 0.05 being approximately 5%, the type I
error is deemed as reasonable if the nominal value falls within the 95% Confidence Interval
(CI). The PRS set-based method is shown by a blue line, Fisher’s method is displayed as
a red line, Simes method is shown as a green line, MAGMA-PCA is displayed as a purple
line, the solid purple line is in the combined test and discovery data and the dashed purple
line is in the test set only, MAGMA-SUMMARY is shown as an orange line, again the
solid orange line is in the combined test and discovery data and the dashed orange line is
in the discovery data only, using the test data to estimate LD.
4.3.1.1 100 SNP Simulation
The first type I error simulation considers the case where 100 independent SNPs belong to
the set. The results for this simulation are seen in Figure 4.6. It can be seen that the CIs
for all methods contains 0.05. Therefore, all methods are comparable in terms of power.
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(b) Discovery set N=50,000
Figure 4.6: Type I Error Comparison of Set-Based Methods; Simulation of 100 inde-
pendent SNPs where none are associated with disease with OR=1 and Test
N=10,000. Note: y-axis scale is not between 0 and 1
4.3.1.2 Simple LD Block
The second type I error scenario represents an LD block. 100 SNPs were simulated which
were not associated with disease, 10 SNPs are in LD and 90 SNPs are independent, where
r2 = 0.2 or r2 = 0.8. Results can be seen in Figure 4.7. As expected, it is seen that
the type I error is largely inflated for Fisher’s method, this is due to the assumption of
independence between SNPs. It is interesting that when LD between SNPs is r2 = 0.2,
this inflation is still seen. This LD strength was selected as it is often the threshold
used for LD pruning, suggesting that Fisher’s will be inflated, even after LD pruning the
data prior to analysis. The inflation for Fisher’s method increases with increasing LD
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between SNPs. Type I error is elevated for the combined MAGMA-PCA method when
the discovery sample size is 50,000 and r2 = 0.2. The power estimates for Fisher’s method
will not be comparable to other methods due to this inflation, although, all other methods
will be comparable to one another.
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Figure 4.7: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD and 90 independent SNPs. Figures 4.7a, 4.7b and 4.7c have r2 = 0.2,
and Figures 4.7d, 4.7e and 4.7f have r2 = 0.8. Figures 4.7a and 4.7d have a
discovery and test sample size of 10,000, Figures 4.7b and 4.7e have a discovery
set N=50,000 and test set N=10,000 and Figures 4.7c and 4.7f have discovery
and test sets with N=30,000. Note: y-axis scale is not between 0 and 1
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4.3.1.3 Complex LD Structure
The next scenario represents a complex LD structure. There are a total of 100 SNPs; 10
SNPs in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6
and 10 SNPs in LD with r2 = 0.8, and 60 independent SNPs. The type I error graph is
seen in Figure 4.8. The type I error is clearly highly inflated for Fisher’s method, so this
is not comparable with other methods.
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Figure 4.8: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6,
10 SNPs in LD with r2 = 0.8 and 60 independent, unassociated SNPs. Note:
y-axis scale is not between 0 and 1.
4.3.1.4 Different LD structure of Discovery and Test Datasets
This next scenario is to represent discovery and test sets which come from differing pop-
ulations. Therefore, the LD structure differs between the discovery set (r2 = 0.8) and the
test set (r2 = 0.6). Type I error can be seen in Figure 4.9. Here, Fisher’s method shows
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the largest inflation, and MAGMA-SUMMARY approach also shows some inflation when
the method is used in the discovery data using the test set to estimate LD. This is likely
due to the MAGMA-SUMMARY set adjusting the discovery data with LD estimates from
the test set (which has lower LD) and therefore, the correction is not large enough.
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Figure 4.9: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with OR∼ N(1, 0.22) and 90 independent, unassociated SNPs where Test LD
is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8). Note: y-axis scale
is not between 0 and 1.
4.3.1.5 Effect Sizes with Varying Direction
This situation considers where effect sizes are not necessarily in the same direction due
to varying MAF [88]. Set-based methods which only use p-values are unable to take the
direction of the SNP effect into account. Therefore, the 10 SNPs which are in LD have
an association which randomly varies in direction. The type I error for this simulation is
seen in Figure 4.10. Again, it is clear that Fisher’s method has inflated type I error in this
case.
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Figure 4.10: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs with
Varying LD with ORs with Randomly Varying Direction and 90 independent,
unassociated SNPs. Note: y-axis scale is not between 0 and 1
4.3.1.6 Real Data Simulation
The final scenario uses real data to assess a true LD structure. 129 SNPs are taken from
real AD GERAD data, and the case-control status is permuted in order to remove the
effect size of any SNPs. The LD structure of these 129 SNPs is seen in Figure 4.5. These
129 SNPs are an area of strong LD (chr1, 50,002,165:52,034,812), full details of these 129
SNPs can be seen in Supplementary Table 11.1. The type I error is seen in Figure 4.11. It
is clear that Fisher’s method has largely inflated type I error, and all other methods are
reasonable.
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Figure 4.11: Type I Error Comparison of Set-Based Methods; Simulation 129 SNPs from
Real Data, with Permuted Phenotypes to Remove Effect Sizes, N=13,164.
Note: y-axis scale is not between 0 and 1
4.3.2 Power Comparison
The power of the PRSset−based method with MAGMA-PCA in the combined set and in
the test set only, MAGMA-SUMMARY in the combined set, MAGMA-SUMMARY in the
discovery set, estimating LD from the test set, and Fisher and Simes methods in the test
set only, is compared using the same simulated scenarios as before, but where some SNPs
have an association with disease.
4.3.2.1 100 SNP Simulation
Figure 4.12 shows the simulation of 100 independent SNPs where 10 of these SNPs are
associated with disease with OR=1.1. All methods have relatively high power in this case,
since the effect of the 10 SNPs is greater than the effect of the noise of the remaining 90
SNPs. The PRSset−based method (solid blue line) has higher or equivalent power compared
to all other methods, MAGMA-PCA in the combined data (solid purple line) also has very
high power, since this is also informed by the discovery set. Simes (solid green line) has
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the lowest power compared to the other methods, this is likely because Simes corrects for
the number of SNPs in the set.
0.00
0.25
0.50
0.75
1.00
0.00 0.01 0.02 0.03 0.04 0.05
P-Value Threshold
P
ow
er
(a) Discovery set N=10,000
0.00
0.25
0.50
0.75
1.00
0.00 0.01 0.02 0.03 0.04 0.05
P-Value Threshold
P
ow
er
(b) Discovery set N=50,000
Figure 4.12: Power Comparison of Set-Based Methods; Simulation of 100 indepen-
dent SNPs where 10% are associated with disease with OR=1.1 and Test
N=10,000.
The next case, seen in Figure 4.13, considers when only 5% of all independent SNPs within
the set are associated with disease, with an OR=1.1. The set-based methods which make
use of the discovery set have higher power than those calculated in the test set only. The
PRSset−based method has equivalent power compared to other set-based methods when
the discovery set has N=50,000. The combined MAGMA-PCA method has higher power
than the PRSset−based method when the discovery sample size is 10,000. Simes has higher
power than Fisher’s (solid red line) method and MAGMA-SUMMARY method (dotted
purple line), this opposes the result seen previously. This is since the methods are testing
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different hypotheses, the alternative hypothesis for Simes is that at least one SNP within
the set is associated with disease, whereas Fisher’s alternative hypothesis is that the set
is associated with disease, therefore Simes will be unaffected by noise from SNPs not
associated with disease.
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Figure 4.13: Power Comparison of Set-Based Methods; Simulation of 100 independent
SNPs where 5% are associated with disease with OR=1.1 and Test N=10,000.
In the final case, shown in Figure 4.14, there are 100 independent SNPs but only one is
associated with disease. Here, most methods have much lower power, due to the noise of
the large number of unassociated SNPs. Simes has relatively good power, again, because
this method is testing whether at least one SNP is associated with disease, so is less affected
by noise. When the discovery set is larger (N=50,000) the MAGMA-PCA method in the
combined set has the highest power, this is likely because it utilises all available raw
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genotype data. MAGMA-SUMMARY also has good power in this case, likely because it
is using the discovery set summary statistics which are based on a larger set than the
methods computed in the test set.
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Figure 4.14: Power Comparison of Set-Based Methods; Simulation of 100 independent
SNPs where 1% are associated with disease with OR=1.1 and Test N=10,000.
4.3.2.2 Simple LD Block
Figure 4.15 shows the case where 10 SNPs were simulated in LD, with r2 = 0.2 and
OR=1.1, and 90 independent SNPs which have no association with disease. A relatively
low value of r2 = 0.2 was chosen since this is a commonly used threshold for LD pruning
in practice for genotype data. As the size of the discovery set increases, the power for
the PRSset−based method increases and is higher than all methods calculated in the test
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set only. Fisher’s method has quite high power, but this should be disregarded due to
the inflated type I error. MAGMA-SUMMARY in the combined test and discovery sets
has highest power in all cases; it is odd how much higher the power is compared to the
MAGMA-PCA approach in the same data. MAGMA-SUMMARY in the discovery set
only has particularly high power compared to other methods when the test set N=10,000
and the discovery set N=50,000, this is because this approach is computing set effects in
the discovery set, which has a larger sample size relative to the test set.
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Figure 4.15: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD and
90 independent SNPs. Figures 4.15a, 4.15b and 4.15c show Simple LD Struc-
ture Simulations where r2 = 0.2, and Figures 4.15d, 4.15e and 4.15f show
Simple LD Structure Simulation where r2 = 0.8. Figures 4.15a and 4.15d
have a discovery and test sample size of 10,000, Figures 4.15b and 4.15e have
a discovery set N=50,000 and test set N=10,000 and Figures 4.15c and 4.15f
have discovery and test sets with N=30,000.
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4.3.2.3 Complex LD Structure
The next scenario represents a complex LD structure. There are a total of 100 SNPs; 10
SNPs in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6
and 10 SNPs in LD with r2 = 0.8, and 60 independent SNPs. The 40 SNPs which are in
LD blocks are all associated with disease, with OR∼ N(1.02, 0.22), and the remaining 60
independent SNPs are unassociated with disease. The power graph is seen in Figure 4.16.
The power is high for all set-based methods, and it is therefore difficult to distinguish
between the approaches. When the test set is smaller (N=10,000) the MAGMA-PCA in
the test set only has the lowest power.
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Figure 4.16: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD with
r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6, 10
SNPs in LD with r2 = 0.8, all 40 SNPs in LD Blocks have OR∼ N(1.02, 0.36),
and 60 independent, unassociated SNPs.
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4.3.2.4 Different LD Structure of Discovery and Test Datasets
In practice it is unlikely that the discovery and test datasets will be obtained from identical
populations. Thus, simulations are undertaken to determine the influence on power for
each of the set-based methods. Again, 10 SNPs in LD which are associated with disease
and 90 independent unassociated SNPs are simulated. The 10 SNPs which are associated
with disease have an OR which comes from a Normal distribution with mean=1.1 and SD=
0.2, so the ORs for individual SNPs differ across populations. The LD in the discovery
set is high with r2 = 0.8 and is moderate in the test set with r2 = 0.6. The MAGMA-
PCA and MAGMA-SUMMARY methods in the combined test and discovery sets are not
presented here, since the combination would result in one set with intermediate LD which
would not be comparable.
These results are seen in Figure 4.17. The PRSset−based method has higher power compared
to MAGMA-PCA in the test set only and has higher power compared to Simes when the
test and discovery set have a sample size of 30,000. The MAGMA-SUMMARY method has
highest power but this is due to the inflated type I error. Fisher’s has equivalent power
to the MAGMA-SUMMARY method when the test and discovery set have N=30,000.
Simes is the method with the highest power which also has reasonable type I error. The
PRS method has an increase in power when the test set is larger (N=30,000 compared
to N=10,000), the test set is used to estimate LD and also adds power to the logistic
regression model which is why this is seen.
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Figure 4.17: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD with
OR∼ N(1.1, 0.22) and 90 independent, unassociated SNPs where Test LD is
moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8).
4.3.2.5 Effect Sizes with Varying Direction
Since real data have SNPs which have varying directions (both risk and protective SNPs),
the next simulation represents this case. As before, 10 SNPs are simulated which have
randomly varying effect sizes and have differing strengths of LD. The 10 SNPs in LD are
associated with disease. The results can be seen in Figure 4.18.
Clearly, the methods which only utilise the p-values have very high power. This is because
the direction of effect is not incorporated into the analysis, and therefore effects which
should cancel are being overemphasised. Both the PRSset−based method and MAGMA-
PCA method incorporate the direction of effect into the set-based analysis, of these two
methods, the PRSset−based method has higher power compared to the MAGMA-PCA
method in the test set only. The PRSset−based method has higher power than MAGMA-
PCA in the combined test and discovery sets, when the test sample size is 10,000.
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Figure 4.18: Power Comparison of Set-Based Methods; Simulation of 10 SNPs with Vary-
ing LD with ORs with Randomly Varying Direction and 90 independent,
unassociated SNPs.
4.3.2.6 Real Data Simulation
The final scenario is created from real data, in order to investigate simulations with a true
LD structure. 129 SNPs from the AD GERAD data were used. The 10 most associated
SNPs in both directions are used to maintain the effect size. A percentage of cases and
controls had their genotype maintained, and the remainder were permuted; this enabled
an effect size to remain while generating new datasets. The results are seen in Figure 4.19.
From the real data simulations, it is seen that the PRSset−based method has the highest
power of all the set-based methods when a true LD structure is simulated. The power for
both PRSset−based methods, MAGMA-PCA and MAGMA-SUMMARY in combined data
are much higher than other set-based methods.
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Figure 4.19: Power Comparison of Set-Based Methods; Simulation 129 SNPs from Real
Data, with Permuted Phenotypes to Maintain Effect Sizes, N=13,164.
4.4 Discussion
This chapter focuses on the use of PRS as a set-based approach. This produces a risk score
per person per set, and informs the set with additional discovery data whilst maintaining
a self-contained test in the test data.
The PRS method requires SNPs to be independent, and therefore, SNPs should be pruned
for LD. Although, this is the choice of the researcher. The simulations presented here with
LD between SNPs of r2 = 0.2 represents the ‘pruned’ case, since 0.2 is a regularly used r2
threshold used in pruning. The simulations presented with LD of r2 = 0.8 represent the
‘unpruned’ case. The type I error for the PRS method in both these cases is similar, but
the power is higher in the unpruned case. When considering the simulations with the real
LD structure, the type I error for the PRS method is slightly inflated.
The PRSset−based method has reasonable type I error in all simulations considered, al-
though it is well known that results can be inflated in the presence of LD [72]. The
difference here may be to do with the size of the set or the strength of LD. Therefore, it
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would still be advisable to LD prune before using this PRSset−based method.
The PRSset−based method has relatively good power compared to all other set-based meth-
ods investigated here. Most importantly, it improves power upon the MAGMA-PCA in
the test data only, so this method is an improvement over the MAGMA approach inves-
tigated in Chapter 3. Additionally, in the simulations with the real data LD structure,
the PRSset−based method has very high power. Therefore, it may be possible to determine
genes or pathways which are associated with AD when using real data. The PRSset−based
method has increasing power as the discovery set sample size increases, this is due to the
increased accuracy of effect size estimates in discovery set. This method has the potential
to discover data-driven pathways, it may be used for prioritisation of subjects for follow-up
studies (e.g. clinical trials) based upon single gene or pathway PRS, and for prioritising
genes for further functional studies (e.g. animal models).
The set-based methods all use slightly different data, and therefore, they are difficult to
compare. In a few cases the combined MAGMA-PCA method had higher power than
the PRSset−based method, however, this requires raw genotype data for both the discovery
and test set, which often will not be available. Fisher’s method is inappropriate in the
presense of LD since it assumes independence between SNPs and has shown very inflated
type I error in the presense of LD. Simes is an appropriate method in the presense of LD
between SNPs, since it considers only whether at least one SNP in the set is associated
with disease. Simes generally has less power since it corrects for False Discovery Rate
(FDR) (this is better than the degrees of freedom penalty in Fisher’s method) in the
presense of LD. The PRSset−based method has fewer false positive associations, since the
test set is informed by the discovery set, false positives are cancelled out whereas this does
not occur in Simes/Fisher’s methods.
The PRSset−based method should be used in LD pruned data as is standard practice when
using PRS, since inflated type I error was observed in the case of a real data LD structure
[72][89][90]. Data can be pruned for LD in two different ways; the first is to randomly
remove SNPs which are in LD above a particular threshold, and the second is intelligent
pruning, which retains the SNPs which are most strongly associated with disease (using the
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--clump option in PLINK). When a number of SNPs are all highly associated with disease,
it is likely that there will be a correlation between these SNPs due to this association,
rather than simply LD. It would therefore be beneficial to improve upon this method by
adjusting for LD between SNPs, without removing the association of SNPs, thus removing
the need to prune the data and increasing power by using a larger number of SNPs.
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5 PRS Approach: Gene-Based and Pathway
Analyses in AD Data
5.1 Introduction
Set-based analyses are a valuable alternative to single-SNP analyses, since the effects of all
SNPs in the gene are combined. This has the potential to improve the power of the analysis
since the overall effect of the set is larger than that of a single SNP. In addition, gene-based
analysis, a gene centred equivalent of set-based analysis, identifies genes associated with
disease rather than a single SNP as a proxy for the gene. In gene-based analyses, genes
are found to be fairly consistently associated with disease across different populations. In
contrast, different SNPs in a set in LD may be found to be associated with a disease in
different samples. Gene-based analyses also directly provide information for functional
analysis [44]. Set-based analysis can also be employed as a pathway analysis, and applied
to sets of SNPs defined by epigenomics for different tissue/cell types.
Gene-based analysis using Brown’s method [52] have been applied to the imputed IGAP
stage 1 and 2 data [21]. Brown’s method combines the p-values for SNPs in a gene whilst
adjusting for LD between SNPs. This analysis found additional genes associated with AD
compared to those from the single-SNP IGAP analysis [20].
A pathway analysis has also been previously published in the AD IGAP data. This used the
ALIGATOR approach [61]; this determines which genes contain at least one SNP below a
particular p-value threshold and compares these to a random gene set to determine whether
the gene set of interest is enriched in AD. Eight pathways were determined from this
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analysis; these were the immune response, regulation of endocytosis, cholesterol transport,
hematopoietic cell lineage, proteasome-ubiquitin activity, reactome hemostasis, clathrin
and protein folding pathways [23][24].
It is possible that the basic principles of polygenic score analysis can also be applied
to individual genes, or to gene-set analyses. The motivation for doing so is somewhat
different than PRS analyses of genome-wide data; rather than predict case-control status
or trait liability captured, the goal in applying the principles of PRS to genes and gene
sets is to detect association to these potentially biologically informative features. As for
genome-wide analyses, genes or gene-set PRS could be used to predict affected status,
or to estimate the gene-specific or pathway-specific SNP liability captured by GWAS.
However, for polygenic disorders where risk is dispersed across hundreds of genes and
multiple gene-sets, self-evidently, gene-specific or pathway-specific SNP liability will be
lower than the liability captured by genome-wide data, and accordingly, such tests will
afford less case-control discriminatory power. Risk scores for each individual per set can be
used to stratify individuals for follow-up studies and prioritise genes for further functional
studies.
The approach of using PRS as a set-based method has been shown to be more powerful
compared to MAGMA-PCA, Fisher and Simes methods in data with a real LD structure
in Chapter 4. The PRSset−based method is able to determine the association of a set with
disease whilst also producing a risk score per subject per set. By producing a risk score,
it is possible to find commonality between genes or pathways using a correlation.
Set-based analyses can be implemented in either directly genotyped or imputed data.
Imputed data has the main advantage that the number of SNPs can be vastly increased
with minimal costs. Therefore, the power of the analyses can be increased with the
additional SNPs. The issues with imputation are that it cannot be done with perfect
accuracy, so it is possible to introduce error into the analyses, the impact of this can be
reduced by quality checking the data and removing any SNPs which are imputed with too
low quality. Additionally, increasing the number of SNPs is a benefit in terms of power,
but may introduce bias as some set-based methods have inflated p-values simply due to
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the number of SNPs in the set.
5.1.1 Objectives
This Chapter focuses on using the PRSset−based approach in real AD data by aiming to:
• Perform a gene-based analysis using the PRSset−based approach in the GERAD geno-
type data.
• Compare PRSset−based real data gene-based results with MAGMA-PCA, MAGMA-
SUMMARY, Simes and Fisher’s methods.
• Perform gene-based analysis in the GERAD imputed data.
• Compare the gene-based results using genotyped and imputed data.
• Investigate whether the PRSset−based method is biased by the number of SNPs in
the gene and compare this to other set-based methods.
• Demonstrate whether genes from the gene-based analysis are represented in con-
served regions.
• Compute PRS pathway scores for the eight pathways previously found to be associ-
ated with AD [23][24] and determine whether the PRS pathways are also associated
with AD.
• Determine whether any correlation is observed between the different PRS pathways
to indicate genes in common and potential biological overlap between pathways.
5.2 Materials and Methods
The PRS set-based method was applied to the AD data discussed in Section 2.1. Two
independent datasets are required for the PRSset−based method, these are the test set
containing individual genotype data and discovery data containing summary statistic in-
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formation for each SNP. The set-based risk scores were produced for individuals in the
GERAD data, this is the test set. The IGAP data excluding GERAD subjects was con-
sidered as the discovery set, using the summary statistics to improve power.
Since it is widely acknowledged that data should be pruned for LD prior to a PRS analysis
[72]; correlation between SNPs was removed using intelligent pruning (--clump option in
PLINK [50]). All SNPs which have not yet been clumped (index SNPs) and have p-values
smaller than the set threshold were used to form clumps of all other SNPs within a 500kb
distance which are in LD with the index SNP based on an r2 threshold of 0.2 [50][51].
The p-value thresholds for both index SNPs and clumped SNPs were set to 1 to include
all possible markers in the gene.
60,510 SNPs from a total of 419,048 total SNPs were retained from this clumping procedure
in the genotyped data.
The HRC imputed GERAD data were additionally used for this analysis, again, these
data were clumped in the same way as the genotyped data, retaining 193,369 SNPs of
6,119,694 total SNPs.
5.2.1 Gene-Based Analysis
The application of PRSs as a gene-based method in AD data was investigated.
The clumped SNPs in GERAD (both genotyped and imputed data separately) were as-
signed to genes using GENCODE (v19) gene models [78]. Only genes with known gene
status and those marked as protein coding were used. SNPs which belong to multiple
genes were assigned to all genes.
A total of 62,179 SNPs were assigned to 11,909 unique genes for the genotype data, where
some SNPs are assigned to multiple genes. The HRC imputed data has 97,339 SNPs
assigned to 12,218 unique genes.
A PRS was generated for each of these genes, and the gene-based PRS was tested for it’s
association with AD using a logistic regression model, adjusting for population covariates
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such as age, sex, ethnicity and PCs to adjust for population stratification.
It was investigated whether the PRSset−based method was biased by the number of SNPs
in the gene using the correlation between the −log10(p-values) and the number of SNPs
in the gene.
Finally, it was assessed whether genes identified are enriched in conserved regions. This
was done both for genes which are evolutionary constrained and for genes in CNS which are
less prone to variation [80]. Of the genes from the gene-based analysis, the number which
were in conserved regions and the number of significant genes using a gene-wide significant
p-value threshold of 2.5×10−6 [83] and a nominal threshold of 0.05 were determined. A chi-
squared test was then used to determine whether an association between gene significance
and whether the genes are in conserved regions exists, if cell counts are small then a
Fisher’s exact test is used in place of a chi-squared test.
5.2.2 Pathway Analysis
A PRS was computed for the set of SNPs which belong to each of the eight pathways
determined as being associated with AD previously [23][24]. These pathways may aid in
the understanding of different forms of AD and may regulate the early stages of the disease
[91]. A self-contained test is determined by a logistic regression model with the pathway
risk score, and a competitive analysis uses a likelihood ratio test to determine the added
benefit of including the pathway risk score to a model including PRS across the whole
genome.
The GERAD genotype data is used for the pathway analysis, and is again informed using
summary statistics from IGAP data excluding the GERAD subjects.
Only SNPs with a p-value less than 0.5 in the IGAP study were used in the pathways.
Each pathway PRS was generated, and the self-contained association of the pathway PRS
with AD was found using a logistic regression model, adjusting for population covariates.
The association of each pathway with AD was assessed, and additionally, the pairwise
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correlation between all pathways was investigated. A Pearson’s correlation test between
every pairwise combination of pathway PRSs was produced (using cor.test() in R software).
It was expected that some correlation between pathways exists, since genes may belong
to more than one biological pathway.
5.3 Results
5.3.1 Gene-Based Analysis
The PRS, MAGMA-PCA, Fisher and Simes gene-based methods were used in AD data in
order to determine if any novel genes associated with AD could be found.
The results for the PRSgene−based method are seen in Table 5.1, the genes displayed are
those which have previously been found to be associated with AD[19][20][21]. No novel
genes were determined using the PRSgene−based method despite simulations showing the
increased power compared to other gene-based methods when a real LD structure was
simulated. This is likely due to the analysis being executed in clumped, genotyped data
only, whereas the reported results were obtained using imputed data and combining two
stages of IGAP [21]. Genes which have reached gene-wide significance replicate findings
from [21] which uses Brown’s method, the p-values from this analysis are also displayed
in Table 5.1.
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Table 5.1: PRS Gene-based Analysis in AD Genotype Data
PRS
Chr Gene No. of SNPs β SE P-value P-value from [21]
19 PVRL2 4 0.328 0.0303 2.9× 10−27 < ×10−300
19 TOMM40 1 0.313 0.0311 6.3× 10−24 NA
1 CR1 2 0.103 0.0293 4.4× 10−4 3.5× 10−7
2 BIN1 6 0.110 0.0300 2.7× 10−4 4.8× 10−6
6 CD2AP 4 0.059 0.0300 5.1× 10−2 8.0× 10−6
7 EPHA1 4 0.041 0.0301 1.7× 10−1 3.9× 10−7
8 CLU 2 0.133 0.0301 9.5× 10−6 1.2× 10−108
11 PICALM 4 0.048 0.0302 1.1× 10−1 1.2× 10−8
19 ABCA7 3 0.097 0.0297 1.2× 10−3 3.0× 10−7
8 PTK2B 5 0.061 0.0302 4.4× 10−2 1.3× 10−4
11 SORL1 8 0.105 0.0308 6.8× 10−4 6.7× 10−5
14 SLC24A4 15 0.034 0.0300 2.6× 10−1 1.0× 10−3
14 RIN3 22 0.061 0.0298 4.0× 10−2 5.6× 10−1
18 DSG2 3 -0.058 0.0299 5.3× 10−2 5.9× 10−1
2 INPP5D 15 0.071 0.0303 1.9× 10−2 NA
5 MEF2C 6 0.034 0.0300 2.5× 10−1 3.2× 10−2
7 NME8 7 -0.003 0.0300 9.3× 10−1 NA
7 ZCWPW1 2 0.066 0.0297 2.5× 10−2 8.3× 10−1
14 FERMT2 5 0.045 0.0294 1.3× 10−1 2.5× 10−3
20 CASS4 2 -0.014 0.0306 6.5× 10−1 4.2× 10−3
From Table 5.2, it is seen that results from Simes’, Fisher’s and MAGMA-PCA meth-
ods are clearly similar to those using the gene-based PRS method. Although the PRS
method seems to have equivalent or smaller p-values for the majority of genes compared
to MAGMA-PCA, Fisher and Simes. Previously published results may differ to these since
they used imputed data and considered SNPs which may be outside of the gene. Only
the PRS method provides the overall gene direction of effect, whereas the other methods
simply provide a measure for the strength of association.
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Table 5.2: Gene-based Analysis Comparison for PRS, MAGMA, Simes’ and Fisher’s Meth-
ods in AD Genotype Data
Chr Gene
No. of
SNPs
PRS
P-value
Simes’
P-value
Fisher’s
P-value
MAGMA-PCA
P-value
19 PVRL2 4 2.9× 10−27 2.1× 10−25 < 1.0× 10−16 4.8× 10−25
19 TOMM40 1 6.3× 10−24 6.4× 10−24 < 1.0× 10−16 3.3× 10−23
1 CR1 2 4.4× 10−4 1.8× 10−3 4.4× 10−4 2.7× 10−3
2 BIN1 6 2.7× 10−4 3.9× 10−3 2.2× 10−4 1.9× 10−3
6 CD2AP 4 5.1× 10−2 2.8× 10−1 2.0× 10−1 4.1× 10−1
7 EPHA1 4 1.7× 10−1 1.4× 10−1 3.4× 10−1 4.7× 10−4
8 CLU 2 9.5× 10−6 1.0× 10−5 2.0× 10−5 10.0× 10−6
11 PICALM 4 1.1× 10−1 8.0× 10−3 2.1× 10−3 2.5× 10−2
19 ABCA7 3 1.2× 10−3 1.7× 10−3 2.0× 10−3 5.7× 10−3
8 PTK2B 5 4.4× 10−2 9.6× 10−3 4.1× 10−2 9.2× 10−2
11 SORL1 8 6.8× 10−4 4.4× 10−2 1.5× 10−2 8.7× 10−2
14 SLC24A4 15 2.6× 10−1 3.9× 10−1 1.6× 10−1 1.8× 10−1
14 RIN3 22 4.0× 10−2 2.2× 10−1 1.2× 10−1 5.4× 10−1
18 DSG2 3 5.3× 10−2 1.1× 10−1 3.0× 10−1 1.6× 10−1
2 INPP5D 15 1.9× 10−2 1.9× 10−1 1.7× 10−3 3.9× 10−2
5 MEF2C 6 2.5× 10−1 2.8× 10−1 2.7× 10−1 2.3× 10−1
7 NME8 7 9.3× 10−1 9.1× 10−1 9.8× 10−1 9.5× 10−1
7 ZCWPW1 2 2.5× 10−2 3.7× 10−2 6.0× 10−3 1.4× 10−2
14 FERMT2 5 1.3× 10−1 5.5× 10−2 3.8× 10−2 2.4× 10−2
20 CASS4 2 6.5× 10−1 5.8× 10−1 5.7× 10−1 5.5× 10−1
Table 5.3 displays the gene-wide significant (p < 2.5 × 10−6) genes from the gene-based
PRS analysis in the imputed data. Three of the six genes are on chromosome 19 and
are therefore likely influenced by APOE and CLU has also previously been identified
as being associated with AD. Two additional genes on chromosomes 8 and 20, CSMD1
and MACROD2, respectively, have been found to be associated with AD from this PRS
gene-based analysis. In fact, CSMD1 has been implicated in AD, familial Parkinson’s
disease [92] and cognitive performance [93]. The MACROD2 gene has been implicated in
neurological disorders [94].
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Table 5.3: Gene-Wide Significant Genes from PRS Gene-based Analysis in AD Imputed
Data
PRS
Chr Gene No. of SNPs β SE P-value
8 CSMD1 579 0.191 0.0393 1.2× 10−6
8 CLU 1 1.540 0.3126 8.4× 10−7
19 BCL3 3 0.828 0.1445 1.0× 10−8
19 PVRL2 9 0.852 0.0699 3.4× 10−34
19 TOMM40 1 1.038 0.1076 5.4× 10−22
20 MACROD2 230 0.410 0.0801 3.0× 10−7
Figure 5.1 shows a plot of the −log10(p-values) for the PRS gene-based analysis using
genotype and imputed data. There are 10,243 genes in common between the gene-based
analysis in the genotype and imputed data. It is clear there is a difference between the
results from either type of data, particularly when considering the right graph in Figure
5.1, with 60% of genes having a smaller p-value from the imputed data compared to
the genotype data. There is a positive correlation between the −log10(p-values) for the
imputed and genotype data (r=0.48, p < 2.2 × 10−16), and this correlation is weakened
when the genes in Table 5.3 are removed (r=0.26, p < 2.2 × 10−16). This correlation
demonstates that there is a difference between the gene-based results from the imputed
and genotype data, since they are not perfectly correlated. This suggests that the gene-
based analysis using the imputed data is more powerful, since it attains smaller p-values
for a large number of genes, due to the inclusion of a larger number of SNPs.
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(b) Genes with −log10(p) ≤ 6
Figure 5.1: Plot of Gene-Based −log10(p-values) Using Genotype and Imputed GERAD
Data
The imputed data includes a larger number of SNPs and therefore, it is expected that the
number of SNPs in each gene is higher for the imputed data. A plot of this is shown in
Figure 5.2.
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Figure 5.2: Plot of Number of Gene SNPs in Genotype and Imputed GERAD Data
5.3.1.1 Correlation Between P-values and the Number of SNPs in a Gene
Bias caused by gene size is an issue which is insufficiently tackled by most available gene-
based methods [84][95]. This is because larger genes may harbour more significant SNPs
by chance, and therefore the correlation between the number of SNPs per gene and the
significance of a gene (−log10(p-value)) in AD data was determined. SNP p-values may be
inflated by population stratification and other confounders. This is okay when reporting
the association of a single SNP with disease, but when combining a number of SNPs, the
overall inflation can be substantial. The results can be seen in Table 5.4.
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Table 5.4: Correlation Between −log10(p-values) of Each Gene-Based Method and the
Number of SNPs in the Gene
Gene-based Method Correlation Coefficient P-value
PRS (clumped) -0.0054 0.555
PRS (unpruned) -0.0105 0.204
MAGMA 0.0255 0.0021
Simes 0.0336 0.0003
Fisher 0.2144 < 1.0× 10−16
Since there were a large number of genes with only 1 SNP (approximately 40%), the
correlations were recalculated excluding these genes to ensure that results are not driven
by these single SNP genes. Results are consistent when single SNP genes are excluded.
Clearly, the PRSgene−based method has no evidence of a correlation with the number of
SNPs in a gene, suggesting that results are not inflated by gene size. However, all other
methods show a correlation with the number of SNPs in the gene, the significant correlation
coefficients are positive, indicating that a stronger association is observed when the set
contains a larger number of SNPs, with there being very strong evidence of a correlation
for Fisher’s method.
The existence of a correlation between the gene size and the rate of false positives was
considered using simulated data, where Nsim=1,000. The correlation between the type I
error and the number of SNPs in the gene was determined for real data with permuted
phenotypes to remove the effect sizes. The results are seen in Table 5.5. It is seen that
there is no correlation between type I error and gene size for PRS and MAGMA-PCA
methods. Fisher’s method has a positive correlation, suggesting that increasing gene size
increases the rate of false positive results. Simes’ method shows an unusual result, it has
evidence of a negative correlation, suggesting that an increase in gene size reduces the
false positive rate. This is likely due to the fact that Simes’ corrects for the number of
SNPs in the gene.
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Table 5.5: Correlation Between Power (p ≤ 0.05) of Each Gene-Based Method and the
Number of SNPs in the Gene
Gene-based Method Correlation Coefficient P-value
PRS 0.4697 0.4247
MAGMA-PCA (Disc+Test Genotype) -0.1631 0.7932
MAGMA-PCA (Test Genotype) -0.2199 0.7223
Simes -0.9401 0.01742
Fisher 0.8734 0.05302
5.3.1.2 Conserved Regions
Loss of Function (LoF) genes from The Exome Aggregation Consortium (ExAC)
As discussed in Section 3.3.1.4, GWAS data was interrogated for genes that are evolution-
ary constrained, i.e, that are less likely to harbour variants of strong effect, probably due
to functional importance. It was assessed whether there was enrichment for either LoF
intolerant genes using the PRS gene-based results in both genotyped and imputed data.
Table 5.6 show the contingency tables at different p-value thresholds, 0.05 and 2.5× 10−6
respectively, for LoF genes based on the PRS gene-based results in genotype data. For
the 11,813 genes from the analysis, there is no evidence that the genes found here are
constrained for both the nominal and gene-wide p-value threshold (p=0.0419 and p=0.4894
respectively). The Fisher’s exact test is used for the gene-wide p-value threshold, since
the cell counts are small.
Table 5.6: Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data
p ≤ 0.05 p > 0.05
in LoF 112 2259
out LoF 550 8892
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 1 2370
out LoF 2 9440
(ii) p ≤ 2.5× 10−6
Since it is possible that some SNPs reside in multiple genes, it is not possible to assume that
genes are independent, and the results in Table 5.6 are not adjusted for this correlation.
Therefore, the analysis is repeated containing only non-overlapping genes, genes which
were within 250kb of another gene were removed, with the most strongly associated gene
retained. These results for the gene-based analysis in the genotype data are seen in Table
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5.7. For the 555 non-overlapping genes, there is no evidence of an enrichment for genes
in conserved regions at either the nominal or gene-wide p-value threshold (p=0.0937 and
p=1 respectively).
Table 5.7: Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data, No Overlapping Genes
p ≤ 0.05 p > 0.05
in LoF 43 64
out LoF 223 225
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 107
out LoF 1 447
(ii) p ≤ 2.5× 10−6
Similarly, the results for the 12,218 genes from the PRS gene-based analysis in imputed
data are seen in Table 5.8. There is some evidence (p=1.39×10−6) at the nominal p-value
threshold that the genes were in constrained regions, although there is no evidence (p=1)
of an enrichment of genes in conserved regions at a gene-wide p-value threshold.
Table 5.8: Number of LoF Genes from the Exome Aggregation Consortium, Imputed Data
p ≤ 0.05 p > 0.05
in LoF 387 2066
out LoF 1182 8583
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 1 2452
out LoF 5 9760
(ii) p ≤ 2.5× 10−6
Table 5.9 shows the analysis in the imputed data was repeated for non-overlapping genes.
Of the 519 genes remaining, there is no enrichment for genes in conserved regions at either
the nominal or gene-wide threshold level (p=1 and p=0.5766 respectively).
Table 5.9: Number of LoF Genes from the Exome Aggregation Consortium, Imputed Data,
No Overlapping Genes
p ≤ 0.05 p > 0.05
in LoF 91 41
out LoF 265 122
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 132
out LoF 4 383
(ii) p ≤ 2.5× 10−6
Conserved Noncoding Sequences (CNS)
The contingency tables showing whether the genes from the PRS gene-based analysis
reside in CNS are seen in Table 5.10 for both nominal and gene-wide p-value thresholds.
The cell counts are small for both tables and therefore a Fisher’s exact test was used
93
to determine whether there was an enrichment of genes in conserved noncoding regions.
There was no evidence of enrichment for either the nominal or gene-wide p-value threshold
(p=1 for both).
Table 5.10: Number of Genes in Conserved Noncoding Sequences, Genotype Data
p ≤ 0.05 p > 0.05
in LoF 1 25
out LoF 661 11126
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 26
out LoF 3 11784
(ii) p ≤ 2.5× 10−6
Since genes may be correlated, the analysis was repeated considering only non-overlapping
genes, results are shown in Table 5.11. Of the 555 non-overlapping genes, there is no
evidence of an enrichment of genes in CNS at the nominal or gene-wide p-value threshold
(p=0.2499 and p=1 respectively).
Table 5.11: Number of Genes in Conserved Noncoding Sequences, Genotype Data, No
Overlapping Genes
p ≤ 0.05 p > 0.05
in LoF 0 3
out LoF 266 286
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 3
out LoF 1 551
(ii) p ≤ 2.5× 10−6
The same analysis was carried out for the 12,218 genes from the PRS gene-based analysis
in the imputed data, the results are seen in Table 5.12. Again, a Fisher’s exact test is used
for both tables due to the small cell counts. No enrichment of genes in CNS is observed
for the gene-wide p-value threshold (p=1), although there is some evidence (p=0.0015) of
an enrichment at the nominal p-value threshold.
Table 5.12: Number of Genes in Conserved Noncoding Sequences, Imputed Data
p ≤ 0.05 p > 0.05
in LoF 9 16
out LoF 1560 10633
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 25
out LoF 6 12187
(ii) p ≤ 2.5× 10−6
For the 519 non-overlapping genes, there is also no enrichment of genes in CNS for either
the nominal or gene-wide p-value threshold (p=1 for both), see Table 5.13.
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Table 5.13: Number of Genes in Conserved Noncoding Sequences, Imputed Data, No Over-
lapping Genes
p ≤ 0.05 p > 0.05
in LoF 1 0
out LoF 355 163
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 1
out LoF 4 514
(ii) p ≤ 2.5× 10−6
There is no consistent enrichment of genes in conserved regions at the gene-wide sig-
nificance level. It is expected that no enrichment would be seen, since AD is a post-
reproductive disorder. Analyses considering non-overlapping genes are consistent, suggest-
ing that the analysis is not biased by correlation between genes, or that the correlation is
minimal.
5.3.2 Pathway Analysis
Eight pathways were found to be associated with AD using the ALIGATOR algorithm in
the IGAP data [23][24]; these pathways are immune response, regulation of endocytosis,
cholesterol transport, hematopoietic cell lineage, proteasome-ubiquitin activity, reactome
hemostasis, clathrin and protein folding. The most strongly associated pathway with AD
is the immune response pathway. The ALIGATOR algorithm [61] defines genes to be
significant if they contain a single SNP with a p-value less than a set threshold, these gene
sets are then compared to randomly generated gene sets, and as such, adjusts for gene
size.
The use of PRS as a set-based method has been shown to be more powerful than other set-
based methods, MAGMA-PCA, Fisher’s and Simes (see Chapter 4 for details). The PRS
approach can be applied to any set of SNPs, e.g. pathways. The PRS method provides
an effect size for the strength and direction of association for each pathway, and produces
a pathway risk score per person.
The PRS pathway scores were computed for the eight pathways previously found to be
associated with AD [23][24]. The results are seen in Table 5.14 for both self-contained
and competitive analyses. The self-contained test does not adjust for a baseline level of
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association, whereas the competitive analysis does, by including the whole genome PRS in
the model. The table also includes the p-values from the original ALIGATOR anaysis for
comparison [61]. A pathway is considered as significant if the p-value is below 1.56×10−3,
using a Bonferroni correction (0.05÷ (8×4)) [71]. It is seen that six of the eight pathways
are associated with AD in the self-contained test; these are immune response, regulation
of endocytosis, cholesterol transport, hematopoietic cell lineage, reactome hemostasis and
clathrin. However, only the immune response and hematopoietic cell lineage pathways
remain significant in the competitive test. ALIGATOR will be less influenced by noise,
since it considers genes to be associated if they contain at least one associated SNP,
whereas the PRS method includes all SNPs with a p-value less than 0.5. This explains why
the ALIGATOR p-values are consistently lower than those from the pathways calculated
using PRS.
Table 5.14: AD Associated Pathways Calculated Using PRS in GERAD data
Pathway Beta SE Psc Pc
ALIGATOR
p-value
1. Immune
response
0.2695 0.0303 5.63× 10−19 4.75× 10−8 0.00266
2. Regulation of
endocytosis
0.0993 0.0300 9.31× 10−4 0.282 0.0002
3. Cholesterol
transport
0.1290 0.0305 2.37× 10−5 2.70× 10−3 0.00024
4. Hematopoietic
cell lineage
0.1530 0.0298 2.84× 10−7 5.04× 10−5 0.00007
5. Proteasome-
ubiquitin activity
0.0876 0.0303 3.89× 10−3 0.328 0.00929
6. Reactome
hemostasis
0.1503 0.0300 5.47× 10−7 0.056 0.00785
7. Clathrin 0.1616 0.0305 1.19× 10−7 5.99× 10−3 0.00038
8. Protein
folding
0.0949 0.0299 1.49× 10−3 0.088 0.00634
The analysis was also repeated removing the APOE region, since this has a large effect
in AD, see Table 5.15. From the self-contained analysis, the same six pathways remain
significant as in the analysis including APOE. However, with the exclusion of the APOE
region, the immune response pathway is no longer significant in the competitive analysis
but the hematopoietic cell lineage pathway remains significant. Note that the PRS path-
way approach finds more consistently significant results in these eight pathways, compared
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to the MAGMA approach, see Chapter 3.
Table 5.15: AD Associated Pathways Calculated Using PRS in GERAD data Excluding
APOE Region
Pathway Beta SE Psc Pc
1. Immune
response
0.1644 0.0302 5.06× 10−8 0.048
2. Regulation of
endocytosis
0.0993 0.0300 9.31× 10−4 0.282
3. Cholesterol
transport
0.1011 0.0305 9.14× 10−4 0.036
4. Hematopoietic
cell lineage
0.1448 0.0298 1.15× 10−6 1.23× 10−4
5. Proteasome-
ubiquitin activity
0.0816 0.0303 0.007 0.410
6. Reactome
hemostasis
0.1449 0.0300 1.39× 10−6 0.075
7. Clathrin 0.1604 0.0305 1.44× 10−7 0.006
8. Protein
folding
0.0906 0.0299 0.002 0.110
The pairwise correlation between all pathways is considered, since this may suggest po-
tential gene-overlap or the biological interaction between pathways. The pathway risk
scores are adjusted for population stratification by regressing the scores against principal
components, and testing the pairwise correlation between the residuals from this model.
Table 5.16 shows the correlation between all of the pathway risk scores. The numbers in
the table correspond to the numbers in Table 5.14. It is seen that the immune response
pathway is highly correlated with all other pathways, possibly due to the impact of APOE.
The cholesterol transport pathway is another which is highly correlated with the majority
of other pathways. Although the correlations are highly significant, the actual correlation
coefficients are fairly low, this is caused by the large sample size. Note, however, that
all correlation coefficients are positive. The largest correlation coefficient is between the
immune response pathway and the reactome hemostasis pathways.
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Table 5.16: Correlations Between AD Associated Pathways, where Correlations were Cal-
culated Using Individual PRS, where PRS is adjusted for population stratifi-
cation (Pathway Numbers Correspond to those in Table 5.14)
Corr.
Coeff
(p-value)
1 2 3 4 5 6 7 8
1
1
(0)
0.1569
(< 2.2× 10−16)
0.0895
(< 2.2× 10−16)
0.1575
(< 2.2× 10−16)
0.0979
(< 2.2× 10−16)
0.3388
(< 2.2× 10−16)
0.1412
(< 2.2× 10−16)
0.0843
(< 2.2× 10−16)
2
1
(0)
0.0323
(2.1× 10−4)
0.0206
(0.0181)
0.0381
(1.2× 10−5)
0.1072
(< 2.2× 10−16)
0.1928
(< 2.2× 10−16)
0.0369
(2.3× 10−5)
3
1
(0)
0.0584
(2.0× 10−11)
0.0602
(4.9× 10−12)
0.0633
(3.7× 10−13)
0.0879
(< 2.2× 10−16)
0.1138
(< 2.2× 10−16)
4
1
(0)
0.0210
(0.0161)
0.0818
(< 2.2× 10−16)
0.0577
(3.4× 10−11)
0.0366
(2.7× 10−5)
5
1
(0)
0.0602
(4.9× 10−12)
0.0489
(2.0× 10−8)
0.0770
(< 2.2× 10−16)
6
1
(0)
0.1668
(< 2.2× 10−16)
0.0565
(8.9× 10−11)
7
1
(0)
0.0544
(4.3× 10−10)
8
1
(0)
5.4 Discussion
No novel genes have been determined using the PRS gene-based approach in the genotype
data, although previous results have been replicated [21]. This is likely due to the use of
LD pruned, genotyped data.
When compared to gene-based results using MAGMA-PCA, Simes or Fisher’s methods,
results from the PRS analysis have at least equivalent or more strongly associated p-
values. These results are consistent with the simulation results in Chapter 4, where the
PRSset−based method is used in simulated data with a real LD structure. This is expected,
since the PRS approach utilises information from the additional discovery data to increase
power.
The gene-based analysis in the GERAD imputed data determines two genes which have not
previously been identified; CSMD1 and MACROD2, both of which seem to be potentially
interesting and biologically relevant candidates in AD. The gene-based analysis in the
imputed data determined 6 gene-wide significant genes whereas only 2 gene-wide significant
genes were found using the genotype data. This suggests the value in using imputed data
which includes additional SNPs and thus can increase the power of the analysis.
Most set-based methods are biased by the number of SNPs in the set [84][95]. It is shown
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that the PRSset−based method is not biased by the number of SNPs in the gene. This
effect is demonstrated in MAGMA-PCA, Simes’ and Fisher’s methods. Although, this
effect only holds for Fisher and Simes’ methods when considering type I error, when the
effect sizes of the SNPs are removed. This is expected for Fisher’s approach, since it
assumes independence between SNPs, and despite the fact that the data is pruned for
LD, a threshold is still used and therefore some correlation will remain. Although Simes’
also shows strong evidence of a correlation, the effect is in the opposing direction, i.e.
association strength is increased when a smaller number of SNPs are in the set. This is
likely because Simes corrects for the number of SNPs in the set, if this number is small, the
correction will also be small, large sets are not an issue for Simes because it only considers
whether one SNP in the set is associated with disease.
It was assessed whether genes from the gene-based analysis were in conserved regions, for
genes which are evolutionary constrained and for genes which reside in CNS. No enrichment
was observed for genes in regions of the genome which are evolutionary constrained, at a
gene-wide significance threshold. As discussed previously, this is expected since AD is a
post-reproductive disorder.
Six of the eight pathways previously found to be associated with AD [23][24] were ad-
ditionally found to be associated using a self-contained test of the PRSset−based method.
Only two pathways remained when a competitive test of association was used; these were
the immune response and hematopoietic cell lineage pathways. Although the immune
response pathway becomes non significant when the APOE region is excluded. These
pathways have previously been tested with the early clinical manifestations of AD, in
particular, the endocytosis pathway was found to be associated with AD, Mild Cognitive
Impairment (MCI) and progression to dementia from cognitively normal [91]. The use
of PRS pathways shows more consistent results with ALIGATOR compared to MAGMA
pathways.
Many of the pathways show a correlation with one another, but the immune response
pathway shows the strongest correlation with other pathways, this is potentially because
it includes the APOE gene.
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The PRSset−based method shows promise in this real data analysis, particularly when
imputed data is used to improve power. The main disadvantage is that this approach does
not account for LD and therefore requires LD pruning which substantially reduces the size
of the data.
The PRSset−based method has the limitation in that it only provides a self-contained test
of association, i.e. it does not take any baseline level of association into account. However,
it would be possible to perform a competitive test of association which does takes account
of the baseline level of association by either; including a whole genome PRS in the logistic
regression model or using a simulation based approach matching SNPs by LD to find the
empirical p-value.
This method can be extended to include any set of SNPs, as demonstrated here by con-
sidering both genes and pathways. It would also be possible to incorporate additional
information into this score, such as gene expression in the brain, Deoxyribonucleic acid
(DNA) methylation or other relevant biological features.
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6 POLARIS: Polygenic LD-Adjusted Risk
Score Set-Based Approach
6.1 Introduction
There would be some benefit in extending the standard PRS approach in order to adjust
for LD between SNPs so that data would not require LD pruning prior to analysis; thus
increasing the number of SNPs in the analysis and improving power (as discussed in
Chapters 4 and 5).
In this chapter, a novel approach to a set-based framework which combines the advantages
of MAGMAs PCA method and PRS is presented. The proposed POLARIS method [96]
aims to improve upon the standard PRS method by correcting the inflated type I error
observed both in standard PRS in the presence of LD [72], and also in set-based analyses
as the number of SNPs in the set grows [84]. POLARIS uses spectral decomposition
of the SNP correlation matrix to adjust the individuals’ allele counts for LD structure.
POLARIS is presented as a self-contained set-based approach in that it compares the test
statistic for the set with the null hypothesis, rather than a competitive approach which
accounts for the baseline level of association across the genome. However, it can be turned
into a competitive method either by including a general whole genome POLARIS in the
analysis, or comparing the set-based POLARIS to those generated from random sets of
genes (matched for the number of SNP-sets/set size/number of SNPs). A self-contained
test of association is beneficial to find the individual risk scores of each set which can
be used in further analyses, however, the strength of the association may be inflated by
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the baseline level of association across the genome. Therefore, a competitive test has the
advantage that it gives a more accurate measure of overall set association since it accounts
for the baseline association.
POLARIS informs the analysis with previously reported effect sizes of the SNP’s associa-
tion with disease. An LD-adjusted PRS is calculated per person per set, and the overall
set effect is computed using regression. Since the score is used as a predictor in a regres-
sion analysis, it is possible to include further population covariates or any other possible
confounders. POLARIS uses all available information, since all PCs are incorporated into
a score, thus avoiding overfitting which may result from only including the top PCs. As
in standard PRS analysis, only one independent variable (apart from extra covariates) is
present in the regression model, rather than the number of predictors being equal to the
number of markers, or the number of chosen PCs. Like the standard PRS approach, an
advantage of this method is that it performs a self-contained test of association in the test
dataset, leveraging the discovery set to increase the power of this test. A significant test
statistic implies significant association specifically in the test sample, unlike a significant
meta-analysis result, where the association evidence could result from other samples. This
might be important if the test sample is of specific interest, e.g. a different ethnicity, or a
different, but related, phenotype.
6.1.1 Objectives
This Chapter aims to:
• Develop a methodology which adjusts standard PRS for LD between SNPs called
POLARIS.
• Assess the type I error and power of POLARIS in simulated data with constructed
and real LD structure.
• Compare the power of POLARIS to that of the regression based approach in MAGMA
which computes principal components for all SNP genotypes and uses an F-test to
find the strength of association between the phenotype and the SNPs (MAGMA-
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PCA). Also compare the power of POLARIS to that of the MAGMA mean-χ2
approach which is used when only summary statistic data is available (MAGMA-
SUMMARY) [55]. POLARIS is not compared to Fisher’s and Simes methods since
they do not adjust for LD.
6.2 Materials and Methods
6.2.1 POLARIS Rationale and Derivation
For M SNPs in a set, the standard PRS combines single-SNP genotypes gi (i = 1, . . . ,M)
into a single regression predictor using single-SNP effect sizes (log(ORi) = βi) taken from
a previous study as coefficients (see also Chapter 4),
PRS =
M∑
i=1
βigi = β
T g. (6.1)
This method implements a 2-stage approach, where independent discovery and test sets
are available. The effect sizes β are determined from the discovery set and a vector of the
number of risk alleles g is obtained from the test set. The underlying assumption is that
individual genotypes are available for the test set, but only summary data (effect sizes β)
for the discovery set are available.
The standard PRS method does not adjust for LD between markers and thus requires
LD pruning [72]. If markers are in LD, the simple weighted sum (Equation 6.1) may give
them undue weight; indeed, if they are in positive LD, they are likely to have a similar
single-SNP effect size and act together, thus giving a larger contribution to the PRS than
a single or uncorrelated marker.
This imbalance due to LD is corrected by replacing the vector g of genotypes with a vector
g˜ of adjusted dosages. Consider the spectral decomposition of the M ×M marker-marker
correlation matrix C,
C =
M∑
k=1
λk xk x
T
k (6.2)
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with eigenvalues λk satisfying
M∑
k=1
λk = trC = M and orthonormal (column) eigenvectors
xk, where trC is the trace (sum of the elements on the main diagonal) of matrix C. The
correlation matrix is the covariance matrix of the joint distribution of individual genotypes
after standardisation of each SNP. Its eigenvectors indicate the directions of the principal
axes of this standardised distribution, and the corresponding eigenvalues give the variances
of the distribution in the corresponding directions. In the absence of LD, these variances
will be equal to 1, and the distribution will be isotropic. However, if there is LD, then
these variances will in general be different, and the standardised distribution will be more
elongated in some principal directions and flattened in others.
This anisotropy can be removed by scaling the standardised joint distribution in the direc-
tion of each principal axis with the inverse square root of the eigenvalue in this direction.
However, adjusting the standardised distribution in this way will not only remove LD, but
also equalise the single marker variances, thus discarding information such as the MAFs.
As our aim is to adjust for LD only, but not for single-SNP variances, the same scaling
transformation is applied to the original, unstandardised joint distribution instead.
More specifically, due to the orthonormality of the eigenvectors, the PRS can be expressed
in a spectral decomposition
PRS = βT g =
M∑
k=1
βTxk x
T
k g. (6.3)
The component xk x
T
k g, which is the part of g along the kth principal axis, has correlation
matrix eigenvalue λk and therefore contributes a disproportionate amount of variance to
PRS unless λk ≈ 1. For an uncorrelated marker, one spectral component will be concen-
trated on this marker, and the corresponding eigenvalue λk ≈ 1.
For our adjustment, the coordinate of g is rescaled in the direction of the kth principal
axis, xTk g, with the inverse square root of the correlation eigenvalue, giving an adjusted
coordinate 1√
λk
xTk g, and hence the rescaled spectral component
1√
λk
xk x
T
k g.
Applying this adjustment to each principal axis will result in an isotropic distribution in
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which the correlation has mostly been removed, for the adjusted dosage vectors
g˜ =
M∑
k=1
1√
λk
(xTk g) = C
− 1
2 g. (6.4)
Note this adjustment of multivariate data by correlation is analogous to the calculation
of the Mahalanobis distance for mean zero data x, xTS−1x = ‖S− 12x‖2, where S is the
covariance matrix [97][98], except that here the correlation matrix is used instead of the
covariance matrix in order to avoid adjusting for single-marker variance.
Using the adjusted dosages g˜ instead of the the original genotype vectors g, obtains an
LD-adjusted Polygenic Risk Score (PRS)
M∑
i=1
βig˜i = β
T g˜ = βTC−
1
2 g =
M∑
i=1
βi
 M∑
k=1
1√
λk
xk(i)
M∑
j=1
xk(j) gj
 . (6.5)
In the sum over the spectral components, indexed by k, the terms with λk = 0, corre-
sponding to principal directions with no variance, are to be omitted, resulting effectively
in a pseudoinverse of the square root of C. In cases of extreme LD, where λk ≈ 0, this
formula will apply a large correction factor to the corresponding component, thus possibly
amplifying small deviations due e.g. to genotyping error. In order to avoid this instability,
a ridge parameter λ0, is introduced, where λ0 =
√
1
N , where N is the number of individ-
uals in the test data, and the adjustment is modified to mitigate the effect of small λk.
This gives rise to the POLARIS risk score,
POLARIS = βT
√
1 + λ0 (C + λ0I)
− 1
2 g =
M∑
i=1
βi
 M∑
k=1
√
1 + λ0
λk + λ0
xk(i)
M∑
j=1
xk(j)gj
 = βT g˜,
(6.6)
where now g˜ =
√
1 + λ0 (C + λ0I)
− 1
2 g =
M∑
k=1
√
1+λ0
λk+λ0
xk x
T
k g, and I is the M ×M unit
matrix. Note that if all markers are uncorrelated, then λk ≈ 1 for all k, which makes
g˜ ≈ g, and consequently POLARIS ≈ PRS.
The adjustment g˜ = C−
1
2 g (or the extension with a ridge parameter) is applied directly
to the vector of genotypes. More precisely, an adjustment of the variance only will be
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achieved by removing the sample mean vector gˆ before the adjustment, giving
g˜ = gˆ + C−
1
2 (g − gˆ) = C− 12 g + (I − C− 12 )gˆ; (6.7)
however, this only amounts to shifting the POLARIS score by a constant βT (I − C− 12 )gˆ,
which is irrelevant in the subsequent regression analysis. Similarly, this would be irrelevant
if the POLARIS score was normalised.
6.2.2 POLARIS Set-Based Analysis Comparison Applied to Simulated Data
The POLARIS methodology is compared to two different MAGMA approaches [55] in
order to assess whether POLARIS has at least equivalent power compared with these
approaches. The first is a regression based approach which computes the principal com-
ponents for SNP genotypes, and determines how strongly associated these SNPs are with
the phenotype of interest using an F-test (MAGMA-PCA). The second MAGMA ap-
proach is designed for when only summary statistic data are available, it uses a mean-χ2
method and permutations to account for LD (MAGMA-SUMMARY), similar to Brown’s
method [52]. Of the set-based methods introduced in Chapter 4, only MAGMA-PCA and
MAGMA-SUMMARY are considered here as these are the only approaches which also
account for LD between SNPs.
To understand detailed differences and similarities between MAGMA approaches and PO-
LARIS, all methods were tested on simulated data, both with a simple extreme constructed
LD pattern and a real-data LD pattern between SNPs. Type I and type II errors were
tested by simulating null effects and introducing some association to the SNPs, respec-
tively.
To generate summary statistic data and genotype data, a simulated dataset was randomly
split into discovery and test sets. The summary statistics for each SNP in the discovery
set were computed. The following different scenarios were simulated.
• Simple LD Block: 10 SNPs in an LD Block with (i) r2 = 0.2 and (ii) r2 = 0.8
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between consecutive SNPs. The ‘causal’ SNP is associated with disease with OR=1.1
and the remaining 9 SNPs have an OR closer to the null value of 1. An additional
90 independent unassociated SNPs are also present in the set, see Figure 6.1 for LD
structure.
• Complex LD: 4 LD Blocks of 10 SNPs each, and 60 independent unassociated
SNPs. Block 1 has pairwise r2 = 0.2, Block 2 has pairwise r2 = 0.4, Block 3 has
pairwise r2 = 0.6, and Block 4 has pairwise r2 = 0.8, all 40 SNPs in LD with OR ∼
N(1.02, 0.36) (OR from a Normal Distribution with mean 1.02 and variance 0.36),
see Figure 6.2 for LD structure. The mean and variance for the sampled effect sizes
are calculated from all SNPs in the IGAP data [20].
• Discovery and Test with Different LD Structure: 10 SNPs in LD with OR∼
N(1.02, 0.36) and 90 independent, unassociated SNPs where test set LD is moderate
(r2 = 0.6) and discovery set LD is high (r2 = 0.8), see Figure 6.3 for the LD
structure.
• Effect Sizes of Varying Direction: It is possible that for certain MAFs, SNPs
in LD have effects in opposite directions [88]. 10 SNPs with varying LD with ORs
with randomly varying direction and 90 independent unassociated SNPs. The LD
structure can be seen in Figure 6.4.
• Real Data Simulations: 115 SNPs from real AD GERAD data [19], see Section
2.1 for a detailed description of the data and Figure 6.5 for LD structure. For a SNP
in a block of strong LD, a number of controls who were homozygous for the risk
allele were set to cases, and an equal number of cases homozygous for the protective
allele were set to controls, thus producing an association with disease.
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(a) r2 = 0.2
(b) r2 = 0.8
Figure 6.1: LD Plot for 100 SNPs in Simple LD Simulations
Figure 6.2: LD Plot for 100 SNPs in Complex LD Simulations
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(a) Test Set r2 = 0.6
(b) Discovery Set r2 = 0.8
Figure 6.3: LD Plot for 100 SNPs in Discovery and Test with Different LD Structure
Simulations
Figure 6.4: LD Plot for 100 SNPs with Varying Effect Sizes Simulation
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Figure 6.5: LD Plot for Real LD Structure with 115 SNPs
The real data simulations in this chapter use a smaller number of SNPs compared to the
same simulations in Chapter 4 (115 SNPs compared to 129 SNPs respectively). The reason
for this is that only SNPs with a p-value greater than 0.1 were included; this was in an
attempt to remove some of the effects in the data so it was possible to better distinguish
between the power of the different approaches.
For these scenarios, the sample size of the discovery dataset was varied in order to deter-
mine the influence of the discovery set sample size on the POLARIS method. Simulations
were run creating data with N=20,000 and N=60,000 individuals, these were split equally
to result in a test and discovery set each with N=10,000 and N=30,000 subjects, respec-
tively. Additionally, the larger set with 60,000 individuals was split such that the test set
had N=10,000 and the discovery set had N=50,000 individuals. The real data simulations
have 13,164 subjects each for the combined discovery and test sets; these data are divided
50/50 and 25/75. In both the discovery and test datasets, 30% of the sample size were
cases.
A total of 1,000 simulations were performed for each scenario. The power to detect the
association between the set and disease is calculated as the proportion of p-values from the
1,000 simulations which were below a given p-value threshold; the p-value thresholds used
were p=0.05, 0.01 and 0.001. 10,000 simulations were used for the real data simulations,
thus enabling a more stringent threshold of 0.0001 to be considered. The power of the
POLARIS method, applied to the test dataset and informed by the discovery dataset, was
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compared to the power of MAGMA-PCA applied to the test dataset only, MAGMA-PCA
to the total unsplit data, MAGMA-SUMMARY using discovery set summary statistics and
test data to estimate LD and MAGMA-SUMMARY in the combined test and discovery
sets.
It was also investigated whether the adjustment using the square inverse of the correlation
matrix was better in terms of power than simply using the inverse of the correlation
matrix. This was the initial approach investigated until the Mahalanobis distance theory
was considered (see Section 6.2.1), so this comparison is to confirm the theoretical equation
with simulations. A type I error and power comparison between the square inverse and
inverse of the correlation matrix was considered for the simple, complex and real LD
structure simulations.
6.3 Results
6.3.1 Type I error
All scenarios outlined above in Section 6.2.2 were tested for type I error rates, where
none of the SNPs have an association to disease (i.e. OR=1) in either the discovery or
test sets. Type I error is deemed acceptable if the nominal value is included in the 95%
CI for estimated type I error rate. The expected type I error is displayed on the type I
error plots (black solid line). The POLARIS results are shown by a solid blue line on the
plots. MAGMA-PCA is displayed as a purple line; the solid purple line is in the test and
discovery data and the dashed purple line is in the test data only. MAGMA-SUMMARY
is shown as an orange line; the solid orange line is in the combined test and discovery data
and the dashed orange line is in the discovery set only, using the test set to estimate LD.
The shaded area surrounding each line displays the 95% CI for the type I error for each
method.
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6.3.1.1 Simple LD Block
Figure 6.6 shows the type I error for the Simple LD simulation example. 10 SNPs out of
100 are in LD with either r2 = 0.2 or r2 = 0.8. The LD structure for these simulations
can be seen in Figure 3.7a. The 95% CIs are also displayed on the figures. The type I
error rate is reasonable in the majority of cases; the nominal value is included in the 95%
CI.
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Figure 6.6: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD and 90 independent SNPs. Figures 6.6a, 6.6b and 6.6c show Simple LD
Structure Simulations where r2 = 0.2, and Figures 6.6d, 6.6e and 6.6f show
Simple LD Structure Simulations where r2 = 0.8. Figures 6.6a and 6.6d have a
discovery and test sample size of 10,000, Figures 6.6b and 6.6e have a discovery
set N=50,000 and test set N=10,000 and Figures 6.6c and 6.6f have discovery
and test sets with N=30,000. Note: y-axis scale is not between 0 and 1.
The comparison between POLARIS which uses the square inverse of the correlation matrix
to adjust for LD (blue solid line), and an adjustment using the inverse of the correlation
matrix only (green solid line) is shown in Figure 6.7. The expected type I error is shown by
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the black solid line. It is seen that the type I error for both adjustments are comparable.
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Figure 6.7: Type I Error Comparison of POLARIS and an Adjustment using the Inverse
of the Correlation Matrix; Simulation of 10 SNPs in LD and 90 independent
SNPs. Note: y-axis scale is not between 0 and 1.
6.3.1.2 Complex LD Structure
The type I error for the simulation with complex LD structure is shown in Figure 6.8. The
first 10 SNPs have pairwise LD r2 = 0.2, the second 10 SNPs have pairwise LD r2 = 0.4,
the third 10 SNPs have pairwise LD r2 = 0.6 and the fourth 10 SNPs have pairwise LD
r2 = 0.8. The remaining 60 SNPs are independent. The nominal value is within the 95%
CI and therefore type I error is reasonable.
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Figure 6.8: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in LD
with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6,
10 SNPs in LD with r2 = 0.8 and 60 independent, unassociated SNPs. Note:
y-axis scale is not between 0 and 1.
The comparison between the standard POLARIS LD adjustment and the adjustment using
the inverse of the correlation matrix for this simulation is seen in Figure 6.9. Again, the
type I error for both adjustments is similar.
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Figure 6.9: Type I Error Comparison of POLARIS and an Adjustment using the Inverse
of the Correlation Matrix; Simulation of 10 SNPs in LD with r2 = 0.2, 10
SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6, 10 SNPs in LD with
r2 = 0.8 and 60 independent, unassociated SNPs. Note: y-axis scale is not
between 0 and 1.
6.3.1.3 Different LD Structure of Discovery and Test Datasets
Figure 6.10 shows the type I error for the simulations which have a different strength of
LD between the test and discovery sets, both sets have 10 SNPs in LD and the remaining
SNPs are independent. The pairwise LD in the test set has pairwise r2 = 0.6 and the
discovery set has pairwise LD r2 = 0.8. Type I error is inflated for MAGMA-SUMMARY
in the discovery data only (dashed orange line), this is due to the fact that LD is estimated
from a test set which has a different LD structure to the discovery set, and so the discovery
set is under-adjusted for LD. MAGMA-PCA and MAGMA-SUMMARY in the combined
data are not presented here, since the combined data will have an average LD and would
therefore not be comparable.
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Figure 6.10: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD with OR∼ N(1, 0.22) and 90 independent, unassociated SNPs where Test
LD is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8). Note: y-axis
scale is not between 0 and 1.
When considering the opposite case; where the test set has high LD (r2 = 0.8) and the
discovery set has moderate LD (r2 = 0.6), see Figure 6.11. The type I error is no longer
inflated for the MAGMA-SUMMARY method, since the LD in the test set which is used
to adjust, is larger than the LD in the discovery set. Therefore, the adjustment will be
more severe in this case.
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Figure 6.11: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs in
LD with OR∼ N(1, 0.22) and 90 independent, unassociated SNPs where Test
LD is high (r2 = 0.8) and Discovery LD is moderate (r2 = 0.6). Note: y-axis
scale is not between 0 and 1.
6.3.1.4 Effect Sizes with Varying Direction
The type I error for the simulation where the association of the SNPs in the LD block
are not all in the same direction is shown in Figure 6.12. Although, for the type I error
case, there are no effect sizes so the direction of effect can not vary. Therefore, this case
is similar to the simple LD case with pairwise r2 = 0.2. As before, type I error is within
the 95% CIs for all methods.
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Figure 6.12: Type I Error Comparison of Set-Based Methods; Simulation of 10 SNPs with
Varying LD with ORs with Randomly Varying Direction and 90 independent,
unassociated SNPs. Note: y-axis scale is not between 0 and 1
6.3.1.5 Real Data Simulation
The type I error for the real data simulations, with the case-control status randomly
permuted in order to remove the effect size of any SNPs, is shown in Figure 6.13. The LD
structure for this scenario can be observed in Figure 6.5. The original (combined) data
(N=13164) is split 50/50, 25/75 and 75/25 into independent test and discovery sets. The
type I error rate is within 95% CIs of expected values for all data splits.
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Figure 6.13: Type I Error Comparison of Set-Based Methods; Simulation of 115 SNPs
from Real Data, with Permuted Phenotypes to Remove Effect Sizes. Note:
y-axis scale is not between 0 and 1.
The comparison between LD adjustment approaches for the real LD structure data is
shown in Figure 6.14. The type I error for both adjustment approaches is comparable.
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Figure 6.14: Type I Error Comparison of POLARIS and an Adjustment using the Inverse
of the Correlation Matrix; Simulation of 115 SNPs from Real Data, with Per-
muted Phenotypes to Remove Effect Sizes. Note: y-axis scale is not between
0 and 1.
6.3.1.6 Power
The power of the POLARIS and MAGMA methods are seen in Figures 6.15-6.22. Each
Figure displays the simulation results for each scenario discussed in Section 6.2.2. On each
graph the solid blue line shows the POLARIS results, the purple dashed line is MAGMA-
PCA in the test set only, the purple solid line is MAGMA-PCA in the combined test and
discovery sets, the solid orange line is MAGMA-SUMMARY in the combined test and
discovery sets and the dashed orange line is MAGMA-SUMMARY in the discovery set
using the test set as an LD reference.
6.3.1.7 Simple LD Structure
The power graphs for the simple LD structure are seen in Figure 6.15. The 10 SNPs
which are in LD are associated with disease with OR=1.1. POLARIS has equivalent
power compared with MAGMA-PCA in the combined discovery and test genotype sets in
almost all cases. In the most likely realistic situation, the discovery set is larger than the
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test set, but only summary statistics are available for the discovery set. MAGMA-PCA on
the combined genotype dataset has higher power where the test N=10,000 and discovery
N=50,000, but here MAGMA-PCA is applied to the individual genotypes of the discovery
and test sets combined (N=60,000), so the sample used to estimate LD and perform the
statistical test is very large, whereas POLARIS uses the discovery set N=50,000 for effect
size estimation and only N=10,000 for LD estimation, and importantly, for statistical
testing. In all cases, POLARIS has higher power than MAGMA-PCA in the test set only,
as is expected, since POLARIS increases power by incorporating information from the
discovery set. MAGMA-SUMMARY in both the combined test and discovery summary
statistic data and the discovery set data only always has very high power compared to
the other methods. It seems unusual that the power is substantially higher using the
summary statistics from identical genotype data, and in particular, higher power when
considering only the discovery set compared to the combined test and discovery genotype
data. Although this effect was demonstrated in simulated data in Section 3.3.3.
The power for POLARIS increases when the size of the test set increases, as this improves
the estimate of LD between markers.
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Figure 6.15: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD and
90 independent SNPs. Figures 6.15a, 6.15b and 6.15c show Simple LD Struc-
ture Simulations where r2 = 0.2, and Figures 6.15d, 6.15e and 6.15f show
Simple LD Structure Simulations where r2 = 0.8. Figures 6.15a and 6.15d
have a discovery and test sample size of 10,000, Figures 6.15b and 6.15e have
a discovery set N=50,000 and test set N=10,000 and Figures 6.15c and 6.15f
have discovery and test sets with N=30,000.
Figure 6.16 shows the power comparison between POLARIS which adjusts for LD using
the square inverse of the correlation matrix and the LD adjustment using the inverse of
the correlation matrix. It is shown that the power using the standard POLARIS LD
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adjustment is higher compared to the LD adjustment using the inverse of the correlation
matrix only. This is likely because by taking the square inverse rather than the inverse,
the adjustment factor is smaller (since
√
1/λk < 1/λk), although type I error graphs show
that this adjustment is still sufficient.
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Figure 6.16: Power Comparison of POLARIS and an Adjustment using the Inverse of the
Correlation Matrix; Simulation of 10 SNPs in LD and 90 independent SNPs.
6.3.1.8 Complex LD Structure
Figure 6.17 shows the power for all methods in the complex LD structure simulations.
SNPs in LD were given effect sizes from the following distribution, OR ∼ N(1.02, 0.36).
All methods have equivalently high power in this simulated data. It is difficult to differ-
entiate between the different methods and conclude which method performs best in this
case. Initially, the effect sizes for SNPs in LD were taken from a distribution with mean
1.1, but this was reduced in an attempt to differentiate between the methods. However,
because 40 (of the 100 total) SNPs have some association with disease, when combined,
the aggregation of these small SNP effects leads to the set of SNPs having a large effect
on disease, which explains the high power despite the small individual SNP effect sizes.
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Figure 6.17: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD with
r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6, 10
SNPs in LD with r2 = 0.8 and 60 independent, unassociated SNPs.
The power for the two different PRS LD adjustment approaches are seen in Figure 6.18.
Again, the power is very high for both approaches and it is therefore difficult to determine
which has optimal power in this case. The effect sizes of SNPs was reduced in order to
attempt to better differentiate between methods, however, due to the number of SNPs
which are associated with disease, this did not help. It may be possible to determine a
difference by reducing the overall number of SNPs which are associated with disease.
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Figure 6.18: Power Comparison of POLARIS and an Adjustment using the Inverse of the
Correlation Matrix; Simulation of 10 SNPs in LD with r2 = 0.2, 10 SNPs in
LD with r2 = 0.4, 10 SNPs in LD with r2 = 0.6, 10 SNPs in LD with r2 = 0.8
and 60 independent, unassociated SNPs.
6.3.1.9 Different LD Structure of Discovery and Test Datasets
For the simulations where the strength of LD differs between the test and discovery sets,
the power graphs are displayed in Figure 6.19. Here, the methods using the test datasets
only and the combined sets are not compared; since the combination of two sets with
differing LD will result in a set with one average LD strength. This is, of course, different
to the LD structure in the test dataset only.
POLARIS is able to increase power using a dataset which has a slightly different LD
structure compared to MAGMA-PCA in the test set only. It is usually expected that the
LD structures in the test and discovery set will be similar, however, POLARIS is able
to utilise this additional data whilst maintaining a self-contained test of association in
the test data only. MAGMA-SUMMARY in the discovery set only has very high power
in this case, this is most likely caused by the highly inflated type I error. The power of
POLARIS increases when the test set sample size increases (N=30,000), this is because
the additional subjects in the test set add power to the logistic regression model used to
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determine the association of the set to disease.
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Figure 6.19: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD with
OR∼ N(1.02, 0.22) and 90 independent, unassociated SNPs where Test LD
is moderate (r2 = 0.6) and Discovery LD is high (r2 = 0.8).
The opposite case where the LD in the test set is high (r2 = 0.8) and LD in the discovery
set is moderate (r2 = 0.6) is shown in Figure 6.20. In this case, the MAGMA-SUMMARY
method does not have as high power compared to the other methods. This is because the
LD will be overadjusted for in this case, rather than underadjusted in the previous case.
POLARIS and MAGMA-SUMMARY have similar power, and MAGMA-PCA has lower
power compared to POLARIS.
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Figure 6.20: Power Comparison of Set-Based Methods; Simulation of 10 SNPs in LD with
OR∼ N(1.02, 0.22) and 90 independent, unassociated SNPs where Test LD
is high (r2 = 0.8) and Discovery LD is moderate (r2 = 0.6).
6.3.1.10 Effect Sizes with Varying Direction
Figure 6.21 shows the power for all methods when the SNPs in LD are not always associ-
ated with disease in the same direction, both within each separate dataset and across the
test and discovery sets. MAGMA-SUMMARY considers p-values only, rather than the
direction of effect whereas POLARIS and MAGMA-PCA take account of the direction of
effect. MAGMA-SUMMARY in the combined test and discovery sets has highest power
compared to the other methods. POLARIS has higher power compared with MAGMA-
PCA in the test datasets. POLARIS also has higher power compared to MAGMA-PCA
in the combined test and discovery sets when the test dataset has sample size N=10,000.
If the researcher is interested in just the set association (independent of direction) then
MAGMA-SUMMARY is appropriate, however, if directionality is important, then PO-
LARIS or MAGMA-PCA should be used.
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Figure 6.21: Power Comparison of Set-Based Methods; Simulation of 10 SNPs with Vary-
ing LD with ORs with Randomly Varying Direction and 90 independent,
unassociated SNPs.
6.3.1.11 Real Data Simulation
Figure 6.22 shows the power graph for the real data simulations. The power of the PO-
LARIS method lies generally between the power of MAGMA-PCA applied to the test set
only and MAGMA-PCA in the combined test and discovery sets. One can see that by
using the information from the discovery set, POLARIS increases the power compared
to using the test set only, but, as is to be expected, not as much as using the individual
genotypes from the discovery set as well as the test set. This increase seen in POLARIS
is reduced when the test set has a large number of individuals (N=7,500) relative to the
discovery set (N=2,500) (see Figure 6.22c). Also note that the power of the MAGMA-
SUMMARY approach exceeds the power of MAGMA-PCA on the same combined dataset,
a demonstration of this effect is discussed in Section 3.3.3.
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Figure 6.22: Power Comparison of Set-Based Methods; Simulation of 115 SNPs from Real
Data
Figure 6.23 shows the power comparison between the standard POLARIS LD adjustment
using the square inverse of the correlation matrix and the LD adjustment using the inverse
of the correlation matrix only. The power for the standard POLARIS approach has higher
power in the simulated data with a real LD structure, although this difference is very
slight, due to the relatively small power for both approaches.
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Figure 6.23: Power Comparison of POLARIS and an Adjustment using the Inverse of the
Correlation Matrix; Simulation of 115 SNPs from Real Data
6.4 Discussion
The main aim of this chapter was to develop a novel methodology which accounts for LD
in the calculation of a PRS. The resulting individual LD-adjusted PRS can also be used
for analysing whether a set of SNPs is associated with disease. This method combines
the advantages of PRS and spectral analysis of the genetic data. The latter suggests a
mathematically sound adjustment for LD and includes a stabilisation parameter (similar
to ridge regression) to cope with cases of extreme LD. It adjusts for LD between SNPs
and informs the analysis with previously reported effect sizes of a SNP’s association with
disease. This adjustment uses the SNP-SNP correlation matrix; however, one could al-
ternatively use the SNP-SNP covariance matrix. For all examples above, this gives very
similar results. The benefits of using the correlation matrix over the covariance matrix
are that SNPs with low MAF are not penalised, i.e. their contribution to the risk score is
equivalent to that of a more common SNP. When partitioning the overall polygenic risk
based on meaningful SNP sets, the method allows both to test for significance of associa-
tion of these sets (set-based analysis) and to provide individual set-specific risk scores for
subjects, which can be further used for risk prediction of subphenotypes with respect to
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the SNP sets.
To assess the quality of the proposed approach, POLARIS for set-based analysis was
compared with the widely used MAGMA software. POLARIS was shown to give the
correct type I error and its power lies between that of MAGMA-PCA applied to the test
dataset only and MAGMA-PCA applied to the combined test and discovery datasets.
MAGMA-SUMMARY is shown to have higher power compared to MAGMA-PCA often
in identical data. In practice, researchers would use all the available genotype data, and
would use PRS based methods if effect sizes only are known for an additional dataset.
The LD adjustment in POLARIS uses the square inverse of the correlation matrix. This
was compared to the use of the inverse of the correlation matrix. The type I error was
consistent for both LD adjustment approaches and the power is at least equivalent and
often higher for the standard POLARIS LD adjustment.
POLARIS has three main advantages. 1) It produces a risk score per person per set,
unlike other set-based methods which only provide a p-value for the strength of association
between the set and disease. This set risk score can be used to stratify individuals for
follow up studies (e.g. clinical trials) and also prioritise genes for further functional studies
(e.g. animal models), supporting the development of precision medicines. 2) POLARIS
can increase power by leveraging the discovery set to perform a self-contained test of
association in the test dataset. Another way to incorporate the discovery set would be to
use meta-analysis, however, this detects an association in the combined set rather than
the test set only. This may be important when the test data differs in some way from the
discovery data, e.g. different ethnicity, or different phenotype. A good example might be
where the test sample uses different diagnostic criteria to measure the same phenotype
(e.g. self-report questionnaire for depression) and one wishes to validate these criteria by
showing that they show association to the same genes as those implicated by the standard
diagnosis. 3) The overall set association can easily be adjusted by population or any other
covariates.
Like the PRSset−based method, POLARIS can be used for any set of SNPs, for example the
whole genome, genes or pathways. Therefore it has the potential of data driven discovery
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of pathways.
POLARIS can also be utilised in a number of cross disorder analyses to determine com-
monality between disorders at a gene-based or pathway-based level. There are a number
of common disorders for which the GWAS summary data are publically available (e.g.
Psychiatric Genomics Consortium). The GWAS data for one disorder can be used to
generate scores per person per gene in another disorder or subphenotype of interest, and
thus test for overlap between disorders at a gene-based level.
The POLARIS method can be extended to add additional information into the score,
such as rare variants from exome sequencing studies. The POLARIS set-based method
is implemented into a freely accessible platform independent software, see Supplementary
section 11.3 for scripts. Large sets have a high computational burden due to the spectral
decomposition of large correlation matrices; recommendations on maximum set size and
the corresponding required computational resource are included with the software.
In this study, POLARIS was applied to test binary traits. However, the POLARIS score
can also be used as a variable (along with other covariates) in regression models for quan-
titative traits.
A limitation of the POLARIS implementation is that currently it is only available as a self-
contained set-based method. However, POLARIS can in principle be used as a competitive
set analysis, adjusting for the baseline level of association in the data either by including
a general PRS in the analysis or comparing the set-based PRS to those generated from
random sets of genes (matched for number of genes/gene size/numbers of SNPs) or random
sets of SNPs (matched for LD, MAF and SNP density).
Another limitation of PRS-type approaches is the imperfect tagging of the underlying
causal variants by SNPs and imperfect effect size estimates. The challenge of selecting
the true set of susceptibility SNPs for PRS modelling to capture heritability has been
pointed out [99]. Our approach can use all SNPs in a set of interest, even when in LD,
and therefore any causal genotyped SNPs will be included. If the causal SNPs are not
present in the sample, then the tagging SNPs only are used. The effect sizes of all SNPs in
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LD will be adjusted according to the LD structure, not according to the causal/non-causal
nature of the SNP.
POLARIS is a valuable extension to standard PRS, by adjusting for LD between markers
and removing the necessity to LD prune data prior to analysis. POLARIS provides a test
of the set’s association with disease whilst also producing subject specific risk scores.
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7 POLARIS: Gene-Based and Pathway
Analyses in AD Data
7.1 Introduction
Set-based analysis is an alternative to single SNP analyses, and may be more powerful
due to the aggregate effect of multiple SNPs being larger than that of individual SNPs.
For example, determining the association of genes rather than SNPs is beneficial since
genes are more robust across different populations [44]. Set-based analyses are being
widely used in the literature and as expected, are able to identify novel genes or pathways
associated with disease. Gene-sets, or pathways, have been assessed and eight have been
found to be associated with AD using the ALIGATOR [61] algorithm [23]. Additionally
134 gene-sets have been identified as being associated with SZ which are related to nervous
system function and development, where gene-sets are defined from single gene functional
studies [100]. Other gene and gene-set analyses were considered in a SZ study investigating
exomic variation which determined an enrichment in genes whose Messenger Ribonucleic
Acid (mRNA) binds to Fragile X Mental Retardation Protein (FMRP) and LoF intolerant
genes [101].
As illustration, the power increase from using a gene-based analysis is shown using MAGMA,
see Chapter 3, where additional genes not discovered using single SNP analyses are deter-
mined. In order to further improve power, PRS was applied to the set-based framework,
see Chapter 4, this incorporates additional information from external data into the anal-
ysis and in addition, provides a risk score per subject for each set. In fact, the use of
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PRS gene-based method in AD imputed data in Chapter 5 led to the identification of two
novel genes: CSMD1 and MACROD2. However, this standard PRS approach requires
independence between SNPs, and therefore the data must be pruned for LD prior to the
analysis.
A pathway analysis offers a higher level of information aggregation, by integrating multiple
genes into a pathway, which implicates a particular biological process. A pathway analysis
has been applied to the AD IGAP data using ALIGATOR [61] and eight pathways have
been found to be associated with AD; these are immune response, regulation of endo-
cytosis, cholesterol transport, hematopoietic cell lineage, proteasome ubiquitin activity,
reactome hemostatis, clathrin and protein folding [23][24]. The PRS set-based approach
was applied to these eight pathways, see Chapter 5, and two pathways were consistently as-
sociated using this method; these were the immune response and hematopoietic cell lineage
pathways. The correlation among these eight pathways was also high (p < 2.2 × 10−16),
although the actual correlation coefficient was often low (r ranges from 0.0201 to 0.3385).
This correlation suggests that some SNPs are shared between different pathways.
To remove the issue with the PRS set-based method where LD pruning is required, PO-
LARIS was introduced, see Chapter 6. POLARIS extends PRS by incorporating an LD
adjustment between SNPs. POLARIS was shown to have adequate power which resided
between MAGMA-PCA in the test set only and MAGMA-PCA in the combined test and
discovery sets. In this chapter POLARIS is applied to real AD data, similarly to Chapter
5. The aim of this chapter is to investigate the power of POLARIS when applied to real
AD data and compare the results with MAGMA-based analyses.
A number of set-based analyses are known to introduce bias in the set-based p-value due to
the size of the set [84][95]. SNP p-values may contain a small amount of inflation, possibly
due to population stratification. When a large number of these SNPs are combined, this
inflation can become substantial, therefore, it was assessed whether POLARIS is influenced
by this bias.
Previous studies [102] have identified that genes found from gene-based analyses are evolu-
tionary constrained, likely due to functional importance. Genes found from the POLARIS
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gene-based analysis were interrogated to determine if they reside in CNS or whether there
is an enrichment of genes which are LoF intolerant. It is expected that no enrichment will
be found, since AD is a post-reproductive disorder.
POLARIS can be implemented in either directly genotyped or imputed data. Imputation is
when the genotypes of a set of SNPs is inferred. This is done using the LD between untyped
SNPs and typed SNPs from a reference panel [103]. A number of different softwares are
available for imputation, such as BEAGLE [104], MaCH [105] and IMPUTE2 [106]. Data
which has been directly genotyped is less likely to contain incorrect genotypes, and is quick
to run computationally, due to the smaller number of SNPs. However, the power of the
analyses can be increased by using imputed data due to the inclusion of a larger number
of SNPs. The imputation accuracy can be controlled by info score or the probability of
correct imputation. These are information metrics which typically take a value between
0 and 1, with 1 indicating high certainty imputation for a SNP; a cutoff for these metrics
of a value greater than 0.4 is often used to remove SNPs which have been imputed with
poor accuracy [103].
7.1.1 Objectives
This Chapter focuses on using POLARIS applied to real AD data by aiming to:
• Perform a gene-based analysis using POLARIS in the GERAD genotype data.
• Compare POLARIS real data gene-based results with those found using MAGMA-
PCA and MAGMA-SUMMARY.
• Perform POLARIS gene-based analysis in the GERAD imputed data.
• Compare the POLARIS gene-based results using genotyped and imputed data.
• Investigate whether POLARIS is biased by the number of SNPs in the gene and
compare this to MAGMA approaches.
• Demonstrate whether genes from the gene-based analysis are represented in con-
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served regions.
• Compute PRS pathway scores for the eight pathways previously found to be asso-
ciated with AD [23][24] and determine whether these pathways are associated with
AD when tested for association using the POLARIS approach.
• Determine whether any correlation is observed between the different POLARIS path-
ways to assess whether there is any statistical commonality between pathways.
7.2 Materials and Methods
POLARIS was applied to the largest and most powerful AD dataset (see detailed de-
scription in Section 2.1). The GERAD data was used as the test set (3,332 cases, 9,832
controls), and IGAP data (17,008 cases, 37,154 controls) excluding GERAD subjects was
used as the discovery set, and is thus used to improve power. A set-based risk score was
produced for every individual in the GERAD data.
POLARIS adjusts for LD between SNPs and therefore, the SNPs were not pruned for
LD and the entire data were used in this analysis. There were 419,048 SNPs in common
between the GERAD and IGAP data.
It was necessary to ensure that SNP alleles were coded in the same direction across both
the discovery (IGAP excluding GERAD subjects) and test (GERAD) datasets. This is
because summary statistics provide an effect size with respect to a particular allele and this
allele must be the same in both datasets. If alleles in IGAP-noGERAD were coded in the
opposite direction to those in GERAD, the summary effect size for the SNP was inverted.
SNPs with alleles AT, TA, CG or GC were excluded since the direction of the effect could
not always be determined when combining two studies. Of the SNPs in IGAP-noGERAD,
103,356 matched those in GERAD, the remaining had effect sizes inverted and no SNPs
were excluded due to ambiguity. An MAF filter of 0.01 was applied to the data.
POLARIS was also implemented to process the data as imputed with HRC, Chapter 5 also
considered the use of gene-based methods in both genotype and imputed data. Again, the
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complete data were used, since LD pruning was not required, a total of 3,169,840 SNPs
were in common between imputed GERAD and IGAP data.
7.2.1 POLARIS Gene-Based Analysis
POLARIS, MAGMA-PCA and MAGMA-SUMMARY were applied to the AD data to
determine gene-wide p-values in two cases. For the first case, only directly genotyped
SNPs from the GERAD data were used (cf. [21], where however, imputed genotype data
were used for IGAP summary statistics analysis). The second case considers the HRC
imputed GERAD data.
SNPs were assigned to genes using GENCODE (v19) gene models [78]. Only genes with
known gene status and those marked as protein coding were used. Two different gene
windows were considered, the first used no window around the gene, only SNPs within
the start and end position of the gene were included, and the second considered SNPs
which were within 35kb upstream and 10kb downstream of the gene. SNPs which belong
to multiple genes were assigned to all those genes.
For the genotype GERAD data, a total of 202,504 SNPs were assigned to 14,620 distinct
genes with a maximum of 1,342 SNPs in a gene and for the HRC imputed GERAD data,
1,122,570 SNPs were assigned to 17,072 distinct genes.
The missing genotypes in real data were imputed as in PLINK [50][51], where missing
genotypes are substituted by 2 ×MAF for each SNP. In the GERAD data, 0.0514% of
genotypes required imputation.
The results of gene-based analyses for AD data using POLARIS were compared to those
from the MAGMA-PCA approach in GERAD data and also the MAGMA-SUMMARY
approach in IGAP data (it was not possible to use MAGMA-PCA in the full IGAP sample,
as the individual genotypes were not available). For the latter, only SNPs present in both
IGAP and GERAD are considered. Prior to the gene-based analysis, SNP summary
statistics for the whole IGAP data were adjusted for the genomic control parameter,
λ=1.087, as reported in [21]. Many gene-based methods which use summary statistics are
139
inflated by the number of SNPs in a gene, this is due to the aggregration of small errors
in single SNP effect size estimation [79][95].
It was then assessed whether genes determined from the gene-based analysis were enriched
in conserved regions; both for genes which are evolutionary constrained and those which
reside in CNS. These regions are less likely to harbour variants of a strong effect or are
less prone to variation. The number of genes from the gene-based analysis with a p-value
below either a nominal (0.05) or gene-wide threshold (2.5× 10−6) and were in conserved
regions were determined. The 2x2 contingency tables have the number of genes with p-
values above and below the p-value threshold and the rows show the number of genes
in/out of LoF regions. The strength of association between location in LoF regions and
p-value was assessed using a chi-squared test. When the cell counts in the 2x2 table were
small a Fisher’s exact test was used to determine the association between gene significance
and location in LoF regions.
7.2.2 POLARIS Pathway Analysis
Pathway analyses can provide insights and lead to biological mechanisms of disease.
A POLARIS score was produced for every GERAD subject for each of the eight pathways
found to be associated with AD (immune response, regulation of endocytosis, cholesterol
transport, hematopoietic cell lineage, proteasome ubiquitin activity, reactome hemostasis,
clathrin and protein folding) [23][24]. A self-contained and competitive test of association
was performed for each of these pathway scores. A self-contained test was implemented
using a logistic regression model of the POLARIS pathway scores regressed with the AD
phenotype. A competitive test for each pathway was performed using a likelihood ratio
test to find the additional benefit of including the POLARIS pathway score to a model
including POLARIS scores across the whole genome.
Only SNPs with a p-value less than 0.5 in the IGAP study are included into the path-
way POLARIS risk score, since it was shown that maximum prediction using PRS was
attained using a p-value threshold of 0.5 [38]. The pathway risk score was used to find
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the association strength of the pathway by including the risk score in a logistic regression
model which adjusts for other population covariates.
The pairwise correlation between all eight POLARIS pathways was also investigated in
order to determine any commonality between the pathways. The Pearson correlation
coefficient was used (cor.test() in R) to test for all pairwise correlations between all eight
pathways.
7.3 Results
7.3.1 POLARIS Gene-Based Analysis
Table 7.1 demonstrates the number and proportion of genes below a particular p-value
threshold for POLARIS (combining IGAP-noGERAD summary statistic data and GERAD),
MAGMA-PCA in GERAD genotype data and MAGMA-SUMMARY in IGAP summary
statistic data. The table shows that there are many more significant associations for
MAGMA-SUMMARY as compared to POLARIS and MAGMA-PCA. However, these re-
sults may be misleading as statistically independent associations in some instances im-
plicate overlapping regions. To define genes as physically independent, we have annealed
associated genes that were not separated by at least 250kb in each analysis separately and
have taken the most associated gene. In the APOE region, significant genes on chromo-
some 19 between 44.4Megabase (Mb) and 46.5Mb were counted as one. The results for
the independent best genes are presented in Table 7.2.
The number of independent significant genes for all p-value thresholds is higher or equal for
POLARIS compared to the MAGMA-PCA approach in GERAD data. This is expected
as POLARIS uses both GERAD and IGAP-noGERAD data, while MAGMA-PCA uses
GERAD genotypes only. The results for the summary statistic approach show higher num-
bers of significant genes for higher significance thresholds. The five gene-wide significant
genes found by the summary statistics approach are: TOMM40, CLU, BIN1, MS4A4E
and CR1, which have all been previously reported as being associated with AD from single
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SNP analyses [19] [20]. For these five genes, POLARIS also finds an association, but does
not always reach gene-wide significance (p = 6.33×10−24, p = 7.17×10−6, 0.00112, 0.00108
and 0.00065 respectively). The difference between the results for MAGMA-SUMMARY
and MAGMA-PCA in the same data could be explained by the inflation seen in the
MAGMA-SUMMARY approach when associated SNPs are in LD, see Section 3.3.3 for
further explanation.
Table 7.1: Comparison of the Number and Proportion of All Genes Below a P-value
Threshold for POLARIS, MAGMA-PCA in GERAD data and MAGMA-
SUMMARY in IGAP data
P-value
Threshold
POLARIS
MAGMA-PCA
in GERAD
MAGMA-SUMMARY
in IGAP
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
1* 14620 14606 14607
0.05 840 0.0575 749 0.0513 783 0.0536
0.01 192 0.0131 162 0.0111 244 0.0167
0.001 30 0.0021 24 0.0016 62 0.0042
0.0001 13 0.0009 9 0.0006 31 0.0021
0.00001 6 0.0004 4 0.0003 21 0.0014
0.000001 4 0.0003 3 0.0002 15 0.0010
∗ Note that the total number of genes (p-values threshold equal to 1) differs, this is due
to some gene exclusions made by MAGMA software.
Table 7.2: Comparison of the Number and Proportion of Independent Genes Below a P-
value Threshold for POLARIS, MAGMA-PCA in GERAD data and MAGMA-
SUMMARY in IGAP data
P-value
Threshold
POLARIS
MAGMA-PCA
in GERAD
MAGMA-SUMMARY
in IGAP
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
1* 563 581 560
0.05 302 0.5364 283 0.4871 255 0.4554
0.01 116 0.2060 98 0.1687 114 0.2036
0.001 19 0.0337 12 0.0207 31 0.0554
0.0001 7 0.0124 4 0.0069 12 0.0214
0.00001 3 0.0053 2 0.0034 9 0.0161
0.000001 2 0.0036 1 0.0017 5 0.0089
∗ Note that the total number of genes (p-values threshold equal to 1) differs, this is due
to some gene exclusions made by MAGMA software.
The number and proportion of genes below particular p-value thresholds are seen in Table
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7.3 for the POLARIS gene-based analysis, MAGMA-PCA approach in GERAD imputed
data and MAGMA-SUMMARY approach in IGAP data containing only SNPs in the
GERAD imputed data. The MAGMA-SUMMARY method determines the largest number
of genes at the most stringent p-value thresholds compared to POLARIS and MAGMA-
PCA. POLARIS finds a larger number of genes at less stringent thresholds (p > 0.001)
compared to both MAGMA approaches. However, some genes may be in overlapping
regions, therefore, Table 7.4 is presented which includes only independent genes. Genes
are defined to be independent by annealing associated genes that were not separated by at
least 250kb and have taken the most associated gene. For the APOE region, all significant
genes on chromosome 19 between 44.4Mb and 46.5Mb were counted as one. Considering
just independent genes, the difference between the MAGMA-SUMMARY method is less
substantial, but a greater number of genes are still determined at low p-value thresholds.
This approach finds 4 additional genes compared to POLARIS; PICALM, CR1, MS4A4E
and BIN1, all of which have previously been identified as being associated with AD.
These genes did not attain gene-wide significance in the POLARIS gene-based analysis
(p=0.0172, p=0.00146, p=0.0002 and p=0.000821 respectively). The difference between
the results using MAGMA-PCA and MAGMA-SUMMARY in the same data is interesting,
and is potentially explained by increased power in MAGMA-SUMMARY when there is
LD between associated SNPs, see Section 3.3.3 for further details.
Table 7.3: Comparison of the Number and Proportion of All Genes Below a P-value
Threshold for POLARIS, MAGMA-PCA in GERAD imputed data and
MAGMA-SUMMARY in IGAP data
P-value
Threshold
POLARIS
MAGMA-PCA
in GERAD
MAGMA-SUMMARY
in IGAP
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
1* 17072 14605 14430
0.05 2037 0.1193 815 0.0558 808 0.0560
0.01 671 0.0393 179 0.0123 282 0.0195
0.001 142 0.0083 21 0.0014 79 0.0055
0.0001 31 0.0018 6 0.0004 46 0.0032
0.00001 9 0.0005 4 0.0003 20 0.0014
0.000001 5 0.0003 3 0.0002 15 0.0010
∗ Note that the total number of genes (p-values threshold equal to 1) differs, this is due
to some gene exclusions made by MAGMA software.
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Table 7.4: Comparison of the Number and Proportion of Independent Genes Below a
P-value Threshold for POLARIS, MAGMA-PCA in GERAD imputed data and
MAGMA-SUMMARY in IGAP data
P-value
Threshold
POLARIS
MAGMA-PCA
in GERAD
MAGMA-SUMMARY
in IGAP
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
No. of
Genes
Prop. of
Genes
1* 557 556 556
0.05 392 0.7038 270 0.4856 251 0.4514
0.01 247 0.4434 112 0.2014 128 0.2302
0.001 92 0.1652 11 0.0198 38 0.0683
0.0001 22 0.0395 2 0.0036 16 0.0288
0.00001 5 0.0090 2 0.0036 8 0.0144
0.000001 2 0.0036 1 0.0018 6 0.0108
∗ Note that the total number of genes (p-values threshold equal to 1) differs, this is due
to some gene exclusions made by MAGMA software.
In the HRC imputed GERAD data, the SNPs are annotated to 17,072 genes. Of these
genes, six reach gene-wide significance, compared to the four genes found using the
GERAD genotype data only. These genes are seen in Table 7.5. The gene-wide sig-
nifcant genes are CLU, BCL3, PVRL2, TOMM40, APOE and CLPTM1 ; these have all
been previously identified as being associated with AD. The majority of these associations
are influenced by APOE since these genes are close in location to the APOE gene. These
results are shown on the Manhattan plot in Figure 7.1, the gene-wide significant genes are
shown in red, and those with a suggestive p-value (2.5× 10−6 < p < 0.00001) are seen in
blue; these are DAB1, ZNF35 and RORA.
Table 7.5: Gene-Wide Significant Genes from POLARIS Gene-based Analysis in AD Im-
puted Data
POLARIS
Chr Gene No. of SNPs β SE P-value
8 CLU 25 0.521 0.1048 6.8× 10−7
19 BCL3 5 0.927 0.1499 6.1× 10−10
19 PVRL2 95 0.637 0.0532 5.7× 10−33
19 TOMM40 20 0.454 0.0351 2.9× 10−38
19 APOE 1 2.247 0.2679 4.9× 10−17
19 CLPTM1 93 0.461 0.0965 1.8× 10−6
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Figure 7.1: Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed GERAD
data
The gene-wide significant genes found when using the MAGMA-PCA approach in the
GERAD imputed data are shown in Table 7.6 and the gene-wide significant genes using
MAGMA-SUMMARY in the IGAP data (containing GERAD SNPs only) are seen in Table
7.7. The overlap of gene-wide significant genes between the three approaches; POLARIS,
MAGMA-PCA and MAGMA-SUMMARY is seen in Figure 7.2. All genes found using
MAGMA-PCA are also found by POLARIS and MAGMA-SUMMARY, and the MAGMA-
SUMMARY approach finds 12 additional gene-wide significant genes.
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Table 7.6: Gene-Wide Significant Genes from MAGMA-PCA Gene-based Analysis in AD
Imputed Data
MAGMA-PCA in GERAD
Chr Gene No. of SNPs P-value
19 BCL3 5 2.7× 10−8
19 PVRL2 92 4.9× 10−35
19 TOMM40 20 1.6× 10−48
Table 7.7: Gene-Wide Significant Genes from MAGMA-SUMMARY Gene-based Analysis
in IGAP Data (GERAD SNPs only)
MAGMA-SUMMARY in IGAP
Chr Gene No. of SNPs P-value
1 CR1 63 4.2× 10−8
2 BIN1 94 2.1× 10−7
8 CLU 13 1.0× 10−11
11 SPI1 16 1.8× 10−6
11 MS4A2 11 2.5× 10−7
11 MS4A4E 48 6.6× 10−8
11 PICALM 117 5.2× 10−9
19 PVR 16 1.4× 10−8
19 CEACAM19 13 2.0× 10−6
19 BCL3 4 2.4× 10−20
19 PVRL2 42 6.8× 10−24
19 TOMM40 6 7.3× 10−32
19 APOC4 8 3.8× 10−9
19 APOC4-APOC2 8 3.8× 10−9
19 CLPTM1 47 2.1× 10−8
19 MARK4 124 2.4× 10−10
19 EXOC3L2 19 9.7× 10−7
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Figure 7.2: Venn Diagram Displaying the Overlap of Gene-Wide Significant Hits from
POLARIS, MAGMA-PCA and MAGMA-SUMMARY
This analysis was repeated using a window around the gene of 35kb upstream and 10kb
downstream since this was found to improve power, as transcriptional regulatory elements
are likely to be contained within this window [76] (see Chapter 3). The 12 gene-wide
significant genes from this analysis are seen in Table 7.8. Again, a large number of genes
reside on chromosome 19, these are likely influenced by the large effect of APOE. Four
novel genes have been identified from this analysis; PPARGC1A, SCARA3, RORA and
ZNF423 [107]. The PPARGC1A gene has been linked to energy metabolism and the
generation of amyloid beta plaques [108] and has potential relevance to the human aging
process. The SCARA3 gene overlaps the gene CLU which has previously been identified
as being associated with AD [19], and has been found to be associated with total brain
volume [109], so is not actually a novel finding. The RORA gene has strong links with AD
associated genes and genes which are differentially expressed in the hippocampus [110].
The ZNF423 gene interacts with genes known to be associated with AD [111]. Therefore,
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these novel genes seem to be sensible candidate genes for AD. Again, these gene-based
results are plotted on a Manhattan plot in Figure 7.3.
Table 7.8: Gene-Wide Significant Genes from POLARIS Gene-based Analysis in AD Im-
puted Data Using a Gene Window (35kb upstream and 10kb downstream)
POLARIS
Chr Gene No. of SNPs β SE P-value
4 PPARGC1A 480 0.877 0.1851 2.2× 10−6
8 SCARA3 240 0.526 0.1064 7.8× 10−7
15 RORA 1813 0.334 0.0674 7.4× 10−7
16 ZNF423 1056 0.551 0.1163 2.1× 10−6
19 BCL3 88 0.377 0.0674 4.2× 10−9
19 CBLC 50 0.605 0.1161 1.8× 10−7
19 BCAM 71 0.556 0.0543 1.4× 10−24
19 PVRL2 160 0.546 0.0299 9.4× 10−75
19 TOMM40 108 0.500 0.0298 3.4× 10−63
19 APOE 55 0.520 0.0315 4.4× 10−61
19 APOC1 34 0.475 0.0315 1.5× 10−51
19 APOC4-APOC2 62 0.615 0.0871 1.6× 10−12
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Figure 7.3: Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed GERAD
data Using a Gene Window 35kb Upstream and 10kb Downstream
7.3.1.1 Correlation Between P-values and the Number of SNPs in a Gene
The issue of bias in the estimation of set-based p-values caused by gene size is insufficiently
tackled by most available methods [84][95]. Larger genes harbour a larger number of
SNPs, and if each SNP has a small inflation in p-value due to, for example, unaccounted
stratification, then these large genes will show greater accumulated inflation. To assess
whether this is an issue in POLARIS, the phenotypes in GERAD data were permuted
to create 1,000 simulations, and for each gene the empirical p-value (the proportion of
gene-based p-values less than 0.05) was computed. The correlation between the number
of SNPs per gene and the empirical p-value of each gene in AD data was then determined.
No evidence (r=0.0009, p=0.9096) of a correlation between the number of SNPs in a gene
and the gene p-value for the POLARIS method was found. Therefore, associations with
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disease observed in larger genes is not simply due to a greater number of SNPs in the
gene. Similarly, we observed no evidence (r=-0.00321, p=0.6977) of an inflation in p-value
for increasing gene size using MAGMA-PCA on GERAD data. When considering the
correlation between the IGAP gene-based p-value and set size, we observe a statistically
significant negative correlation (r=-0.083, p< 2.2 × 10−16) when MAGMA-SUMMARY
is used on summary data, indicating that the higher the number of SNPs, the lower the
set-based p-value.
7.3.1.2 Conserved Regions
Loss of Function (LoF) genes from The Exome Aggregation Consortium (ExAC)
As discussed in Section 3.3.1.4, GWAS data was interrogated for genes that are evolution-
ary constrained, probably due to functional importance. It was assessed whether there
was enrichment for either LoF intolerant genes using the POLARIS gene-based results in
both genotyped and imputed data.
Table 7.9 show the contingency tables at different p-value thresholds, 0.05 and 2.5× 10−6
respectively, for LoF genes based on the POLARIS gene-based results in genotype data.
For the 14,620 genes from the analysis, there is no evidence that the genes found here are
constrained for both the nominal and gene-wide p-value threshold (p=0.7786 and p=0.5665
respectively). The Fisher’s exact test is used for the gene-wide p-value threshold, since
the cell counts are small.
Table 7.9: Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data
p ≤ 0.05 p > 0.05
in LoF 162 2595
out LoF 678 11185
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 1 2756
out LoF 3 11860
(ii) p ≤ 2.5× 10−6
The analysis presented in Table 7.9 does not adjust for potential correlation between
genes. Since the same SNPs may be assigned to multiple genes, it is not possible to
assume independence between genes. Therefore, the analysis is repeated removing genes
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within 250kb of one another, retaining the most significantly associated gene. The results
for the gene-based analysis are shown in Table 7.10. There are 563 genes which do not
overlap, these show no enrichment for genes in conserved regions at either the nominal or
gene-wide p-value threshold (p=0.9166 and p=1 respectively).
Table 7.10: Number of LoF Genes from the Exome Aggregation Consortium, Genotype
Data, No Overlapping Genes
p ≤ 0.05 p > 0.05
in LoF 53 44
out LoF 249 217
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 97
out LoF 2 464
(ii) p ≤ 2.5× 10−6
Similarly, the results for the 17,072 genes from the POLARIS gene-based analysis in im-
puted data are seen in Table 7.11. There is no evidence that the genes were in constrained
regions based on nominal and gene-wide significance p-values (p=0.07 and p=0.28).
Table 7.11: Number of LoF Genes from the Exome Aggregation Consortium, Imputed
Data
p ≤ 0.05 p > 0.05
in LoF 380 2560
out LoF 1657 12475
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 2 2938
out LoF 4 14128
(ii) p ≤ 2.5× 10−6
Again, this analysis was repeated for non-overlapping genes from the gene-based analysis
in the imputed data. The results are shown in Table 7.12, for the 557 non-overlapping
genes, there is no evidence that the genes are enriched in conserved regions at either the
nominal or gene-wide p-value thresholds (p=0.9052 and p=0.3505 respectively).
Table 7.12: Number of LoF Genes from the Exome Aggregation Consortium, Imputed
Data, No Overlapping Genes
p ≤ 0.05 p > 0.05
in LoF 75 33
out LoF 317 132
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 1 107
out LoF 1 448
(ii) p ≤ 2.5× 10−6
These results indicate that there is no significant increase in the number of significant
genes in conserved regions. This finding is opposite to that found in Schizophrenia [102],
where authors observed that common GWAS signals are highly enriched among genes
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under strong selection pressures.
Conserved Noncoding Sequences (CNS)
The contingency tables showing whether the genes from the POLARIS gene-based analysis
reside in CNS are seen in Tables 7.13 for both nominal and gene-wide p-value thresholds.
The cell counts are small for both tables and therefore a Fisher’s exact test was used
to determine whether there was an enrichment of genes in CNS. There was no evidence
of enrichment for either the nominal or gene-wide p-value threshold (p=0.4026 and p=1,
respectively).
Table 7.13: Number of Genes in Conserved Noncoding Sequences, Genotype Data
p ≤ 0.05 p > 0.05
in LoF 0 27
out LoF 840 13753
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 27
out LoF 4 14589
(ii) p ≤ 2.5× 10−6
The analysis considering only non-overlapping genes from the gene-based analysis in geno-
type data is shown in Table 7.14. For the 563 non-overlapping genes, there is no evidence
of genes being enriched in CNS at either p-value threshold (p=1 for both).
Table 7.14: Number of Genes in Conserved Noncoding Sequences, Genotype Data, No
Overlapping Genes
p ≤ 0.05 p > 0.05
in LoF 0 0
out LoF 302 261
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 0
out LoF 2 561
(ii) p ≤ 2.5× 10−6
The same analysis was carried out for the 17,072 genes from the POLARIS gene-based
analysis in the imputed data, the results are seen in Table 7.15. Again, a Fisher’s exact
test is used for both tables due to the small cell counts. No enrichment of genes in CNS
is observed for either the nominal or gene-wide p-value threshold (p=0.137 and p=1,
respectively).
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Table 7.15: Number of Genes in Conserved Noncoding Sequences, Imputed Data
p ≤ 0.05 p > 0.05
in LoF 6 22
out LoF 2031 15013
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 28
out LoF 6 17038
(ii) p ≤ 2.5× 10−6
Table 7.16 shows the analysis considering only non-overlapping genes. For these 557 genes,
there is no evidence of an enrichment of genes in CNS at either the nominal or gene-wide
p-value threshold (p=0.5586 and p=1 respectively).
Table 7.16: Number of Genes in Conserved Noncoding Sequences, Imputed Data, No Over-
lapping Genes
p ≤ 0.05 p > 0.05
in LoF 3 0
out LoF 389 165
(i) p ≤ 0.05
p ≤ 2.5× 10−6 p > 2.5× 10−6
in LoF 0 3
out LoF 2 552
(ii) p ≤ 2.5× 10−6
Across all these different analyses, there is consistently no enrichment at the gene-wide p-
value threshold for genes in either Loss of Function (LoF) regions or Conserved Noncoding
Sequences (CNS). The analyses considering non-overlapping genes show consistent results,
suggesting there is little correlation between genes, or that this correlation has little impact
on the chi-squared test. It is anticipated that there will no enrichment of genes associated
with AD in LoF or CNS since AD is a post-reproductive disorder.
7.3.2 POLARIS Pathway Analysis
The POLARIS pathway scores were computed for the eight pathways previously found
to be associated with AD [23][24], see Table 7.17. Both self-contained and competitive
tests are presented, where a self-contained test demonstrates whether the pathway is as-
sociated with AD, whereas the competitive test demonstrates whether a pathway shows
an association with AD which is independent of the baseline level of association. The
p-values from the original ALIGATOR analysis [61] are also presented in the table for
comparison. A pathway is considered as significant if the p-value is below 3.125 × 10−3,
using a Bonferroni correction (0.05÷ (8×2)) [71]. All eight pathways are significant in the
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self-contained analysis, and four pathways withstand the adjustment for baseline associa-
tion; these are the immune response, cholesterol transport, hematopoietic cell lineage and
the clathrin pathways. The additional pathways found to be associated with AD demon-
strate the power of the POLARIS method from utilising all available data. The number
of significant pathways from the competitive test is greater using POLARIS compared
to using PRS or MAGMA. ALIGATOR p-values are consistently lower than those from
POLARIS, this is because ALIGATOR selects genes with at least one significant SNP
whereas pathways calculated using POLARIS include all SNPs with a p-value less than
0.5 so is more influenced by noise.
Table 7.17: AD Associated Pathways Calculated Using POLARIS in GERAD data
Pathway Beta SE Psc Pc
ALIGATOR
p-value
1. Immune
response
0.2754 0.0305 1.57× 10−19 4.30× 10−10 0.00266
2. Regulation of
endocytosis
0.1295 0.0301 1.73× 10−5 0.0279 0.0002
3. Cholesterol
transport
0.1428 0.0305 2.73× 10−6 8.55× 10−5 0.00024
4. Hematopoietic
cell lineage
0.1560 0.0299 1.76× 10−7 6.27× 10−6 0.00007
5. Proteasome-
ubiquitin activity
0.1070 0.0305 0.0004 0.0285 0.00929
6. Reactome
hemostasis
0.1317 0.0301 1.18× 10−5 0.0434 0.00785
7. Clathrin 0.1734 0.0306 1.42× 10−8 0.0002 0.00038
8. Protein
folding
0.0949 0.0301 0.0016 0.0471 0.00634
The correlations between all eight POLARIS pathway risk scores is shown in Table 7.18.
Again, the pathway numbers correspond to those in Table 7.17 and the pathway risk
scores are adjusted for population stratification by regressing the scores against principal
components, and testing the pairwise correlation between the residuals from this model.
Similarly to before, all pathways are strongly correlated with one another, although the
actual correlation coefficients are very close to zero. The small p-values are due to the large
number of individuals (N=13,164). The immune response pathway is most strongly corre-
lated with all other pathways. The immune response and reactome hemostasis pathways
have the largest positive correlation coefficient (r=0.3214).
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Table 7.18: Correlations Between AD Associated Pathways, where Correlations were Cal-
culated Using Individual PRS Estimated With POLARIS, where POLARIS is
adjusted for population stratification (Pathway Numbers Correspond to those
in Table 7.17)
Corr.
Coeff
(p-value)
1 2 3 4 5 6 7 8
1
1
(0)
0.1659
(< 2.2× 10−16)
0.0861
(< 2.2× 10−16)
0.1531
(< 2.2× 10−16)
0.0815
(< 2.2× 10−16)
0.3214
(< 2.2× 10−16)
0.1326
(< 2.2× 10−16)
0.0732
(< 2.2× 10−16)
2
1
(0)
0.0524
(1.8× 10−9)
0.0237
(0.0064)
0.0335
(0.0001)
0.1070
(< 2.2× 10−16)
0.2137
(< 2.2× 10−16)
0.0266
(0.0023)
3
1
(0)
0.0735
(< 2.2× 10−16)
0.0464
(1.0× 10−7)
0.0557
(1.6× 10−10)
0.0948
(< 2.2× 10−16)
0.0883
(< 2.2× 10−16)
4
1
(0)
0.0059
(0.4962)
0.0791
(< 2.2× 10−16)
0.0547
(3.3× 10−10)
0.0389
(8.0× 10−6)
5
1
(0)
0.0552
(2.3× 10−10)
0.0419
(1.6× 10−6)
0.0574
(4.3× 10−11)
6
1
(0)
0.1441
(< 2.2× 10−16)
0.0514
(3.6× 10−9)
7
1
(0)
0.0451
(2.3× 10−7)
8
1
(0)
7.4 Discussion
This chapter aimed to apply the POLARIS methodology introduced in Chapter 6 to the
real AD data as both a gene and pathway based analysis.
Initially, a gene-based analysis was performed using the genotype GERAD data as the
test set and IGAP data excluding the GERAD subjects was used to inform the analysis.
POLARIS determined more statistically significant genes than the MAGMA-PCA method
in the same GERAD data, since it uses the additional IGAP set. MAGMA-SUMMARY
in the IGAP data has determined the largest number of gene-wide significant genes, al-
though, as discussed in Section 3.3.3, this method seems to have unusually large power in
summary statistics compared to the original genotype data. POLARIS does not identify
any novel genes here, since this only considers genotype data, despite being informed with
IGAP-noGERAD effect sizes. Perhaps the lack of novel genes identified could be due to
heterogeneity between studies in IGAP, effects apparent in GERAD may be cancelled out
by opposing effects in the other consortia.
The gene-based results in the HRC imputed GERAD data find a larger number of gene-
wide significant genes compared to the analysis in the genotype data, suggesting the
increased power of using the imputed data. No novel genes were determined until a
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gene window was expanded around the gene, 35kb upstream and 10kb downstream. This
reiterates the finding that the use of a window around the gene includes more informative
SNPs and hence enhances the statistical power, since the window includes transcriptional
regulatory elements in the gene. The three novel genes found to be associated with AD
are PPARGC1A, RORA and ZNF423, all of which have credible biological relevance to
AD [107].
PPARGC1A (peroxisome proliferator-activated receptor gamma co-activator 1alpha) is a
transcriptional coactivator involved in a wide range of cellular and physiological functions.
It is part of the PGC-1 family of transcriptional coactivators that mainly regulate mito-
chondrial biogenesis to in turn regulate the cellular energy metabolism [112]. The gene
product, PGC-1, is an interacting partner of a wide range of nuclear receptors and tran-
scription factors. It is associated with a wide-range of biological processes (Gene Ontol-
ogy, http://www.ensembl.org), including response to a variety of cellular and external
stimuli, cellular glucose homeostasis, circadian rhythm, regulation of neuron apoptosis,
etc. Previous animal model work has shown that overexpression of hPGC-1 in APP23
mice improved spatial and recognition memory, along with significant reduction of Aβ
deposition [108]. Furthermore, hPGC-1 overexpression also reduced the levels of proin-
flammatory cytokines and microglial activation [113][108]. This suggests a direct link with
recent genetic evidence of microglia-mediated innate immune response involvement in AD
[22]. In addition, an activation of PGC-1 by EKR and p38 inhibitors have been shown to
improve spatial and learning memory in Aβ-injected rats [114]. PPARGC1A has also been
implicated in the pathogenesis of other neurodegenerative disorders, namely Huntington’s
and Parkinson’s diseases [115].
Retinoic acid receptor-related orphan receptor alpha (RORA) is a nuclear hormone re-
ceptor and is involved in a variety of functions; such as circadian rhythm, cholesterol
metabolism and inflammation [116]. RORA binds to genomic regions of transcription start
sites of more than 3,000 genes in human monocytic and endothelial cell lines [117]. RORA
and PPARGC1A are close biological partners, with PGC-1 stimulating the expression of
a number of clock genes through the coactivation of the ROR family of orphan nuclear
receptors [118]. RORA has been shown to be linked to other genes previously implicated
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in AD [111] and has also been implicated in a large number of neuropsychiatric disorders,
such as post-traumatic stress disorder [119]. Furthermore, RORA trans-activates Il-6 and
is thought to be neuro-protective in astrocytes and anti-inflammatory in peripheral tissues
[120]. The two genes, RORA and PPARGC1A provide further evidence of the involvement
of inflammation in the pathogenesis of AD.
Finally, ZNF423 is a nuclear protein that belongs to the Kruppel-like C2H2 zinc finger
proteins. ZNF423 directs bone morphogenetic protein (BMP)-dependent signalling ac-
tivity and aberrant forms impede B cell differentiation [121]. Furthermore, an increased
gene-expression of ZNF423 has been associated in patients with systemic lupus erythe-
matosus pointing to an impaired function of B cells in human mesenchymal stem cells
[122]. ZNF423 resides in an AD-specific protein network [111]. ZNF423 is likely in-
volved in DNA damage repair [123]. Previously, it also has been shown that missense
and LoF variants are likely pathogenic for abnormality of brain morphology, Joubert syn-
drome and Nephronophthisis with autosomal dominant or autosomal recessive inheritance
(www.omim.org,https://www.ncbi.nlm.nih.gov/clinvar/). These disorders present
with a range of phenotypic characteristics, with the central nervous system being affected
too (more specifically the cerebellar vermis). In nur12 mouse model (with introduced
nonsense mutation in exon 4 of the mouse Zfp423 gene), [124] observed loss of the corpus
callosum, reduction of hippocampus, and a malformation of the cerebellum reminiscent
of patients with Dandy-Walker syndrome. Within the cerebellum, Zfp423 was observed
to be expressed in both ventricular and external germinal zones. Loss of Zfp423 was also
observed to lead to diminished proliferation by granule cell precursors in the external ger-
minal layer and abnormal differentiation and migration of ventricular zone-derived neurons
and Bergmann glia [124].
It was demonstated that POLARIS results are not inflated by set size (number of SNPs
in the gene), this effect was also not observed using MAGMA-PCA but was seen using
MAGMA-SUMMARY.
As has been observed previously, genes determined from the gene-based analysis show no
enrichment in conserved regions, in either evolutionary constrained regions or in CNS.
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This is expected in AD because it is a post-reproductive disorder.
POLARIS pathway risk scores were produced for the eight pathways previously found
to be associated with AD [23][24]. All eight of the POLARIS pathway risk scores were
found to be associated with AD from the self-contained test. Four of these pathways
remain associated after adjustment for baseline association; these are the immune response,
cholesterol transport, hematopoietic cell lineage and clathrin pathways. The strongest
correlation is between the immune response and reactome hemostasis pathways.
A Python code has been made available at github.com/BakerEA/POLARIS, a copy of the
code is in the Supplementary Material Section 11.3. This code is able to handle set-based
analyses when the sets contain less than 200 SNPs. The code is command line based,
includes the SNP to gene annotation, allele flipping, POLARIS and logistic regression.
POLARIS could also be used in a similar way to the regular PRS approach whereby
all SNPs across the genome are included. This is computationally demanding, and is
not available in the current software. A newer software is currently under development
which is written in C and aims to accommodate a larger number of SNPs and speed up
calculations.
POLARIS has the advantages that 1) it produces a risk score per person per set. This
can help to identify subjects for clinical trials and further functional studies. 2) POLARIS
successfully adjusts for LD between SNPs and therefore LD pruning is not required prior
to analysis. 3) POLARIS is able to utilise additional data to improve power whilst main-
taining a test of association in the original data. 4) POLARIS is not influenced by the
number of SNPs in the set, large sets are not biased and more likely to be significant.
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8 POLARIS: Polygenic LD-Adjusted Risk
Score Whole Genome Based Approach
8.1 Introduction
PRS is most widely used to determine the overall polygenicity of disease by combining
the effects of common SNPs which show some association to disease, but do not reach the
genome-wide significance threshold (p < 5× 10−8). PRS has been used to show the poly-
genic contribution in a number of different complex disorders, such as AD [38], Parkinson’s
disease [125] and SZ [37]. PRS unlocks the latent information and is therefore able to ex-
plain a larger amount of heritability compared to genome-wide significant SNPs only [37].
Studies have shown that including loci which do not reach genome-wide significance into
the polygenic score have increased estimated heritability in AD [126]. Another motivation
for using whole genome PRS is to predict disease case/control status or the trait liability
of all SNPs, and it is expected that using all SNPs will have better discriminatory power
than prediction based on set-specific risk scores.
POLARIS [96] has been shown to be a powerful set-based method compared to MAGMA
approaches. POLARIS produces a risk score per individual per set of SNPs whilst ad-
justing for LD between SNPs. Like standard PRS [37], POLARIS is applicable to any set
of SNPs, including all SNPs across the whole genome. In this Chapter the use of PO-
LARIS as a whole genome approach is examined in the genotyped GERAD data, using
IGAP-noGERAD (IGAP data excluding GERAD subjects) as weights in the score.
POLARIS uses the square inverse of the correlation matrix between SNPs in order to cor-
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rect genotypes for LD, giving LD adjusted dosages. Clearly, using all SNPs in the genome
will require the inversion of a large matrix (419,048 x 419,048 for genotyped GERAD data
and 3,169,840 x 3,169,840 for imputed GERAD data) which is highly computationally
demanding. The simplest approach to reduce the computational burden is to split all
SNPs across the genome into chromosomes; it is assumed there is no LD between SNPs
on different chromosomes (Chr1: 32,285 x 32,285 in genotyped GERAD data and 240,991
x 240,991 in the imputed GERAD data; Chr22: 6,301 x 6,301 in genotyped GERAD data
and 42,381 x 42,381 in imputed GERAD data). The whole genome risk score is then sim-
ply a sum of all chromosomal risk scores. However, with the increasingly widespread use of
imputed data, the number of SNPs per chromosome remains large and therefore this still
has computational issues. Another approach to resolve the computational burden would
be to use a sliding window of SNPs, although the windows must overlap and therefore,
it is complicated to adjust for LD when there are multiple measures for each SNP. Due
to the large dimensionality of the imputed GERAD data and to make results comparable
with [21] and [38], only the genotyped GERAD data is used in this chapter. The approach
which computes the POLARIS score per chromosome, and then sums the chromosomal
scores is used; this is the simplest method since it does not require defining the LD region
size.
LDpred [127] is an alternative method to POLARIS which also adjusts effect sizes for the
LD structure of SNPs. LDpred uses a Bayesian approach which estimates the posterior
mean effect sizes from the discovery data and the LD information in the SNPs. For
large sample sizes, the β adjustment in LDpred corresponds to multiplying the effect
sizes (βs) by the inverse of the correlation matrix. LDpred has two different models,
the infinitesimal model which assumes that all SNPs are causal and the noninfinitesimal
model which assumes some SNPs are not causal. The noninfinitesimal models use a p-
value threshold for the inclusion of SNPs, here, the p-value threshold used is 1, so that all
SNPs are included. The p-value thresholding is equivalent to that used in both POLARIS
and PRS.
POLARIS [96] uses spectral decomposition of the SNP correlation matrix to adjust the
individuals’ allele counts for LD structure, however, this is equivalent to adjusting the
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effect sizes (β) or weights which are used in the risk score. For this reason, POLARIS
used on all SNPs across the whole genome is compared to LDpred.
In this chapter, POLARIS is evaluated by comparing results calculated using POLARIS
with those found using unadjusted PRS [37] and LDpred [127] on simulated and real AD
data. The effect size adjustment in POLARIS and LDpred are also compared.
PRS across the whole genome is often used for disease prediction; to determine whether the
polygenic component of disease is able to predict whether a subject is a case or control.
This has been investigated using standard PRS in pruned GERAD data (using the --
clump option in PLINK, which prioritises SNPs which are most associated with disease,
hereafter referred to as intelligent pruning), where the maximum prediction accuracy for
AD is found by incorporating PRS using a p-value threshold of 0.5 into a model including
the number of APOE -4 alleles, the number of APOE -2 alleles, a PRS including index
SNPs from the 20 GWAS hits, age and sex, giving an Area Under the Curve (AUC) of
0.782 [38]. This has been calculated as 90% of the total prediction accuracy available,
based on genetics alone [128]. The impact of using the POLARIS score in these prediction
models is assessed to determine if POLARIS is able to improve upon prediction accuracy
using just APOE effects and GWAS hits.
8.1.1 Objectives
This Chapter aims to:
• Compare the power of POLARIS to LDpred and unadjusted PRS in both simulated
and real AD GERAD data, using effect sizes from IGAP-noGERAD .
• Compare the LD adjustment of the effect sizes (βs) in POLARIS and LDpred in
simulated data. This is to observe the changes in βs after LD adjustment, in data
where the LD structure is defined and therefore simple to interpret.
• Consider POLARIS as a whole genome PRS approach in real AD data.
• Discuss the computational issues with running POLARIS in large sets of SNPs and
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consider possible solutions. POLARIS involves the inversion of the correlation ma-
trix, which can be computationally expensive when the matrix is large.
• Assess whether POLARIS across the whole genome is able to predict AD case-control
status. This prediction accuracy is compared to that using PRS in intelligently
pruned data [38].
8.2 Materials and Methods
8.2.1 POLARIS
POLARIS [96] is a method which adjusts genotypes for LD, creating a dataset containing
independent LD adjusted genotypes which can then be used to compute a polygenic score.
POLARIS has been introduced as a set-based method, but is applicable to any set of SNPs,
including all SNPs across the genome. The simplest approach to do this is to compute the
POLARIS score for all SNPs on each chromosome, and then sum across the chromosomal
scores to determine a whole genome risk score. This simple chromosomal approach was
used in this chapter, since it does not require the definition of the size of the LD region.
Due to the higher dimensionality of the imputed data, only the genotyped GERAD data
is used in this analysis.
8.2.2 LDpred
LDpred [127] is a Bayesian approach which also adjusts the standard PRS for LD between
SNPs. It does this by determining the posterior mean effect size for each SNP using a
prior on effect sizes (βs) and estimating LD from an external reference panel.
When sample sizes are large, the LDpred β adjustment is simply done by multiplying the
βs by the inverse of the correlation matrix, see Equation 8.1.
β˜ ≈ D−1β (8.1)
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where β˜ are the LD adjusted effect sizes, D is the correlation matrix between SNPs
estimated from the test set and β are the original effect sizes from the discovery set.
POLARIS produces risk scores whilst adjusting for LD between SNPs. The adjustment
in POLARIS using the square inverse of the correlation matrix was compared to using
an adjustment of the inverse of the correlation matrix; it was shown that the type I
error was consistent, but POLARIS gave higher power, see Chapter 6. However, LDpred
is expected to differ slightly from the results adjusting for LD using the inverse of the
correlation matrix, since if only a proportion of SNPs are assumed to be causal, a Markov
Chain Monte Carlo (MCMC) method is used, as an explicit solution is too complicated
[127].
LDpred avoids the computational issue of handling large matrices by performing the LD
adjustment in smaller regions, since the LD matrix is approximately block diagonal. Al-
though, the user has to define the size of the region, this can be difficult and some LD
between SNPs could be missed if the defined region is too small.
LDpred takes the effect sizes (βs) from the discovery data, and uses the genotype data
available in the test set in order to estimate the LD structure between SNPs.
8.2.3 Comparison between POLARIS, PRS and LDpred
To understand detailed differences and similarities between POLARIS, PRS and LDpred,
these approaches were used on extreme simulated data and real data LD patterns between
SNPs. Both type I and type II errors were investigated by simulating null effects and
introducing some association to the SNPs.
Genotype (test) data and summary statistic (discovery) data were simulated in order to
compare the power between POLARIS and LDpred. A dataset was simulated which was
then randomly split into discovery and test sets. The summary statistics for each SNP in
the discovery set were computed. The following LD structure was simulated: 4 LD Blocks
of 10 SNPs each, and 60 independent unassociated SNPs. Block 1 has pairwise r2 = 0.2,
Block 2 has pairwise r2 = 0.4, Block 3 has pairwise r2 = 0.6, and Block 4 has pairwise
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r2 = 0.8, all 40 SNPs in LD with OR ∼ N(1.02, 0.36) (OR from a Normal Distribution
with mean 1.02 and variance 0.36). The mean and variance for the sampled effect sizes
were calculated from all SNPs in the IGAP data [20]. The LD structure for this simulated
data is seen in Figure 8.1.
Figure 8.1: LD Plot for 100 SNPs in Complex LD Simulations
Only POLARIS and LDpred were compared in this simulated scenario; PRS requires LD
pruning and since only SNPs in LD are associated with disease, these would be removed
by LD pruning. So PRS would show very low power compared to the other methods.
The sample size of both the test and discovery dataset was varied in order to determine the
influence of sample size on all methods. Test set sample sizes were N=1,000 and N=10,000
and discovery set sample sizes were N=10,000 and N=50,000. In both the discovery and
test datasets, 30% of the sample size were cases.
A total of 1,000 simulations were performed. The power to detect the association between
the score and disease is calculated as the proportion of p-values from the 1,000 simulations
which were below a given p-value threshold; the p-value thresholds used were p=0.05, 0.01
and 0.001.
To ensure LDpred [127] was comparable to POLARIS, the LD structure was estimated
from the test dataset to adjust effect sizes in the discovery set, using an LD radius of 100
SNPs (the number of SNPs on each side of the focal SNP for which LD should be adjusted)
and other parameters as default. Both the infinitesimal model and p-value threshold of 1
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are presented for simulated data, where the infinitesimal model assumes that all markers
are causal.
The β adjustment between POLARIS and LDpred were plotted in order to compare the
adjustment between the two approaches. The first simulation was taken for the case where
the test set N=1,000 and the discovery set N=10,000 and where the test and discovery
sample sizes are both 10,000. Each of the 100 SNPs were plotted along the x-axis and the
original and adjusted βs were plotted on the y-axis. Vertical lines were used to demonstrate
the differences between the strength of LD in each of the LD blocks, so the degree of
adjustment is comparable. The LDpred approach substantially reduces the magnitude of
the β values, so for these plots, the adjusted βs have been scaled by the gradient between
the original and adjusted βs in the independent SNPs.
POLARIS, PRS and LDpred were additionally compared on all SNPs in both pruned
and unpruned real AD data. The GERAD [19] data (GWAS) data (3,332 cases, 9,832
controls) were used as the test dataset and the IGAP [20] data (17,008 cases, 37,154
controls) excluding GERAD subjects were used as the discovery data in order to inform
all analyses with association effect sizes (βs). Data is pruned using an r2 threshold of 0.2,
and both random and intelligent pruning (--indep and -- clump options in PLINK [50][51]
respectively) were considered, where intelligent pruning retains the most associated SNPs.
The unpruned genotyped GERAD data contains 419,048 SNPs, the intelligently pruned
data contains 60,510 SNPs and the randomly pruned data has 94,277 SNPs. All analyses
excluded chromosome 19 to remove the large effect of APOE.
For this study, only directly genotyped SNPs from the GERAD data were used, since this
makes the results directly comparable with [21] and [38]. The GERAD data and IGAP
data excluding GERAD subjects have 419,048 SNPs in common.
It was necessary to ensure that SNP alleles were coded in the same direction across both
the discovery (IGAP excluding GERAD subjects) and test (GERAD) datasets. This is
due to the effect sizes for a SNP being relative to a specific allele, so this reference allele
must be consistent across the two datasets. If alleles in the discovery set were coded in
opposite direction to those in GERAD, the summary effect size for the SNP was inverted.
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SNPs with alleles AT, TA, CG or GC were excluded since the direction of the effect could
not always be determined when combining two studies. Of the SNPs in the discovery set,
103,356 matched those in GERAD, the remaining had effect sizes inverted and no SNPs
were excluded due to ambiguity. An MAF filter of 0.01 was applied to the data.
The missing genotypes in real data were imputed as in PLINK [50][51], where missing
genotypes are substituted by 2 ×MAF for each SNP. In the GERAD data, 0.0514% of
genotypes required imputation.
The whole genome risk scores were computed using a number of different individual p-
value thresholds for the inclusion of SNPs (p=0.0001, 0.001, 0.01 0.05, 0.1, 0.2, 0.3, 0.4,
0.5, 0.6, 0.7, 0.8, 0.9, 1) and a logistic regression model was used to determine the overall
association of the risk score with AD, adjusting for population covariates such as age, sex,
ethnicity and PCs.
8.2.4 Prediction Modelling Using POLARIS
The ability of the whole genome POLARIS score to predict whether an individual has
AD or not was investigated. The sensitivity, specificity and AUC are computed for the
POLARIS scores with each individual p-value threshold. Sensitivity is the probability of
correctly predicting a person has AD and the specificity is the probability of correctly
predicting a person does not have AD. The AUC is found from a Receiver Operating
Characteristic (ROC) curve which plots the sensitivity on the y-axis and 1-specificity on
the x-axis; an AUC of 1 shows perfect prediction ability and a value of 0.5 represents no
prediction accuracy, or the equivalent of randomly guessing whether a person will have
AD or not. These values are computed using the pROC package in R software.
Prediction models included the POLARIS score along with a number of other covariates;
the number of APOE 4 alleles, the number of APOE 2 alleles, the PRS score containing
the 20 GWAS index SNPs (see Supplementary Table 11.2 for details), age and sex in order
to compare with the PRS prediction analysis in intelligently pruned GERAD data [38].
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8.3 Results
8.3.1 Comparison Between POLARIS, PRS and LDpred
8.3.1.1 Simulation Results
Firstly, the comparison between LDpred and POLARIS in simulated data is considered.
The simulated data have 4 LD Blocks of 10 SNPs each, and 60 independent unassociated
SNPs. Figure 8.2 displays the type I error for the different methods with the corresponding
95% CIs. In all type I error and power graphs, POLARIS is displayed as the blue line, the
infinitesimal LDpred model is shown by the solid red line and the LDpred model using a
p-value threshold of 1 is displayed by the dashed red line. Type I error is slightly higher in
LDpred compared to POLARIS when the discovery set N=10,000, but the nominal value
still resides within the 95% CI. The results for all sample sizes seem reasonable, with the
LDpred type I error being slightly inflated when the test and discovery set have N=10,000.
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Figure 8.2: Type I Error Comparison Between POLARIS and LDpred: Simulation of 10
SNPs in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD
with r2 = 0.6, 10 SNPs in LD with r2 = 0.8 and 60 independent, unassociated
SNPs.
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The power comparison between POLARIS and LDpred is shown in Figure 8.3. The two
methods have very similar power for all simulated sample sizes.
It is evident that POLARIS and LDpred have almost identical power in all cases, and it
is difficult to differentiate between the two methods. Figure 8.4 shows the same plots, but
zoomed into a specific point on the y-axis in order to observe slight differences between
POLARIS and LDpred. The power is slightly higher for POLARIS compared to LDpred,
except when the test and discovery set N=10,000, this is the same case where LDpred has
inflated type I error compared to POLARIS, so perhaps this explains the difference here.
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Figure 8.3: Power Comparison Between POLARIS and LDpred: Simulation of 10 SNPs
in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10 SNPs in LD with
r2 = 0.6, 10 SNPs in LD with r2 = 0.8, all 40 SNPs in LD Blocks have
OR∼ N(1.02, 0.36), and 60 independent, unassociated SNPs.
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Figure 8.4: Power Comparison Between POLARIS and LDpred with a closeup of y-axis:
Simulation of 10 SNPs in LD with r2 = 0.2, 10 SNPs in LD with r2 = 0.4, 10
SNPs in LD with r2 = 0.6, 10 SNPs in LD with r2 = 0.8, all 40 SNPs in LD
Blocks have OR∼ N(1.02, 0.36), and 60 independent, unassociated SNPs.
The β adjustment for LD in both POLARIS and LDpred for the first simulation from
the 1,000 simulations is seen in Figure 8.5; the dots represent the original βs and the
crosses are the LD adjusted βs. For LDpred, the noninfinitesimal model with p < 1 is
used, although the results for the infinitesimal model are very similar (not presented here).
LDpred reduces the magnitude of β, so the β adjustment plots have the adjusted βs scaled
by the gradient between the original and adjusted β values for independent SNPs. The β
adjustment in POLARIS and LDpred was investigated using a discovery set with N=10,000
and a test set with both N=1,000 and N=10,000 in order to estimate LD structure. For
POLARIS, there is little to no adjustment in the 60 independent SNPs, with the amount
of adjustment decreasing with increasing sample size of the test set. This is likely due to
the LD between markers being better estimated in the larger set. For SNPs in LD, there is
adjustment in the β values, with the degree of adjustment increasing for higher LD, again,
this is more pronounced when the test set has a larger sample size. The 60 independent
SNPs also have little to no adjustment using LDpred, which is expected. When the test
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set is small (N=1,000), SNPs in LD have adjusted β values, with the largest adjustment in
the LD block with the highest r2 value, this is similar to the results for POLARIS. For a
larger test set (N=10,000), the β adjustment in LDpred is far less pronounced, and almost
absent for intermediate r2 = 0.4, 0.6. This is counterintuitive; and the LDpred paper [127]
does not suggest any reason why large sample sizes may affect the β adjustment, since
large samples lead to the adjustment seen in Equation 8.1. The only explanation would be
that the difference is caused by the numeric MCMC method used for the non-infinitesimal
model.
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Figure 8.5: Comparison Between β Adjustment in POLARIS and LDpred
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8.3.1.2 Real AD Data Results
The overall p-values for the whole genome in the GERAD data using a logistic regres-
sion model of risk scores were compared between POLARIS (solid line), unadjusted PRS
(dashed line), and LDpred (dotted line) depending on the individual p-value threshold
used as criterion for the inclusion of SNPs. The comparison was performed for unpruned
data (green lines in Figure 8.6), for intelligently pruned data, where the most associated
SNPs are retained (r2 threshold 0.2, red lines in Figure 8.6), and for randomly pruned
data (r2 threshold 0.2, blue lines in Figure 8.6). In order to assess the influence of the
well-known strong association of APOE, the comparison excluded chromosome 19.
When data are either intelligently or randomly pruned for LD, the results for POLARIS,
PRS and LDpred are very similar at all p-value thresholds. This is to be expected,
as LD has been largely removed in these cases, so POLARIS and LDpred will make
no or only small adjustments to the weights (βs). Intelligently pruned data show more
significant results throughout compared to randomly pruned data, since highly associated
SNPs are prioritised for inclusion. For larger inclusion thresholds, these data reach a stable
maximum significance plateau at about p-value threshold p=0.5 in all methods; similar
results for PRS were reported in [38]. When unpruned data are used, the results for PRS
are more significant at all p-value thresholds than PRS in clumped and randomly pruned
data on the whole genome. This is because PRS will be inflated by the LD between SNPs,
by overaccounting for the effect of SNPs in LD. LDpred has increased overall significance in
unpruned data, with higher significance levels than PRS in unpruned data. LDpred reaches
a maximum overall significance at a p-value threshold of 0.1. For POLARIS, the overall
significance increases with increasing p-value threshold, reaching a maximum beyond the
values achieved for PRS and LDpred. This shows that POLARIS and LDpred unlock
the information contained in SNPs which are not individually associated, but still have
p-values below about 0.5, but POLARIS achieves a higher maximum overall significance.
POLARIS, however, is sensitive to the signal-to-noise ratio; the green curve in Fig.8.6
decreases when SNPs with p > 0.5 are included. The reason for this may be that POLARIS
increases the variance of the β distribution, and therefore, these unassociated SNPs have
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a detrimental effect on the overall score compared to PRS. In an attempt to remove this
effect, POLARIS has been altered and the whole genome analysis was rerun. The first
approach was to set any βs which had a corresponding p-value above a particular threshold
(i.e. p=0.8, 0.9) to zero. The second approach was to determine if the adjusted βs were
larger than the original βs, and to return the adjusted value to the original if this was the
case. Unfortunately, neither of these approaches removed the signal-to-noise sensitivity in
POLARIS. The power for unpruned PRS is slightly higher than POLARIS when the p-
value inclusion threshold is less than 0.1, this may be attributed to the inflated type I error
in unpruned PRS compared to POLARIS. When lower p-value inclusion thresholds are
used, the −log10(p-values) are lower than when a higher inclusion threshold is used. This
may reflect that there are fewer markers with small p-values, which only explain a limited
fraction of disease heritability. PRS, POLARIS and LDpred are designed to incorporate
the combined effect of SNPs which do not individually reach genome-wide significance in
order to unlock this latent information and explain a larger proportion of the heritability
[37].
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Figure 8.6: Plot of the −log10(p-value) at different p-value inclusion thresholds for PO-
LARIS, LDpred and PRS, in unpruned, intelligently pruned and clumped data.
173
8.3.2 Extensions to POLARIS
The original POLARIS methodology is extended such that it utilises the fact that the
number of individuals, N , is often fewer than the number of SNPs, M , across the whole
genome. An update to POLARIS decomposes the NxN matrix rather than the MxM
matrix when N < M . The eigenvalues and eigenvectors of this NxN matrix are then
adjusted to correspond with those for the MxM matrix. Eigenvectors which have eigen-
values < 0 are removed, thus computing the pseudoinverse of the correlation matrix. The
results discussed previously do not use the pseudoinverse, perhaps this may reduce the
signal-to-noise sensitivity observed in POLARIS.
POLARIS is able to use dosage data rather than genotype data. The expected dosage
value is computed using Equation 8.2. This expected value is then used in the POLARIS
score rather than the genotype.
E[genotype] = 2×P(dominant homozygote)+1×P(heterozygote)+0×P(recessive homozygote)
(8.2)
8.3.2.1 POLARIS software
POLARIS has been implemented into a software written in Python, which can be found at
github.com/BakerEA/POLARIS. This software is aimed at using POLARIS in a set-based
framework, a maximum set size of 200 SNPs is able to be used in this software. The
software reads data in the form of PLINK binary files and additionally annotates SNPs
to genes, ensures effect sizes are with respect to the same alleles in the test and discovery
sets, produces the POLARIS score and also finds the set association with disease.
Clearly, the currently available software is unable to undertake the whole genome analyses
which have been carried out in this chapter. All analyses in this chapter were carried out
using a Matlab code. This is a crude code which requires a substantial amount of data
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preparation and Matlab is not freely available, and thus this code has not been made
publically available. The extensions to POLARIS such as using dosage data rather than
genotype data was implemented in an R code, but is not avaiable in the current software.
The current Python software has a maximum set size and therefore is not possible to be
used for very large data or sets. Theoretically, as considered in this chapter, POLARIS is
able to be used for any set of SNPs, ideally including all SNPs across the whole genome.
The code used for the analyses in this chapter is not suitable for other researchers and
therefore, a new code written in C is under development in order to allow POLARIS to
be used across the whole genome. The issue with large sets is that a huge amount of
Random Access Memory (RAM) is required to compute the square inverse of the corre-
lation matrix and this is very slow as a large number of computations are required. The
C code attempts to utilise the LAPACK [129] and ScaLAPACK [130] packages which op-
timise matrix inversion, and are able to run in parallel. This software is still undergoing
development before it will be released for the use of other researchers.
8.3.3 Prediction Modelling Using POLARIS
The whole genome POLARIS score can be used to predict whether a subject has AD or
not. The prediction ability of the POLARIS score to predict AD cases was assessed in the
GERAD data.
The sensitivity is the probability of correctly predicting whether a person has AD and the
specificity is the probability of correctly predicting that a person does not have AD.
The AUC is used to determine the prediction accuracy of the model. An AUC value of
1 is when the model is perfectly able to predict whether or not a subject has AD, and a
value of 0.5 corresponds to randomly guessing whether or not a person has AD.
Tables 8.1-8.4 show the results for these prediction models. The four different tables
correspond to a POLARIS score which includes different SNPs. The four different scores
are detailed below:
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1. Excluding 20 GWAS index SNPs and excluding the APOE region (Chr 19: Base
Position (BP) 44.4Mb-46.5Mb)
2. Including all SNPs
3. Excluding 20 GWAS index SNPs, the APOE region and 10,697 heterogeneous SNPs
in the IGAP data
4. Excluding 10,697 heterogeneous SNPs in the IGAP data
The tables show the prediction values for a number of different models. The first is a
model just containing the number of APOE 4 alleles. The second shows the additional
prediction accuracy provided by the number of APOE 2 alleles and the presense of the 20
GWAS SNPs, details of the index SNPs for these 20 GWAS hits are seen in Supplementary
Table 11.2. The remaining models include the addition of POLARIS in the model, at a
number of different p-value thresholds for SNP inclusion.
The AUC for the intelligently pruned GERAD data using PRS has been shown to be
0.782. This is 90% of the maximum prediction accuracy possible from genetic information
only [38].
From Table 8.1 the maximum prediction accuracy (AUC=0.759) includes POLARIS in
the model, using a p-value threshold of 0.4. A substantial proportion of the prediction
accuracy is provided by the number of APOE 4 alleles. There is some improvement using
the addition of the number of APOE 2 alleles and the 20 GWAS index SNPs. There is
then also an increase in prediction accuracy when POLARIS is included in the model,
suggesting the polygenic impact of SNPs which do not reach genome-wide significance.
When comparing genetics alone, the maximum AUC for POLARIS is 0.744 compared to
the AUC of PRS in pruned GERAD data of 0.745. There is a smaller difference between
AUC when considering genetics alone.
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Table 8.1: POLARIS Prediction Modelling, Excluding 20 GWAS hits and APOE region
Model Sensitivity Specificity AUC AUC (+age+sex)
4 0.593 0.746 0.678 0.713
4 + 2 + 20 GWAS SNPs 0.665 0.665 0.714 0.732
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.0001) 0.667 0.667 0.716 0.734
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.001) 0.668 0.668 0.719 0.737
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.01) 0.672 0.672 0.727 0.743
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.05) 0.677 0.677 0.736 0.751
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.1) 0.677 0.677 0.739 0.755
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.2) 0.682 0.682 0.743 0.758
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.3) 0.682 0.682 0.743 0.758
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.4) 0.680 0.680 0.744 0.759
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.5) 0.680 0.680 0.743 0.758
The maximum AUC seen in Table 8.2 is 0.760, again, this is when POLARIS is included
where the p-value threshold is 0.3. The maximum AUC in pruned GERAD data using
PRS was 0.782 when PRS using a p-value threshold of 0.5 is included in the model [38].
The maximum AUC in POLARIS when ignoring age and sex is equivalent to the AUC
found using PRS [38], although this is attained at a lower p-value threshold in POLARIS
compared to PRS (0.3 and 0.5 respectively).
Table 8.2: POLARIS Prediction Modelling, Including 20 GWAS hits and APOE region
Model Sensitivity Specificity AUC AUC (+age+sex)
4 0.593 0.746 0.678 0.713
4 + 2 + 20 GWAS SNPs 0.665 0.665 0.714 0.732
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.0001) 0.667 0.667 0.718 0.735
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.001) 0.665 0.665 0.721 0.738
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.01) 0.672 0.672 0.729 0.745
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.05) 0.678 0.678 0.737 0.752
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.1) 0.678 0.678 0.741 0.756
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.2) 0.683 0.683 0.745 0.760
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.3) 0.684 0.684 0.745 0.760
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.4) 0.680 0.680 0.745 0.760
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.5) 0.681 0.681 0.744 0.759
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.6) 0.677 0.677 0.742 0.757
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.7) 0.680 0.680 0.740 0.755
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.8) 0.682 0.681 0.738 0.753
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.9) 0.680 0.680 0.736 0.751
4 + 2 + 20 GWAS SNPs + POLARIS(p<1) 0.677 0.677 0.732 0.748
Table 8.3 shows the maximum prediction accuracy to be 0.765, when POLARIS consider-
ing only SNPs with a p-value less than 0.2 is included. When considering the prediction
accuracy of models including genetic information only, POLARIS attains a higher maxi-
mum AUC of 0.750 compared to that of 0.745 using PRS [38].
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Table 8.3: POLARIS Prediction Modelling, Excluding 20 GWAS hits, APOE region and
10,697 heterogeneous IGAP SNPs
Model Sensitivity Specificity AUC AUC (+age+sex)
4 0.593 0.746 0.678 0.713
4 + 2 + 20 GWAS SNPs 0.665 0.665 0.714 0.732
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.0001) 0.670 0.670 0.716 0.734
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.001) 0.670 0.671 0.721 0.738
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.01) 0.674 0.674 0.730 0.745
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.05) 0.680 0.680 0.740 0.755
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.1) 0.679 0.679 0.745 0.760
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.2) 0.686 0.687 0.750 0.765
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.3) 0.685 0.685 0.750 0.764
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.4) 0.685 0.685 0.750 0.764
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.5) 0.684 0.683 0.748 0.763
Table 8.4 shows the maximum prediction accuracy across all of the different POLARIS
scores constructed. The AUC is 0.766 when a POLARIS score including SNPs with p-
values less than 0.2 is included. This value is slightly lower than the AUC using PRS,
this is likely due to the inflation in PRS caused by very small LD which is not removed
by LD pruning. It is also noteworthy that POLARIS attains maximum prediction at a
smaller p-value threshold (0.2 compared to 0.5). Again when ignoring age and sex in the
prediction model, POLARIS attains a higher maximum AUC of 0.751 when a p-value
threshold of 0.2 is used, compared to 0.745 found using PRS in pruned data.
Table 8.4: POLARIS Prediction Modelling, Including 20 GWAS hits and APOE region
and Excluding 10,697 heterogeneous IGAP SNPs
Model Sensitivity Specificity AUC AUC (+age+sex)
4 0.593 0.746 0.678 0.713
4 + 2 + 20 GWAS SNPs 0.665 0.665 0.714 0.732
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.0001) 0.663 0.663 0.717 0.734
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.001) 0.667 0.667 0.722 0.739
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.01) 0.673 0.672 0.731 0.747
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.05) 0.682 0.682 0.742 0.757
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.1) 0.683 0.683 0.746 0.761
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.2) 0.686 0.686 0.751 0.766
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.3) 0.685 0.685 0.751 0.765
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.4) 0.688 0.688 0.750 0.765
4 + 2 + 20 GWAS SNPs + POLARIS(p<0.5) 0.682 0.682 0.749 0.764
Table 8.5 displays the AUC for all three methods; POLARIS, PRS and LDpred. The
PRS AUC is taken from Escott-Price et al. (2015) [38]. LDpred requires the proportion
of causal SNPs, cf, to be defined; prediction results are presented for cf=0.0001 and 1.
The LDpred prediction results are higher when all SNPs are assumed to be causal. All
approaches give similar results, with POLARIS having the highest prediction for genetics
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only (excluding age and sex) and PRS having the highest prediction when including age
and sex.
Table 8.5: Prediction Comparison Between POLARIS, PRS and LDpred; Excluding 20
GWAS hits, APOE region and 10,697 heterogeneous IGAP SNPs
POLARIS PRS LDpred, cf=1 LDpred, cf=0.0001
Model AUC
AUC
(+age+sex)
AUC
AUC
(+age+sex)
AUC
AUC
(+age+sex)
AUC
AUC
(+age+sex)
α + RS(p<0.0001) 0.716 0.734 0.717 - 0.716 0.734 0.717 0.734
α + RS(p<0.01) 0.730 0.745 0.729 - 0.724 0.740 0.717 0.735
α + RS(p<0.05) 0.740 0.755 0.738 - 0.733 0.748 0.717 0.735
α + RS(p<0.1) 0.745 0.760 0.740 - 0.736 0.752 0.717 0.735
α + RS(p<0.5) 0.748 0.763 0.745 0.782 0.738 0.754 0.717 0.735
where cf represents the proportion of SNPs assumed to be causal in LDpred and α = 4
+ 2 + 20 GWAS SNPs.
8.4 Discussion
This chapter presents the use of POLARIS for all SNPs across the whole genome. PO-
LARIS combines the advantages of PRS and spectral analysis of the genetic data. The
motivation for this is to predict case/control status or the trait liability captured by all
SNPs, this will have more case/control discriminatory power than set-specific prediction.
POLARIS has the advantage in this whole genome approach that data does not require LD
pruning prior to analysis, as the LD correction occurs as part of the POLARIS approach.
LDpred is an alternative Bayesian method which adjusts effect sizes (βs) for LD between
SNPs. LDpred has an infinitesimal model which assumes that all SNPs are causal, and
the noninfinitesimal model does not. The noninfinitesimal model uses a p-value threshold
for the inclusion of SNPs, similar to the p-value inclusion thresholds used in POLARIS
and PRS.
In simulated data, POLARIS and LDpred show equivalent power for all sample sizes
considered, but POLARIS has slightly higher power, except when test and discovery sets
have N=10,000, although LDpred has mildly inflated type I error in this case.
The β adjustment for LD between SNPs was also compared between POLARIS and
LDpred; both methods show little to no adjustment when there is no LD between SNPs,
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but LDpred shows some unusual results when the test set used to estimate LD is larger,
with very small adjustment in the case of moderate LD. This opposes the POLARIS
adjustment which shows increasing adjustment with increasing LD between SNPs, as ex-
pected.
POLARIS is shown to be a powerful method in application to the whole genome com-
pared to LDpred in the real AD data. POLARIS has a larger maximum −log10(p-value)
compared to both LDpred and unadjusted PRS. Power for the POLARIS method is in-
creased by thresholding the SNPs included in the score, although this then decreases when
the p-value threshold is greater than 0.5, suggesting the sensitivity of POLARIS to the
signal-to-noise ratio. This is demonstrated in AD data, see Figure 8.6, where the strength
of association with AD is increased as the inclusion threshold increases; the additional in-
formation contained in SNPs which are not individually associated are incorporated into
the score. Of course, if POLARIS is used for a sequence of inclusion thresholds, then a
multiple testing correction of the results will need to be applied, as for standard PRS.
POLARIS is computationally expensive when the score is computed for a large number
of SNPs. This is because matrix inversion of a large correlation matrix requires huge
amounts of RAM and computational time. A set-based POLARIS software written in
Python is currently available, although it is only able to compute the POLARIS score
for a maximum of 200 SNPs in a set, therefore, this software is not able to be used for
whole genome analysis, particularly with the increasing use of imputed data with a larger
number of SNPs. An updated software written in C is currently under development which
will enable the production of a POLARIS score for a larger number of SNPs, by utilising
packages created to optimise matrix inversion. Ideally, the software will be able to invert
correlation matrices of at least 500,000 SNPs.
The POLARIS score is able to well predict whether a person has AD or not (AUC including
age and sex=0.766), this is almost as high as the reported AUC for PRS which is 0.782.
When considering genetics only, POLARIS has higher prediction accuracy (AUC=0.751)
compared to that found using PRS in pruned data (AUC=0.745). POLARIS has higher
prediction accuracy based on genetics alone, because the data does not require LD pruning
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and thus more SNPs are included in the score. When age and sex are additionally included
in the model to assess prediction accuracy, PRS is better able to predict case/control status
compared to POLARIS. This could be explained by the additional SNPs included in the
POLARIS score potentially being linked to aging, so perhaps the effect of age is partially
explained by these SNPs.
Prediction accuracy is increased above APOE and GWAS signals by including the PO-
LARIS score, suggesting the polygenicity of AD, since SNPs which do not reach genome-
wide significance still contribute to the ability to differentiate between cases and controls.
The main difference between POLARIS and LDpred is that POLARIS uses the square
inverse of the correlation matrix, whereas LDpred uses the inverse. In essense, LDpred
adjusts the genotypes and the βs for LD, but POLARIS adjusts the genotypes only. In
POLARIS, it is not necessary to adjust the βs as well since these are calculated for each
SNP separately, so are not influenced by LD. This approach is more similar to using
the PRS method in pruned data, since LD is only removed from the test set, and βs
remain unadjusted. POLARIS uses the correlation matrix to adjust the test set, assuming
that correlation seen is LD between the SNPs rather than a correlation caused by SNPs
which are associated with disease. Figure 8.7 shows the correlation caused by associated
SNPs, this is done by running 1,000 simulations generating two independent SNPs which
were both associated with disease in 10,000 individuals. The strength of each SNP’s
association to disease was varied from OR = 1 to OR = 4. Both SNPs had a MAF of either
0.2 or 0.3. The overall correlation, and the correlation in cases and controls separately
was computed for each simulation. The mean of these values was found across all 1,000
simulations. In cases only and controls only the correlation coefficients are approximately
zero, suggesting that SNPs are independent. However, there is a larger correlation in all
the data, with correlation coefficient r increasing as the strength of association and MAF
increase. LDpred applies the assumption of no association between SNPs and disease
in the test set to the discovery data which is not appropriate when SNP effect sizes in
the discovery set are known. This may explain the larger maximum −log10(p-value) in
POLARIS compared to LDpred in real AD data, since it does not over adjust for LD.
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Figure 8.7: Plot of Correlation Coefficient, r, for Varying ORs. In All Data (Black)
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MAF=0.3 (dashed)
PRS has consistently lower p-values compared to multivariable regression with all SNPs in
the PRS; this is because the SNPs contributing to the PRS are prioritised for association
with the disease, so the risk alleles will be more common among cases for each SNP.
Therefore, even if associated SNPs are pruned for LD, they appear to be correlated because
they are associated with disease. In POLARIS, all SNPs are included in the score, and
so there is not as high a proportion of associated SNPs and this effect may not be seen.
Although it depends on the SNPs which are selected, if those on the genotype chip were
prioritised to be associated with disease, then perhaps this same effect would be seen.
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9 Application of POLARIS as Cross Disorder
Analysis
9.1 Introduction
GWAS studies have helped to determine the genetic architecture of a number of complex
disorders. A larger amount of heritability is explained using PRS over single SNP effects
found from GWAS. PRS [37] incorporates the effect of a large number of SNPs across the
whole genome, not all of which individually reach genome-wide significance [131].
PRS can also be used to find commonality between different disorders. Brain disorders
display comorbidity and often share symptomatic manifestations, suggesting potential
biological overlap; for example, depression and anxiety have been shown to overlap [131].
The summary statistics from a related disorder can be utilised to incorporate additional
information [132].
It is possible to identify disease aetiology or shared clusters of phenotypes by examining
the genetic correlation between disorders, since this may identify shared genetic liability
[133]. LD Score regression [134] has the functionality to compute cross-disorder genetic
correlations using GWAS summary statistics and is not affected by sample overlap [135].
Like PRS, POLARIS can be used as a gene-based analysis using AD GERAD data and the
effect sizes (weights) from other disorders. This chapter demonstrates this potential appli-
cation of POLARIS, whereas other chapters consider single traits only. Genes which reach
gene-wide significance from this analysis can potentially display commonality between AD
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and other disorders. Significant genes may implicate particular disease mechanisms which
are shared by the two disorders. A profile of significant genes across a number of different
disorders may aid in a better understanding of the aetiology of AD. It may also be pos-
sible to differentiate different disorders since the gene effect sizes can be compared across
different disorders.
Most GWAS studies are required to make GWAS summary statistics publically available.
The analysis which we suggest in this chapter focuses predominantly on other brain disor-
ders; of which a wide selection are available on the Psychiatric Genetics Consortium (PGC)
website [35], for example SZ, Bipolar disorder (BIP), Major depressive disorder (MDD).
In addition, the cross disorder gene analysis also investigates commonality between AD
and Parkinson’s Disease (PD) [136] and AD and Coronary Artery Disease (CAD) [137].
9.1.1 Objectives
This Chapter aims to;
• Demonstrate the application of POLARIS as a cross-disorder analysis.
• Investigate the genetic correlation between AD and a number of psychiatric disorders,
PD and CAD. This will determine any potential biological overlap between disorders.
• Compute gene-based POLARIS scores for AD in GERAD data using all different
disorders as weights for the score. This may determine genes in common between
disorders which may explain the biological mechanisms underlying the disorders.
9.2 Materials and Methods
POLARIS has been demonstrated as a single-trait method, but it is possible to use PO-
LARIS as a multi-trait or cross-disorder analysis. Cross disorder gene-based analyses can
be used to determine genes which are in common between AD and a number of differ-
ent disorders. This may enable the identification of potential disease mechanisms which
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explain how AD develops, and which mechanisms are in common with other disorders.
The disorders which have had summary statistic data downloaded, and the number of
SNPs in common between both genotyped and imputed GERAD data (Ncases=3,332,
Ncontrols=9,832) are seen in Table 9.1. There are multiple versions for a number of
disorders; all versions are considered in this analysis. A large number of GWAS studies
in a number of disorders use controls from the WTCCC, so these were removed from the
GERAD data (N=168 were removed) in order to maintain independence between the two
datasets.
Table 9.1: Information on Disorders with Data Downloaded
Disorder Year No. Individuals No. SNPs
No. Common SNPs
with genotyped GERAD
No. Common SNPs
with imputed GERAD
Anxiety 2016 17,310 6,330,995 409,824 2,665,838
Major depressive disorder 2015 10,640 6,208,598 347,966 1,121,378
Major depressive disorder 2012 18,759 1,235,109 377,064 530,406
Bipolar disorder 2012 16,731 2,427,220 347,602 975,863
Schizophrenia 2012 51,695 1,252,901 342,789 510,050
Parkinson’s disease 2014 17,352 7,734,960 415,137 2,158,500
Autism spectrum disorder 2015 9,499,589 417,196 3,243,956
Schizophrenia 2014 150,064 9,444,230 414,604 3,240,793
Attention deficit hyperactivity disorder 2013 5,422 1,230,535 352,782 503,667
Autism spectrum disorder 2013 10,263 1,168,835 386,458 538,616
Bipolar disorder 2013 11,810 1,233,533 330,116 490,280
Major depressive disorder 2013 16,610 1,232,793 377,777 524,588
Schizophrenia 2013 17,115 1,237,958 340,112 502,349
Neuroticism 2015 137,178 9,181,138 412,737 5,979,941
Bipolar disorder 51,710 13,414,632 417,618 3,321,367
Epilepsy 2014 34,853 5,968,967 312,344 2,807,803
Schizophrenia 35,976 8,064,799 409,803 1,234,241
Schizophrenia (info > 0.9) 35,976 5,471,113 360,141 1,103,578
Coronary artery disease 2017 63,731 9,026,567 416,003 3,080,078
9.2.1 Genetic Correlation
LD Score [134] is a software which is able to compute the genetic correlation [135] between
disorders by LD score regression, using only GWAS summary statistics. This method uses
the fact that SNPs in high LD will have higher χ2 statistics compared to SNPs in low
LD when considering polygenic traits. This is applicable to multiple disorders by using
the product of z-scores from two different datasets. LD score regression does not require
the two datasets to be independent, since overlap between the datasets only effects the
intercept in the model rather than the genetic correlation estimate [135].
The genetic correlation was computed between AD data (both GERAD genotype and
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IGAP summary statistics) and all other disorders. These genetic correlations were plotted
into a heatmap using the corrplot package in R software. The heatmap displays both
the direction and strength of the correlation and the associated p-value, indicating the
statistical significance of the genetic correlation. The genetic correlation is presented to
indicate potential disorders which may have common underlying mechanisms, disorders
which are highly correlated may have more genes in common found from the POLARIS
gene-based analysis.
9.2.2 Cross Disorder POLARIS
POLARIS gene-based method [96] is a powerful method which extends upon the advan-
tages of PRS [37] by additionally adjusting for LD between SNPs. The SNP weightings
used in the score may be from a different trait than that in the test data. The LD adjust-
ment in POLARIS uses the spectral decomposition of the correlation matrix to adjust AD
SNP genotypes and replace them with LD adjusted dosages. This produces a risk score
for AD weighted with SNP effect sizes from another disorder.
Merged SNPs between the test and discovery sets were assigned to genes using GENCODE
(v19) gene models [78]. Only genes with known gene status and those marked as protein
coding were used. There was no window used around the gene, only SNPs within the start
and end position of the gene were included.
POLARIS scores are calculated per subject per gene and the overall association of the
gene is determined using logistic regression of AD status on the LD adjusted polygenic
risk score and additional population covariates. POLARIS is utilized in a number of cross
disorder analyses to determine any commonality between AD and psychiatric disorders,
PD or CAD. This is done by training on psychiatric, PD or CAD data and testing in AD
GERAD data. Publically available GWAS data from the PGC [35] (http://www.med.
unc.edu/pgc/results-and-downloads), data from the International Parkinsons Disease
Genomics Consortium [136] and UK Biobank data for CAD [137] were used to determine
overlap between AD and a number of disorders at a gene-based level. The full list of
disorders investigated is seen in Table 9.1.
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The cross disorder analysis initially considered the AD GERAD genotype data, and was
then repeated in the GERAD imputed data, since this is likely more powerful as it contains
a larger number of SNPs.
9.3 Results
9.3.1 Genetic Correlation
The genetic correlation between all disorders and AD as computed from LD Score regres-
sion [134][135] are shown in the heatmap in Figure 9.1. The heatmap shows the pairwise
correlation between all disorders. The size of the block represents the p-value, with the
largest square being a p-value of 0 and no square representing a p-value of 1. The colour
of the square represents the genetic correlation coefficient, red shows a positive correlation
and blue shows a negative correlation, these fade to white for a correlation of zero.
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Figure 9.1: Plot of the Genetic Correlation Between All Disorders
There are multiple versions of the same data, for example SZ, from Figure 9.1 it is seen
that these groups of studies which represent the same trait have high positive correlation.
There is one exception to this; mdd2015 is negatively correlated with the other major
depressive disorder studies. The two AD datasets, GERAD and IGAP show a strongly
associated positive correlation. Of course, GERAD is a subset of the IGAP data, however,
the genetic correlation estimate is not effected by this overlap, as only the intercept is
influenced by this overlap in LD score regression [135]. The strong genetic correlation
between the GERAD and IGAP data is likely due to both consortia containing GWAS
data for AD and hopefully share similar SNPs.
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The genetic correlation between AD and other disorders does not have particularly small
p-values, with the lowest being 0.001 with bipolar disorder (bip new). AD shows no genetic
correlation with PD [138], MDD or neuroticism. AD displays a positive correlation with SZ
and BIP and a negative correlation with Attention deficit hyperactivity disorder (ADHD),
anxiety, Autism spectrum disorder (ASD) and CAD.
9.3.2 Cross Disorder POLARIS
For each of the disorders listed in Table 9.1, a table for the gene-wide significant genes
for the multi-trait analysis between AD and each disorder are presented. The tables show
all genes which reach gene-wide significance (p < 2.5 × 10−6), and genes with suggestive
significance (2.5× 10−6 < p < 0.00001) are shown in italics. For each disorder, a table for
both genotyped and imputed data are presented, unless no at least suggestively significant
genes were determined.
The APOE locus is present in all analyses, although it is not as strongly associated as
in AD PRS. The presence of APOE in the cross-disorder analyses is due to the very
large effect in the AD data, rather than a commonality between AD and other disorders.
The effect is so large in the AD data, that even with a SNP weighting of approximately
zero from the other disorder, the effect of APOE remains. Therefore, the APOE locus is
removed from all analyses, any genes on chromosome 19 between base positions 44.4Mb
and 46.5Mb. Similarly, CLU is found to be associated for almost all of the cross-disorder
analyses, this is again influenced by the strong effect in AD rather than any commonality
between AD and other disorders, so is not presented in the results.
9.3.2.1 Attention Deficit Hyperactivity Disorder (ADHD)
The gene-based results from the cross disorder analysis in AD weighted with ADHD effect
sizes is seen in Table 9.2. In the GERAD genotype data, there is suggestive evidence that
IL1RL1 has an association with AD supported by ADHD; this gene is on chromosome 2
and is an interleukin receptor which is part of the immune response [139]. In fact, IL1RL1
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has been identified in an immunity pathway for psychiatric disorders (SZ, BIP and MDD)
[76].
Table 9.2: Results for AD Gene-Based Analysis Using ADHD Summary Statistics as
Weights
GENE CHR NoSNPs P
IL1RL1 2 4 8.9× 10−6
(i) GERAD genotype data
GENE CHR NoSNPs P
IL1RL1 2 145 4.9× 10−6
(ii) GERAD imputed data
In the imputed GERAD data, again IL1RL1 shows a suggestive commonality between
AD and ADHD.
9.3.2.2 Anxiety
The gene-based cross-disorder analysis using anxiety weights in AD GERAD genotype
data and imputed data only determine genes within the APOE locus or CLU.
9.3.2.3 Autism Spectrum Disorder (ASD)
The gene-based results for genes in common between AD and ASD are shown in Table 9.3.
In the genotype data, only genes in the APOE locus or CLU are found to be gene-wide
significant.
Table 9.3: Results for AD Gene-Based Analysis Using ASD Summary Statistics as Weights
Data Version GENE CHR NoSNPs P
2015 BSND 1 14 8.5× 10−6
(ii) GERAD imputed data
In the GERAD imputed data, with the 2015 version of the ASD data, the BSND gene
which resides on chromosome 1 shows a suggestive association.
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9.3.2.4 Bipolar Disorder (BIP)
The gene-based results for AD GERAD genotype data weighted with BIP effect sizes are
seen in Table 9.4. In all versions of the BIP data, only CLU or genes in the APOE region
show any association.
Table 9.4: Results for AD Gene-Based Analysis Using BIP Summary Statistics as Weights
Data Version GENE CHR NoSNPs P
Latest CSDC2 22 26 1.6× 10−6
(ii) GERAD imputed data
In the GERAD imputed data a large number of genes in the APOE locus are gene-wide
significant (not presented). In addition, CSDC2 on chromosome 22 is in common between
BIP and AD.
9.3.2.5 Coronary Artery Disease (CAD)
The AD gene-based analysis using CAD weightings only determines association with genes
in the APOE locus or CLU in both the genotype and imputed data.
9.3.2.6 Major Depressive Disorder (MDD)
Aside from genes in the APOE region, there are no genes which reach even a suggestive
significance of commonality between AD and MDD in the genotype or imputed data.
9.3.2.7 Neuroticism
Table 9.5 shows the results for the gene-based analysis in AD using neuroticism effect sizes
as weights. This analysis in the genotype data found no gene-wide significant genes other
than those in the APOE locus.
191
Table 9.5: Results for AD Gene-Based Analysis Using Neuroticism Summary Statistics as
Weights
GENE CHR NoSNPs P
ZNF525 19 57 1.1× 10−6
(ii) GERAD imputed data
The cross disorder analysis using the imputed GERAD data as a test set also only finds
an association with a gene which is likely caused by the large effect of APOE ; ZNF525,
but does not reside within the defined APOE locus.
9.3.2.8 Parkinson’s Disease (PD)
Table 9.6 shows the results from the gene-based analysis in AD with POLARIS weights
from PD. In the GERAD genotype data, ZNF525 shows a suggestive association, this
gene is on chromosome 19, approximately 7Mb upstream of the APOE region, so this
association may be caused by APOE.
Table 9.6: Results for AD Gene-Based Analysis Using PD Summary Statistics as Weights
GENE CHR NoSNPs P
ZNF525 19 5 3.3× 10−6
(i) GERAD genotype data
GENE CHR NoSNPs P
ZNF525 19 57 2.7× 10−6
(ii) GERAD imputed data
The GERAD imputed data also only finds a suggestive association with the ZNF525 gene
which is on chromosome 19. Again, this is close to the APOE locus so it may be affected
by APOE.
9.3.2.9 Schizophrenia (SZ)
The results for the gene-based analysis in AD weighted with SZ effect sizes are seen in
Table 9.7. For all versions of the SZ data, no gene-wide or suggestively associated genes
are found in common between genotype AD data and SZ.
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Table 9.7: Results for AD Gene-Based Analysis Using SZ Summary Statistics as Weights
Data Version GENE CHR NoSNPs P
2014 BSND 1 14 6.9× 10−6
Latest TMEM61 1 28 9.3× 10−6
(ii) GERAD imputed data
The cross disorder analysis carried out in the imputed GERAD data finds two additional
suggestively significant genes across all versions of the SZ data. Both suggestive genes
reside on chromosome 1, these are BSND and TMEM61.
9.4 Discussion
This Chapter demonstrates the application of POLARIS as a multi-trait or cross disorder
analysis, where the effect sizes used to weight the score are for a disorder which differs to
the phenotype used in the logistic regression model.
A few gene-wide or suggestively significant genes are identified from this cross-disorder
analysis, the biological implication of these genes requires further investigation. The effect
of APOE in AD data is still apparent, despite informing the POLARIS score with effect
sizes from other disorders, APOE was detected in all analyses with p< 10−20. Clearly,
the effect of APOE in AD dominates the effects of other disorders, but this does not
indicate commonality between genes in the APOE locus, therefore, these results should
be interpreted with care. This is also seen for the CLU gene which is strongly associated
with AD, and is therefore present in the majority of cross-disorder analyses, however, this
does not suggest that CLU is associated with both disorders, but rather that the effect of
CLU in AD dominates the other disorder. Therefore, genes which have a strong effect in
one disorder in a cross-disorder analysis should always be carefully assessed.
This analysis has been carried out in both genotype and imputed data, the use of imputed
AD data adds strength to this analysis and results in stronger and additional associations.
However, in the case of CLU, in a number of cases the gene-wide significance seen in
genotype data disappears when imputed data is used, this may be due to the effect of
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additional SNPs cancelling the effect of SNPs in the genotype data only. In the genotype
data, only two SNPs are included in CLU which have almost no LD with one another. In
the imputed data, 25 SNPs are included in CLU, some of these SNPs show very high LD
with one another, see Figure 9.2 for the LD structure of SNPs in CLU. This differing LD
structure may explain why associations with CLU are apparent in the genotype data but
not in the imputed data.
(a) Genotype
Data
(b) Imputed Data
Figure 9.2: LD Plot for CLU SNPs
Cross-disorder gene-based analyses may find genes which contribute to common clinical
outcomes/symptoms and therefore treatments could be directed to these symptoms.
Predominantly only genes which are within the APOE locus or have been previously
identified by AD GWAS, e.g. CLU, and as such only represent the association in AD have
been determined. Some additional suggestive or non-GWAS genes have been found, such
as IL1RL1 and CSDC2, although further research is necessary to assess whether these
genes have credible biological implications in AD. The gene-wide significance threshold
used in this analysis (p < 2.5 × 10−6) does not take account of the multiple disorders
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tested, so these additional genes would likely not withstand the additional multiple testing
correction.
Understanding the relationship between two disorders or phenotypes can lead to the infer-
ence of GWAS summary statistics based on a function of disorders/phenotypes which each
have GWAS summary statistics available. This approach is termed GWIS; Genome-wide
Inferred Study [140], and would be particularly applicable to psychiatric disorders which
have a substantial shared phenotype, for example, cognition in schizophrenia and bipolar
disorder. This approach may be applicable in that summary statistics for disorders which
are related can be inferred and used in the POLARIS score as weights.
The causes of genetic correlation can not be investigated using the POLARIS method. A
novel Genomic Structural Equation Modelling (SEM) [133] method has been developed
which enables the comparison of a number of multivariate genetic architectures. This
would be a suitable extension to this analysis to further investigate significant findings.
Additionally, the results from cross-disorder analyses can be used to improve disease pre-
diction. For genetically correlated disorders, it is possible to increase the disease risk
prediction accuracy by including information from the correlated disorder. The approach
to do this is called weighted multi-trait summary statistic best linear unbiased predictor
(wMT-SBLUP) [141].
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10 Discussion and Implications
10.1 Conclusions
The gold standard of medical treatment is to develop personalised medicines, the best way
to approach this is using genetics. Complex traits such as AD have been shown to have a
large number of genes associated with them. These have been identified using the GWAS
method, which require large sample sizes to detect the small individual effect of SNPs.
In order to determine novel variants associated with AD, it is necessary to use methods
which gain power compared to GWAS.
The primary aim of this thesis was to extend methods beyond GWAS in order to identify
novel genes associated with AD. The POLARIS method has been introduced and is a pow-
erful extension to the PRS approach which takes account of LD between SNPs. Therefore,
data is not required to be pruned to remove LD and thus more information is able to be
incorporated into the risk score. POLARIS aggregates the small individual SNP effects
for all SNPs within a set into a larger polygenic component, whilst weighting with SNP
effect sizes from an independent dataset. This POLARIS approach can be applied to any
set of SNPs such as genes, pathways and the whole genome.
The POLARIS methodology was applied to the latest imputation of the GERAD data for a
gene-based analysis. Three novel genes associated with AD were determined; PPARGC1A,
RORA and ZNF423. These novel genes all have credible biology related to AD. In addition,
two novel genes, CSMD1 and MACROD2 were found using the PRS gene-based method,
also in the HRC imputed GERAD data.
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10.2 Discussion
The analyses in this thesis are carried out in very large (N=13,164) recently imputed
GWAS data where individual genotype data are available, additionally, the largest avail-
able GWAS in AD containing summary statistics only is utilised to increase power. Re-
cently available methods which have been shown to be more powerful than standard meth-
ods are used. The use of the best methods and large data enable this to be a valid study,
and results found are reliable. However, replication of determined genes in an independent
dataset would be desirable.
Set-based analysis has been shown to be a powerful approach compared to single SNP
analyses. A set is considered to be any set of SNPs. The small effect of individual SNPs
are combined into a larger aggregate effect, and therefore there is more power to be able
to find an association. Gene-based analyses are more robust than single SNP analyses
across different populations. For single SNP analyses, because of the LD between SNPs,
different SNPs may be determined in different populations. Pathway or gene-set analyses
combine genes which have a similar biological function. By determining these pathway
associations with disease, it is possible to implicate biological mechanisms of disease.
Gene-based analysis has been shown to be more powerful than single SNP analyses by
using the gene-based analysis available in MAGMA software, additional independent gene
associations are determined in identical data. The difficulty with a gene-based analysis
is how to define the gene, whether just to include SNPs within the start and end base
position of the gene or whether to include a window around the gene. Therefore, it was
additionally investigated and shown that using a flanking region of 35kb upstream and
10kb downstream around the gene to contain transcriptional elements increases the power
of a gene-based analysis.
PRS is a method to determine the polygenic component of disease from these GWAS
signals, by combining the genotypes of SNPs and weighting them with SNP effect sizes
from an independent dataset. PRS can be considered as a set-based analysis by only
considering SNPs within the set in the risk score. This produces a risk score per person
per set. The association of the set-based risk score and disease can then be assessed
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using a regression model adjusting for population covariates. PRS as a set-based method
was compared to MAGMA-PCA, MAGMA-SUMMARY, Simes’ and Fisher’s methods in
simulated data. The PRS set-based method improves upon the power of MAGMA-PCA in
the test set only and has particularly high power when a real LD structure is considered.
The PRS set-based method was then applied to the real AD GERAD data, using the
IGAP-noGERAD summary statistics as weights. Both a gene-based and pathway analy-
sis were considered. Two additional genes, CSMD1 and MACROD2, have been found to
be associated with AD from the PRS gene-based analysis in the imputed GERAD data.
CSMD1 has been implicated in AD, familial Parkinson’s disease [92] and cognitive per-
formance [93]. The MACROD2 gene has been implicated in neurological disorders [94].
Pathway PRSs were produced for the pathways which have been previously identified as
associated with AD; two of these pathway risk scores were associated with AD when ad-
justing for the baseline PRS association, these pathways were the immune response and
hematopoietic cell lineage pathways. The PRS method has the advantage of producing a
risk score per person per set, and this score can be used for further functional analyses, or
prioritising subjects for clinical trials. The PRS approach is also able to improve power by
using the SNP effect sizes from an independent dataset to weight the score. The main issue
with this PRS method is that data must be pruned for LD prior to producing the score,
this removes a large amount of data, in addition, the method requires two independent
datasets, one of which must contain individual genotype data.
The POLARIS methodology was introduced to extend upon the PRS method by addition-
ally adjusting for LD between SNPs so that data does not require LD pruning. POLARIS
uses the spectral decomposition of the correlation matrix to produce LD adjusted dosages
for each individual, these adjusted dosages are then used in the risk score. POLARIS
was compared to both MAGMA-PCA and MAGMA-SUMMARY in both simulated and
real data. POLARIS was shown to give correct type I error in all simulated data, and
therefore is successfully adjusting for the LD between SNPs. The power of POLARIS lies
between that of MAGMA-PCA in the test set only and MAGMA-PCA in the combined
test and discovery set. In practice, researchers would use all available genotype data, and
would only use PRS or POLARIS if an additional independent dataset containing sum-
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mary statistics were available. A POLARIS software is available for set-based analyses,
but this is only able to handle very small sets due to the computational demand of matrix
inversion. An updated software is currently under development which aims to be able to
handle larger sets and reduce computational time. POLARIS set-based approach was ap-
plied to the real GERAD AD data using IGAP-noGERAD summary statistics as weights.
Three novel genes were found when the gene-based analysis was considered in imputed
GERAD data using a gene window of 35kb upstream and 10kb downstream which incor-
porates additional transcriptional elements into the gene. The three novel genes found
to be associated with AD are PPARGC1A, RORA and ZNF423, all of which have bio-
logical relevance to AD. PPARGC1A is linked to the generation of amyloid plaques and
energy metabolism, RORA is differentially expressed in the hippocampus and ZNF423
resides in an AD-specific protein network. POLARIS pathway scores were produced for
the eight pathways previously found to be associated with AD. Four of these POLARIS
pathways are associated after adjustment for the baseline level of association; these are the
immune response, cholesterol transport, hematopoietic cell lineage and clathrin pathways.
Like PRS, POLARIS produces a risk score per person per set which is useful for future
analyses, and increases power by incorporating an additional external dataset and by not
requiring LD pruning which utilises all available information.
PRS is most often used to determine the overall polygenicity of disease by incorporating
all SNPs which show some association to disease, but do not reach genome-wide signif-
icance. Like PRS, POLARIS is also applicable to any set of SNPs, including all SNPs
across the genome. POLARIS was compared to LDpred which is an alternative method
which also adjusts for LD and computes a risk score. POLARIS computed across the
whole genome in GERAD data using IGAP-noGERAD summary statistics as weights has
a larger maximum −log10(p-value) compared to both LDpred and PRS. Although, it is
also seen that POLARIS is sensitive to the signal-to-noise ratio caused by the inclusion
of SNPs which have high p-values. This sensitivity requires further investigation and the
POLARIS methodology altered in order to remove this issue. The POLARIS score is
able to well predict whether a person has AD or not (AUC including age and sex=0.766),
this is almost as high as the reported AUC for PRS which is 0.782. When considering
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genetics only, POLARIS has higher prediction accuracy (AUC=0.751) compared to that
found using PRS in pruned data (AUC=0.745). POLARIS has higher prediction accu-
racy based on genetics alone, because the data does not require LD pruning and thus
more SNPs are included in the score. When age and sex are additionally included in
the model to assess prediction accuracy, PRS is better able to predict case/control status
compared to POLARIS. This could be explained by the additional SNPs included in the
score potentially being linked to aging, so perhaps the effect of age is partially explained
by these SNPs. Prediction accuracy is increased above APOE and GWAS signals by
including the POLARIS score, suggesting the polygenicity of AD, since SNPs which do
not reach genome-wide significance still contribute to the ability to differentiate between
cases and controls. This whole genome analysis should also be carried out in the imputed
GERAD data, the inclusion of additional SNPs may improve the prediction accuracy of
the POLARIS score. This analysis requires the development of the POLARIS C code
which doesn’t require the use of too much RAM or computational time. Whilst improving
the POLARIS methodology, it should be considered whether it is possible to incorporate
additional functional information into the score, by using a different weighting for the
SNPs in the score, such as methylation or expression values.
PRS has consistently lower p-values compared to multivariable regression with all SNPs in
the PRS; this is because the SNPs contributing to the PRS are prioritised for association
with the disease, so the risk alleles will be more common among cases for each SNP.
Therefore, even if associated SNPs are pruned for LD, they appear to be correlated because
they are associated with disease. In POLARIS, all SNPs are included in the score, and
so there is not as high a proportion of associated SNPs and this effect may not be seen.
Although it depends on the SNPs which are selected, if those on the genotype chip were
prioritised to be associated with disease, then perhaps this same effect would be seen.
The POLARIS method so far has been utilised using independent datasets for the same
trait. The final analysis investigates the use of weighting the POLARIS gene-based score
with effect sizes from alternative, potentially related disorders. This enables the identifica-
tion of genes in common between disorders and may implicate potential biological mecha-
nisms in AD. This gene-based analysis was weighted for a number of different psychiatric
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disorders, CAD and PD. Some genes show at least a suggestive association, however, these
associations will likely not withstand the additional multiple testing correction required
due to the number of different disorders assessed. This work may also be further extended
by comparing the POLARIS scores and score using the Genomic Structural Equation
Modelling (SEM) [133] method which compares multivariate genetic architectures.
10.3 Limitations
For all genes determined in this thesis, it would be desirable to replicate these findings in
an independent dataset, however, it is often difficult to get access to data which contains
individual genotypes.
POLARIS is sensitive to signal-to-noise ratio; by using higher p-value inclusion thresholds,
the overall POLARIS significance decreases due to the inclusion of a larger number of
unassociated SNPs. A number of approaches were trialed in an attempt to remove this
issue, but unfortunately none were successful. Given more time, this sensitivity would
have been further investigated, it is hoped that using the pseudoinverse for the whole
genome approach might resolve this issue.
The current POLARIS software available to other researchers is only appropriate as a set-
based analysis, where the SNP sets do not exceed 200 SNPs. This is due to computational
limitations; the amount of time required for the analysis and the amount of RAM necessary
for the computation of the square inverse. An updated software is under development, but
unfortunately it was not possible to complete this in time for the completion of this thesis.
The new software uses packages which have been optimised for large matrix inversion, and
will aim to enable researchers to use POLARIS as a whole genome approach.
Due to time limitations, the cross-disorder analysis was simply used to demonstrate the
application of POLARIS as a multi-trait analysis but was not able to be extended to in-
vestigate alternative methods which are able to investigate the cause of genetic correlation
[133] or use correlated traits to further improve prediction accuracy [141].
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10.4 Further Work
Using the POLARIS and PRS gene-based analyses, five novel genes have been determined;
these are CSMD1, MACROD2, PPARGC1A, RORA and ZNF423. Research has shown
that these genes are biologically credible in AD, but further work is required to replicate
these findings in independent data and functional studies are necessary to further assess
the biological implications of these genes.
The POLARIS methodology requires further investigation to remove the signal-to-noise
sensitivity observed in Chapter 8. This effect may be removed by using the pseudoinverse
of the correlation matrix, since the whole genome analysis in this thesis does not use this
approach. The ability to further test POLARIS would be aided by the development of an
improved POLARIS software in C, which aims to reduce RAM and computational time
requirements. Once this software is available, it would be possible to compute the whole
genome POLARIS score in the GERAD imputed data which may be able to better predict
whether or not a subject will develop AD.
In this thesis, the POLARIS methodology has only been used with a binary phenotype,
however, quantitative traits may also be assessed by using a linear regression model. Cur-
rently, the set-based POLARIS software is only able to determine the association between
POLARIS and binary traits, using a logistic regression model, however, the software will
be updated to handle quantitative traits. Additionally, the software is only available as a
self-contained test, this may also be updated to allow for a competitive test of association,
which adjusts for the baseline level of association in the data.
For POLARIS there is also the possibility to use alternative weightings, such as functional
SNP information like gene expression or methylation, instead of SNP effect sizes in alter-
native data. This may enable better AD risk prediction by the incorporation of relevant
functional information.
It was noted in Chapter 8 that LDpred gives some strange β adjustments in the simulated
data compared to POLARIS; investigation into the LDpred methodology does not fully
explain the observed results, so additional research into this effect is necessary.
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10.5 Implications
The production of a more accurate risk score using POLARIS means that subjects at high
and low risk can be determined and used in clinical trials. Also, gene and pathway scores
for each individual can be used to prioritise genes for functional studies to help aid in the
understanding of the aetiology of AD. The inclusion of functional information into this
score may enable an even more accurate prediction of disease.
Long term, the ability to accurately determine a person’s disease risk which can be mea-
sured from birth may be hugely beneficial in the area of personalised medicine. It may
lead to individuals being able to manage their health based on their disease risk, or for
diseases to be treated prior to any symptom development. In addition, treatments can be
tailored to a person’s genetic information, which may aid in better response to treatments
or reduced side effects using these precision medicines.
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11 Supplementary Material
11.1 129 SNPs in Real Data Simulations
Table 11.1: Details of 129 SNPs Used in Real Data Simulations
CHR SNP BP MAF BETA SE P HWE P
1 rs11808115 50002165 0.0469 -0.1003 0.06783 0.1392 0.003202
1 rs4926816 50019849 0.3158 -0.03482 0.03075 0.2574 0.2761
1 rs1999875 50049490 0.1055 -0.0345 0.04616 0.4548 0.1277
1 rs11587574 50053885 0.08912 0.03151 0.04938 0.5234 0.7069
1 rs10888663 50081573 0.05323 -0.03818 0.06329 0.5463 0.1405
1 rs7540606 50086414 0.05318 -0.03739 0.0633 0.5548 0.1402
1 rs12741784 50088819 0.3748 -0.02467 0.02936 0.4008 0.8379
1 rs2051086 50105201 0.3233 -0.02594 0.03038 0.3933 0.9841
1 rs4408195 50128198 0.3641 -0.03757 0.02946 0.2023 0.5469
1 rs10489864 50161927 0.06659 0.07062 0.0558 0.2056 0.3614
1 rs11205641 50185075 0.4221 -0.03648 0.02878 0.205 0.7887
1 rs1474910 50192150 0.2233 -0.03369 0.03414 0.3237 0.5294
1 rs10788917 50227177 0.3644 -0.03866 0.02945 0.1894 0.5224
1 rs4926542 50263773 0.3155 -0.0201 0.03056 0.5107 0.9678
1 rs17105782 50286109 0.05269 -0.0489 0.0638 0.4434 0.19
1 rs17099766 50289163 0.04688 -0.105 0.06785 0.1218 0.00169
1 rs4926831 50290101 0.4228 -0.03158 0.02878 0.2726 0.7209
1 rs12128108 50293421 0.2249 -0.03435 0.03412 0.3141 1
1 rs4421632 50319197 0.09575 -0.07284 0.04922 0.1389 0.1445
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1 rs10888672 50359987 0.3696 -0.02439 0.02931 0.4053 0.3999
1 rs12403905 50372032 0.3696 -0.02532 0.02932 0.3878 0.4321
1 rs9659092 50443589 0.4297 -0.03989 0.02874 0.1651 0.6311
1 rs4420126 50468739 0.3243 -0.02662 0.03037 0.3808 0.8893
1 rs4259707 50528591 0.2324 -0.0457 0.03374 0.1756 0.7881
1 rs6673246 50554373 0.05258 -0.0333 0.06363 0.6008 0.1885
1 rs4298778 50557867 0.04735 0.04141 0.06588 0.5297 0.3834
1 rs11583200 50559820 0.3822 -0.01865 0.02932 0.5247 0.3757
1 rs967582 50582172 0.3531 -0.006237 0.02957 0.833 0.4341
1 rs9436444 50589798 0.2278 -0.05812 0.03409 0.08823 0.9408
1 rs9436447 50590732 0.2279 -0.05847 0.0341 0.08639 0.9211
1 rs10493151 50598750 0.05269 -0.03855 0.06431 0.5489 0.3821
1 rs6588376 50602495 0.207 -0.06551 0.03552 0.06514 0.2322
1 rs3902720 50605337 0.3142 -0.07366 0.03078 0.01671 0.9355
1 rs17105974 50620945 0.05409 -0.06484 0.06341 0.3065 0.4424
1 rs2988269 50641944 0.3169 -0.07517 0.0307 0.01436 1
1 rs2841871 50684937 0.02739 -0.08059 0.08854 0.3627 0.8703
1 rs4926853 50709222 0.3324 0.0006043 0.0302 0.984 0.4318
1 rs17381266 50717206 0.09998 -0.03933 0.04794 0.412 0.146
1 rs3001644 50722989 0.08057 -0.05735 0.05286 0.278 0.5565
1 rs12030672 50735395 0.2452 -0.01705 0.03296 0.605 0.6546
1 rs12123613 50743010 0.07316 -0.02479 0.05452 0.6493 0.3036
1 rs1393637 50753599 0.03487 -0.00829 0.07768 0.915 0.5174
1 rs1875645 50789880 0.4546 0.002194 0.02834 0.9383 0.2836
1 rs6689749 50800516 0.4816 -0.01785 0.02825 0.5274 0.2421
1 rs4491095 50802855 0.3943 -0.01201 0.029 0.6788 0.8125
1 rs1393632 50814015 0.4608 -0.008859 0.02837 0.7549 0.5626
1 rs3862267 50822565 0.4603 -0.005301 0.02837 0.8518 0.5276
1 rs2765895 50822914 0.4846 -0.01975 0.02828 0.485 0.453
1 rs12071347 50839158 0.3002 -0.002649 0.0309 0.9317 0.7874
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1 rs7525764 50844697 0.4878 0.003591 0.02823 0.8988 0.2873
1 rs3907676 50863202 0.3034 -0.002218 0.03078 0.9426 0.65
1 rs1278537 50882159 0.4736 0.01204 0.02817 0.6691 0.07458
1 rs12142848 50918388 0.0664 -0.02758 0.0571 0.6291 0.4817
1 rs3827730 50937848 0.3274 -0.05654 0.0303 0.06201 0.6069
1 rs12065210 50942784 0.09306 0.009107 0.04846 0.8509 0.2558
1 rs3789576 50945526 0.0901 0.001364 0.04928 0.9779 0.3383
1 rs10888690 50960521 0.4078 -0.004109 0.02865 0.8859 0.1005
1 rs7535374 50966897 0.1158 -0.04391 0.04501 0.3292 0.08108
1 rs1149795 50972564 0.1106 0.1015 0.0446 0.0229 0.3081
1 rs11581155 50976306 0.07748 -0.06596 0.05354 0.2179 0.2723
1 rs1846522 50981205 0.08707 0.001927 0.05006 0.9693 0.3517
1 rs17387024 50993178 0.1529 -0.01913 0.03931 0.6264 0.1892
1 rs11587909 51050799 0.2794 -0.03417 0.0315 0.278 0.1045
1 rs7543272 51069102 0.1515 -0.02935 0.03967 0.4593 0.6843
1 rs12120719 51092829 0.09407 -0.04238 0.04893 0.3864 0.7981
1 rs9803853 51094008 0.4312 -0.03606 0.02817 0.2006 4.703e-05
1 rs11577260 51094117 0.06386 -0.05915 0.05881 0.3145 0.884
1 rs17383851 51095318 0.2784 -0.02421 0.0315 0.4421 0.1133
1 rs12567589 51110167 0.06385 -0.05968 0.05881 0.3102 0.884
1 rs10493152 51128777 0.1736 -0.02598 0.03733 0.4864 0.1141
1 rs12759925 51134336 0.1111 0.07165 0.04413 0.1044 0.0469
1 rs7515597 51159347 0.4017 -0.03352 0.02847 0.2391 4.474e-05
1 rs12085479 51199116 0.4022 -0.03498 0.02846 0.219 3.571e-05
1 rs12084054 51242141 0.08805 -0.009357 0.04993 0.8513 0.3851
1 rs7522611 51257608 0.4229 -0.01934 0.02826 0.4936 0.0001419
1 rs6656410 51259041 0.1154 -0.04863 0.04521 0.2821 0.04026
1 rs3789587 51266474 0.08827 -0.005157 0.04983 0.9176 0.357
1 rs6692340 51280132 0.1183 0.1316 0.04324 0.002332 0.1217
1 rs17391220 51293463 0.1149 -0.04734 0.04524 0.2954 0.0537
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1 rs1849553 51318005 0.2864 -0.0205 0.03082 0.506 4.051e-06
1 rs1464081 51335094 0.1162 0.1292 0.04356 0.003006 0.1375
1 rs11585772 51384790 0.2824 -0.02041 0.03136 0.5152 0.1322
1 rs6698809 51407584 0.3339 -0.02086 0.02984 0.4845 0.0343
1 rs6695869 51413205 0.423 -0.02117 0.02821 0.453 3.408e-05
1 rs11578799 51424556 0.03454 -0.04989 0.0786 0.5256 1
1 rs1341980 51449001 0.3344 -0.01529 0.02979 0.6078 0.02197
1 rs2487824 51462439 0.4216 -0.01382 0.02827 0.6248 0.000162
1 rs17389502 51468754 0.2715 -0.02229 0.03183 0.4838 0.3547
1 rs11588271 51470242 0.3224 -0.0155 0.03013 0.6069 0.06948
1 rs3813634 51475488 0.4217 -0.002077 0.02835 0.9416 0.003785
1 rs11205801 51484626 0.06095 0.05541 0.05857 0.344 0.9394
1 rs12078447 51499525 0.1049 0.01221 0.04616 0.7915 0.963
1 rs17106389 51500769 0.1498 0.0255 0.03954 0.519 0.7841
1 rs12088739 51506886 0.08831 0.00503 0.0498 0.9195 0.5514
1 rs12130529 51510825 0.06391 0.0373 0.05736 0.5155 0.5117
1 rs11205807 51535380 0.04524 -0.1309 0.07014 0.062 0.4183
1 rs4926877 51541808 0.08753 -0.04648 0.05044 0.3568 0.2747
1 rs7530673 51558856 0.06974 -0.07407 0.05648 0.1897 0.6866
1 rs17392154 51611227 0.1138 -0.04343 0.04531 0.3379 0.1415
1 rs12074413 51616379 0.1462 -0.02171 0.04023 0.5895 0.8069
1 rs11205821 51631884 0.0539 -0.1167 0.06412 0.0688 0.1453
1 rs12740598 51684980 0.06701 -0.1057 0.05771 0.0671 0.1253
1 rs4926884 51699726 0.1124 -0.00591 0.04501 0.8955 0.7596
1 rs12728955 51709522 0.06181 -0.06868 0.05939 0.2475 0.1139
1 rs6701572 51719315 0.08323 -0.04614 0.05168 0.372 0.4931
1 rs616055 51734386 0.1491 0.05987 0.03923 0.1269 0.3192
1 rs474668 51750909 0.3231 -0.06099 0.0304 0.04481 0.4981
1 rs12734773 51754726 0.0784 -0.02622 0.05289 0.62 0.5461
1 rs12074459 51762087 0.1967 -0.0289 0.03571 0.4184 0.4236
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1 rs12134299 51781211 0.2599 -0.02608 0.03237 0.4204 0.6833
1 rs11205836 51804731 0.1885 -0.02914 0.03624 0.4213 0.279
1 rs2185592 51811930 0.05797 -0.1093 0.0621 0.0784 0.632
1 rs17567 51826921 0.2305 0.04791 0.03363 0.1543 0.2481
1 rs6673480 51859242 0.07096 -0.01194 0.05545 0.8295 0.7408
1 rs1065754 51873951 0.3425 0.007555 0.02976 0.7996 0.474
1 rs1149789 51919013 0.2946 -0.03276 0.03114 0.2928 0.6446
1 rs1275838 51928088 0.06185 -0.003308 0.05899 0.9553 0.8215
1 rs6659310 51950522 0.2307 0.04873 0.03363 0.1473 0.2195
1 rs1275837 51962205 0.05053 -0.04014 0.06525 0.5384 0.7849
1 rs7541084 51989591 0.4273 -0.04208 0.0286 0.1412 0.4027
1 rs12139552 51992336 0.1327 -0.03191 0.04178 0.445 0.1727
1 rs7411629 52005824 0.2097 0.04094 0.03468 0.2378 0.7523
1 rs17394299 52008153 0.3006 0.01488 0.03078 0.6287 0.494
1 rs6588412 52016713 0.4878 -0.03956 0.0283 0.1621 0.553
1 rs12075035 52023412 0.3156 0.01439 0.03032 0.6349 0.276
1 rs17398598 52024908 0.2602 -0.01252 0.03219 0.6974 0.2482
1 rs7534689 52026384 0.4328 0.01111 0.02838 0.6955 0.07584
1 rs12038297 52033122 0.1093 -0.02996 0.04574 0.5124 0.8932
1 rs17394584 52034812 0.1956 -0.02845 0.0359 0.4281 1
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11.2 21 GWAS Index SNPs
Table 11.2: 21 GWAS Index SNPs with Summary Stats from IGAP Stage 1
SNP Chr BP Closest Gene MAF OR 95% CI Meta p-value
rs6656401 1 207692049 CR1 0.197 1.17 1.12-1.22 7.7× 10−15
rs6733839 2 127892810 BIN1 0.409 1.21 1.17-1.25 1.7× 10−26
rs10948363 6 47487762 CD2AP 0.266 1.10 1.07-1.14 3.1× 10−8
rs11771145 7 143110762 EPHA1 0.338 0.90 0.87-0.93 8.8× 10−10
rs9331896 8 27467686 CLU 0.379 0.86 0.84-0.89 9.6× 10−17
rs983392 11 59923508 MS4A6A 0.403 0.90 0.87-0.93 2.8× 10−11
rs10792832 11 85867875 PICALM 0.358 0.88 0.85-0.91 6.5× 10−16
rs4147929 19 1063443 ABCA7 0.190 1.14 1.10-1.20 1.7× 10−9
rs3865444 19 51727962 CD33 0.307 0.91 0.88-0.94 5.1× 10−8
rs9271192 6 32578530 HLA-DRB5/HLA-DRB1 0.276 1.11 1.07-1.16 1.6× 10−8
rs28834970 8 27195121 PTK2B 0.366 1.10 1.07-1.14 3.3× 10−9
rs11218343 11 121435587 SORL1 0.039 0.76 0.70-0.83 5.0× 10−11
rs10498633 14 92926952 SLC24A4/RIN3 0.217 0.90 0.87-0.94 1.5× 10−7
rs8093731 18 29088958 DSG2 0.017 0.54 0.43-0.67 4.6× 10−8
rs35349669 2 234068476 INPP5D 0.488 1.07 1.03-1.10 9.6× 10−5
rs190982 5 88223420 MEF2C 0.408 0.92 0.89-0.95 2.5× 10−6
rs2718058 7 37841534 NME8 0.373 0.93 0.90-0.96 1.3× 10−5
rs1476679 7 100004446 ZCWPW1 0.287 0.92 0.89-0.96 7.4× 10−6
rs10838725 11 47557871 CELF1 0.316 1.08 1.04-1.11 6.7× 10−6
rs17125944 14 53400629 FERMT2 0.092 1.13 1.07-1.19 1.0× 10−5
rs7274581 20 55018260 CASS4 0.083 0.87 0.82-0.92 1.6× 10−6
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11.3 POLARIS Python Script
11.3.1 POLARIS master.py
1 #!/usr/bin/env python
2
3 ##############################################
4 # #
5 # POLARIS: POlygenic Ld - Adjusted RIsk Score #
6 # #
7 ##############################################
8 # #
9 # Copyright (C) 2017 Emily Baker #
10 # and Cardiff University #
11 # #
12 # This program is free software: you can #
13 # redistribute it and/or modify #
14 # it under the terms of the GNU General #
15 # Public License as published by #
16 # the Free Software Foundation , either #
17 # version 3 of the License , or #
18 # (at your option) any later version. #
19 # #
20 # This program is distributed in the hope #
21 # that it will be useful , #
22 # but WITHOUT ANY WARRANTY; without even #
23 # the implied warranty of #
24 # MERCHANTABILITY or FITNESS FOR A #
25 # PARTICULAR PURPOSE. See the #
26 # GNU General Public License for more #
27 # details. #
28 # #
29 # You should have received a copy of the #
30 # GNU General Public License #
31 # along with this program. If not , see #
32 # <http ://www.gnu.org/licenses/>. #
33 # #
34 # BakerEA@Cardiff.ac.uk #
35 # Emily Baker , MRC Centre for #
36 # Neuropsychiatric Genetics and Genomics , #
37 # Hadyn Ellis Building , Maindy Road , #
38 # Cardiff , Wales , UK , CF24 4HQ #
39 # #
40 ##############################################
41
42 ###########################
43 # Import packages #
44 ###########################
45
46 import sys
47 import POLARIS_function as f
48 import pandas as pd
49 import numpy as np
50 from numpy import linalg as LA
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51 import os
52 import os.path
53 import time
54 from mpi4py import MPI
55 from mpi4py.MPI import ANY_SOURCE
56 import math
57
58 ###########################
59 # Find MPI parameters #
60 ###########################
61
62 size = MPI.COMM_WORLD.Get_size ()
63 rank = MPI.COMM_WORLD.Get_rank ()
64
65 timer_start=time.time()
66
67 #################################
68 # Define command line arguments #
69 #################################
70
71 total_arg = len(sys.argv)
72
73 #print (sys.argv)
74
75 #print (total_arg)
76
77 options = ["--INFILE "]
78 options.append("--OUTFILE ")
79 options.append("--SUMM")
80 options.append("--ANNOT")
81 options.append("--RUN -ANNOT")
82 options.append("--THR")
83 options.append("--COVAR")
84
85 #print (options)
86
87 # Check for even number of input parameters
88 if ((total_arg -1) % 2 != 0):
89 print (" Incorrect number of input arguments ")
90 exit()
91
92 # Scan input arguments
93 input_options ={}
94 input_options[’--INFILE ’]=str("input ")
95 input_options[’--OUTFILE ’]=str(" output ")
96 input_options[’--SUMM ’]=str ("")
97 input_options[’--ANNOT ’]=str(" gencode_annot ")
98 input_options[’--THR ’]=str ("1")
99
100 for i in range(1, total_arg ):
101 if sys.argv[i] in options:
102 x=str(sys.argv[i])
103 input_options[x]=str(sys.argv[i+1])
104
105 #print (input_options)
106
211
107 if (input_options[’--INFILE ’] == "input "):
108 print ("No input file specified ")
109 exit()
110
111 if (input_options[’--OUTFILE ’] == "output "):
112 print ("No output file specified ")
113 input_options[’--OUTFILE ’] = input_options[’--INFILE ’]
114
115 if (input_options[’--SUMM ’] == ""):
116 print ("No summary statistic file specified ")
117 exit()
118
119 if (’--ANNOT ’ not in input_options) & (’--RUN -ANNOT ’ \
120 not in input_options ):
121 print ("No annotation options specified ")
122 exit()
123
124 if (float(input_options[’--THR ’]) >1) | \
125 (float(input_options[’--THR ’]) <0):
126 print (" Invalid p-value threshold given ")
127 exit()
128
129
130 input_filename=str(input_options[’--INFILE ’])
131 output_filename=str(input_options[’--OUTFILE ’])
132 summ_filename=str(input_options[’--SUMM ’])
133 annot=str(input_options[’--ANNOT ’])
134 thr=float(input_options[’--THR ’])
135 covar_filename=str(input_options[’--COVAR ’])
136
137 #print (annot)
138 #print (input_filename)
139 #print (output_filename)
140 #print (summ_filename)
141 #print (thr)
142 #print (covar_filename)
143
144 ###########################
145 # Check Data Format #
146 ###########################
147
148
149 filename= str(input_filename) + "_chr1.fam"
150 if os.path.isfile(filename ):
151 by_chr =1
152 else:
153 by_chr =0
154
155 if rank ==0:
156 if by_chr ==1:
157
158 #Combine bim files
159 command ="for chr in {1..22} X Y; do cat " \
160 + str(input_filename )+ "_chr$chr.bim; done > " \
161 + str(input_filename) + ".bim"
162 os.system(command)
212
163
164 #Set overall fam file
165 command ="cat " + str(input_filename) + "_chr1.fam > " \
166 + str(input_filename) + ".fam"
167
168 MPI.COMM_WORLD.Barrier ()
169
170 log_filename= "log_" + str(output_filename)
171
172 ###########################
173 # Run Annotation Function #
174 ###########################
175
176 if ’--RUN -ANNOT ’ in input_options:
177 l_border=float(str(input_options[’--RUN -ANNOT ’]). split ( ’ , ’)[0])*1000
178 u_border=float(str(input_options[’--RUN -ANNOT ’]). split ( ’ , ’)[1])*1000
179
180 if rank ==0:
181 log=open(log_filename , ’a’)
182 log.write(" Running Annotation ")
183 log.write ("\n")
184 log.close()
185 print (" Running Annotation ")
186
187 f.annotation(input_filename , output_filename , annot , \
188 l_border , u_border)
189
190 if rank ==0:
191 log=open(log_filename , ’a’)
192 log.write(" Annotation Complete ")
193 log.write ("\n")
194 log.close()
195 print (" Annotation Complete ")
196
197 MPI.COMM_WORLD.Barrier ()
198
199 ###########################
200 # Create Unique Gene List #
201 ###########################
202
203 if (’--RUN -ANNOT ’ not in input_options) & \
204 (’--ANNOT ’ in input_options ):
205 annot_filename=annot
206 else:
207 annot_filename= str(output_filename) + ". annot"
208
209 annot_data=pd.read_table(annot_filename)
210
211 unique_filename= "unique_genes_" + str(output_filename)
212
213 uni_genes=annot_data.drop_duplicates(subset=[’GENE ’], \
214 keep=’last ’)
215 uni_genes[’GENE ’]. to_csv(unique_filename , header=None ,
216 index=None , sep=’\t’)
217
218 MPI.COMM_WORLD.Barrier ()
213
219
220 ###########################
221 # Perform Allele Matching #
222 ###########################
223
224 if rank ==0:
225 log=open(log_filename , ’a’)
226 log.write(" Perform Allele Matching ")
227 log.write ("\n")
228 log.close()
229 print (" Perform Allele Matching ")
230 f.allele_match(summ_filename , input_filename , \
231 output_filename , thr)
232
233 log=open(log_filename , ’a’)
234 log.write(" Allele Matching Complete ")
235 log.write ("\n")
236 log.close()
237
238 MPI.COMM_WORLD.Barrier ()
239
240 #############################
241 # Split summary file by chr #
242 #############################
243
244 if rank ==0:
245 command= "mkdir summ"
246 os.system(command)
247
248 filename= str(output_filename) + ".summ"
249
250 data=pd.read_table(filename)
251
252 filename=str(output_filename) + ".summ.snps"
253
254 data[’SNP ’]. to_csv(filename , header=None , \
255 index=None , sep=’\t’)
256
257 for chr in range (1 ,23):
258
259 chr_data=data[data.CHR==chr]
260 filename ="./ summ /"+ str(output_filename) + \
261 "_chr" + str(chr) + ".summ"
262 chr_data.to_csv(filename , header=True , \
263 index=None , sep=’\t’, na_rep ="NA")
264
265 MPI.COMM_WORLD.Barrier ()
266
267 ###########################
268 # Recode PLINK data #
269 ###########################
270
271 if rank ==0:
272 command= "mkdir data_" + str(output_filename)
273 os.system(command)
274
214
275 MPI.COMM_WORLD.Barrier ()
276
277 a= int(math.floor (22/ size))
278 b=int(22-(a*size))
279
280 if ((rank +1)<=b):
281 start_chr =(( rank)*a)+ (rank +1)
282 end_chr= start_chr + a
283 elif ((rank +1)==(b+1)):
284 start_chr= ((rank)*a)+( rank +1)
285 end_chr= start_chr + a - 1
286 else:
287 start_chr= (b*a) + (b+1) + ((rank -b)*(a-1)) + \
288 (rank -b)
289 end_chr= start_chr + a - 1
290
291 MPI.COMM_WORLD.Barrier ()
292
293 for chr in range(start_chr ,end_chr +1):
294
295 if by_chr ==0:
296
297 command =" plink2 --bfile " + str(input_filename) + \
298 " --extract " + str(output_filename) + \
299 ".summ.snps --recodeA --chr " + str(chr) + \
300 " --out ./data_ "+ str(output_filename )+"/" + \
301 str(input_filename) + "_chr" +str(chr)
302 os.system(command)
303
304 elif by_chr ==1:
305
306 command5 =" plink2 --bfile " + str(input_filename) + \
307 "_chr" + str(chr) + " --extract " + str(output_filename) \
308 + ".summ.snps --recodeA --out ./data_ "+ str(output_filename )+ \
309 "/" + str(input_filename) + "_chr" + str(chr)
310 os.system(command5)
311
312 command2 ="sed ’1d’ ./data_ "+ str(output_filename )+"/" + \
313 str(input_filename )+ "_chr" +str(chr)+ ".raw > ./ data_"+ \
314 str(output_filename )+"/" + str(input_filename )+ "_chr" + \
315 str(chr) + "_nohead.raw"
316 os.system(command2)
317
318 command3= "head -n 1 ./data_ "+ str(output_filename )+"/" + \
319 str(input_filename )+ "_chr" +str(chr)+ ".raw > ./ data_" + \
320 str(output_filename )+"/" + str(input_filename )+ "_head_chr" +str(chr)
321 os.system(command3)
322
323 command4= "rm ./data_ "+ str(output_filename )+"/"+ \
324 str(input_filename )+ "_chr" +str(chr)+ ".raw"
325 os.system(command4)
326
327 MPI.COMM_WORLD.Barrier ()
328
329
330 for chr in range(start_chr , end_chr +1):
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331 filename1 =" data_ "+ str(output_filename )+"/" + \
332 str(input_filename )+ "_head_chr" + str(chr)
333
334 infile= open(filename1 , ’r’)
335 firstline=infile.readline ()
336 head=firstline.split()
337 infile.close()
338
339 id=head [0:6]
340 head=head [6: len(head)]
341 head=[x[:-2] for x in head]
342 header= np.array(id + head)
343 header=header.tolist ()
344
345 outfile=open(filename1 , ’w’)
346 outfile.write(" ".join(header ))
347 outfile.close()
348
349 MPI.COMM_WORLD.Barrier ()
350
351 ###########################
352 # Run POLARIS #
353 ###########################
354
355 if rank ==0:
356 command= "mkdir results"
357 os.system(command)
358 log=open(log_filename , ’a’)
359 log.write(" Running POLARIS ")
360 log.write ("\n")
361 log.close()
362 print (" Running POLARIS ")
363
364 f.polaris(input_filename , output_filename , annot_filename)
365
366 MPI.COMM_WORLD.Barrier ()
367
368 if rank ==0:
369 log=open(log_filename , ’a’)
370 log.write(" POLARIS Complete ")
371 log.write ("\n")
372 log.close()
373
374 ###########################
375 # Run Logistic Regression #
376 ###########################
377
378 if rank ==0:
379 log=open(log_filename , ’a’)
380 log.write(" Running Logistic Regression ")
381 log.write ("\n")
382 log.close()
383 print (" Running Logistic Regression on POLARIS ")
384 f.logit(input_filename , output_filename , covar_filename)
385
386 MPI.COMM_WORLD.Barrier ()
216
387
388 if rank ==0:
389 log=open(log_filename , ’a’)
390 log.write(" Logit Complete ")
391 log.write ("\n")
392 log.close()
393
394 ###########################
395 # Delete old files #
396 ###########################
397
398 if rank ==0:
399 command= "rm ./summ /*"
400 os.system(command)
401
402 command2= "rm ./data_" + str(output_filename )+ "/*"
403 os.system(command2)
404
405 command3= "rmdir summ"
406 os.system(command3)
407
408 command4= "rmdir ./data_" + str(output_filename)
409 os.system(command4)
410
411 command5= "rm ./ results /" + str(output_filename) + "_chr*"
412 os.system(command5)
413
414
415 MPI.COMM_WORLD.Barrier ()
416
417 timer_end= time.time()- timer_start
418
419 if rank ==0:
420 print (timer_end)
11.3.2 POLARIS function.py
1 #!/usr/bin/env python
2
3 ##############################################
4 # #
5 # POLARIS: POlygenic Ld - Adjusted RIsk Score #
6 # #
7 ##############################################
8 # #
9 # Copyright (C) 2017 Emily Baker #
10 # and Cardiff University #
11 # #
12 # This program is free software: you can #
13 # redistribute it and/or modify #
14 # it under the terms of the GNU General #
15 # Public License as published by #
16 # the Free Software Foundation , either #
17 # version 3 of the License , or #
18 # (at your option) any later version. #
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19 # #
20 # This program is distributed in the hope #
21 # that it will be useful , #
22 # but WITHOUT ANY WARRANTY; without even #
23 # the implied warranty of #
24 # MERCHANTABILITY or FITNESS FOR A #
25 # PARTICULAR PURPOSE. See the #
26 # GNU General Public License for more #
27 # details. #
28 # #
29 # You should have received a copy of the #
30 # GNU General Public License #
31 # along with this program. If not , see #
32 # <http ://www.gnu.org/licenses/>. #
33 # #
34 # BakerEA@Cardiff.ac.uk #
35 # Emily Baker , MRC Centre for #
36 # Neuropsychiatric Genetics and Genomics , #
37 # Hadyn Ellis Building , Maindy Road , #
38 # Cardiff , Wales , UK , CF24 4HQ #
39 # #
40 ##############################################
41
42 ###########################
43 # Import packages #
44 ###########################
45
46 import pandas as pd
47 import numpy as np
48 from numpy import linalg as LA
49 from scipy import stats
50 import statsmodels.api as sm
51 import math
52 from mpi4py import MPI
53 from mpi4py.MPI import ANY_SOURCE
54
55 import time
56
57 np.set_printoptions(suppress=True)
58
59 #######################
60 # Annotation function #
61 #######################
62
63 def annotation(input_filename , output_filename , \
64 annot , l_border , u_border ):
65
66 annot=pd.read_table(annot)
67
68 filename= str(input_filename) + ".bim"
69
70 snps=pd.read_table(filename , header=None)
71
72 size = MPI.COMM_WORLD.Get_size ()
73 rank = MPI.COMM_WORLD.Get_rank ()
74
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75 a= int(math.floor(len(annot.index )/size))
76 b=int(len(annot.index)-(a*size))
77
78 if ((rank +1)<=b):
79 start_gene =(( rank)*a)+ (rank +1)
80 end_gene= start_gene + a
81 elif ((rank +1)==(b+1)):
82 start_gene= ((rank)*a)+( rank +1)
83 end_gene= start_gene + a - 1
84 else:
85 start_gene= (b*a) + (b+1) + ((rank -b)*(a-1)) + (rank -b)
86 end_gene= start_gene + a - 1
87
88 MPI.COMM_WORLD.Barrier ()
89
90 results=pd.DataFrame ()
91 #results_list =[]
92
93 for gene in range(start_gene -1, end_gene ):
94
95 gene_name=annot.iloc[gene][’GENE ’]
96 gene_chr=annot.iloc[gene][’CHR ’]
97 gene_start=annot.iloc[gene][’BP_START ’]
98 gene_end=annot.iloc[gene][’BP_END ’]
99
100 gene_info= str(gene_name )+"_"+str(gene_chr )+ \
101 "_"+str(gene_start )+"_"+str(gene_end)
102
103 gene_snps=snps.loc[(snps [0]== gene_chr) & \
104 (snps [3]>=( gene_start -float(l_border ))) & \
105 (snps [3]<=( gene_end+float(u_border )))]
106
107 #print(gene_snps)
108
109 if len(gene_snps.index )!=0:
110 gene_snps.loc[: ,6]= str(gene_info)
111
112 del gene_snps [2]
113
114 if len(gene_snps.index )!=0:
115 results=pd.concat ([results ,gene_snps], axis =0)
116
117 #print(results)
118
119 results_list=results.values.tolist ()
120
121 del results
122
123 MPI.COMM_WORLD.Barrier ()
124
125 if rank ==0:
126
127 for proc in range(1,size):
128
129 local_a=MPI.COMM_WORLD.recv(source=proc)
130
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131 results_list.extend(local_a)
132
133 del local_a
134 else:
135
136 MPI.COMM_WORLD.send(results_list , dest =0)
137
138 MPI.COMM_WORLD.Barrier ()
139
140 if rank ==0:
141 results=pd.DataFrame(results_list)
142
143 results.columns= [’CHR ’, ’SNP ’, ’BP ’, ’A1 ’, ’A2 ’, ’GENE ’]
144
145 filename= str(output_filename )+ ".annot"
146
147 results.to_csv(filename , header=True , index=None , sep=’\t’)
148
149 ############################
150 # Allele Matching Function #
151 ############################
152
153 def allele_match(summ_filename , input_filename , \
154 output_filename , thr):
155
156 # Read in Unique Gene file #
157 summ=pd.read_table(summ_filename)
158 #print (summ)
159 #print (len(summ.index ))
160
161 summ=summ.drop_duplicates(subset=[’SNP ’], keep=’last ’)
162
163 #summ[’A1 ’] = map(lambda x: x.upper(), summ[’A1 ’])
164 #summ[’A2 ’] = map(lambda x: x.upper(), summ[’A2 ’])
165
166 summ=summ[summ.P<=thr]
167
168 filename= input_filename + ".bim"
169
170 repl=pd.read_table(filename , header=None)
171
172 #print (repl)
173
174 data=repl.merge(summ , left_on =[1], right_on=[’SNP ’])
175
176 #print (data)
177 #print (len(data.index ))
178
179 for i in range(len(data.index )):
180 if ((data.iloc[i][4]== data.iloc[i][’A2 ’]) & \
181 (data.iloc[i][5]== data.iloc[i][’A1 ’])):
182 data.set_value(i, ’BETA ’, -(data.iloc[i][’BETA ’]))
183 data.set_value(i, ’A1 ’, str((data.iloc[i][4])))
184 data.set_value(i, ’A2 ’, str((data.iloc[i][5])))
185
186 for i in range(len(data.index )):
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187 if ((data.iloc[i][4]!= data.iloc[i][’A1 ’]) | \
188 (data.iloc[i][5]!= data.iloc[i][’A2 ’])):
189 if data.iloc[i][’A1 ’]=="A":
190 data.set_value(i, ’A1 ’, "T")
191 elif data.iloc[i][’A1 ’]=="C":
192 data.set_value(i, ’A1 ’, "G")
193 elif data.iloc[i][’A1 ’]=="G":
194 data.set_value(i, ’A1 ’, "C")
195 elif data.iloc[i][’A1 ’]=="T":
196 data.set_value(i, ’A1 ’, "A")
197 if data.iloc[i][’A2 ’]=="A":
198 data.set_value(i, ’A2 ’, "T")
199 elif data.iloc[i][’A2 ’]=="C":
200 data.set_value(i, ’A2 ’, "G")
201 elif data.iloc[i][’A2 ’]=="G":
202 data.set_value(i, ’A2 ’, "C")
203 elif data.iloc[i][’A2 ’]=="T":
204 data.set_value(i, ’A2 ’, "A")
205
206 for i in range(len(data.index )):
207 if ((data.iloc[i][4]== data.iloc[i][’A2 ’]) & \
208 (data.iloc[i][5]== data.iloc[i][’A1 ’])):
209 data.set_value(i, ’BETA ’, -(data.iloc[i][’BETA ’]))
210 data.set_value(i, ’A1 ’, str((data.iloc[i][4])))
211 data.set_value(i, ’A2 ’, str((data.iloc[i][5])))
212
213 data=data.loc[(data [4]== data[’A1 ’]) & (data [5]== data[’A2 ’])]
214
215 data=data[data.columns [6: len(data.columns )]]
216
217 filename= str(output_filename) + ".summ"
218
219 #print (len(data.index ))
220
221 data.to_csv(filename , header=True , index=None , \
222 sep=’\t’, na_rep ="NA")
223
224
225 ####################
226 # POLARIS Function #
227 ####################
228
229 def polaris(input_filename , output_filename , annot_filename ):
230
231 # Read in Unique Gene file #
232 unigene_names =[" GENE"]
233 unique_filename =" unique_genes_" + str(output_filename)
234 unigene=pd.read_table(unique_filename , names=unigene_names)
235
236 unigene[’CHR ’]= unigene[’GENE ’]. str.split(’_’,1).str [1]
237 unigene[’CHR ’]= unigene[’CHR ’]. str.split(’_’,1).str [0]
238
239 # Read in Annot Data #
240 annot=pd.read_table(annot_filename , sep=’\t’)
241
242 filename= str(input_filename) + ".fam"
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243
244 fam=pd.read_table(filename , \
245 names=[’FID ’, ’IID ’, ’PID ’, ’MID ’, ’SEX ’, ’PHENOTYPE ’], sep=’ ’)
246 fam=fam[[’FID ’, ’IID ’, ’PHENOTYPE ’]]
247
248 Nind=len(fam.index)
249
250 #Split genes by processor
251 size = MPI.COMM_WORLD.Get_size ()
252 rank = MPI.COMM_WORLD.Get_rank ()
253
254 for chr in range (22):
255
256 chr=chr+1
257
258 if rank ==0:
259
260 filename1 ="data_" + str(output_filename) + "/" + \
261 str(input_filename )+ "_head_chr" + str(chr)
262 filename2 ="data_" + str(output_filename) + "/" + \
263 str(input_filename )+ "_chr" + str(chr) + "_nohead.raw"
264 filename3 ="summ/" + str(output_filename )+ "_chr" + \
265 str(chr) + ".summ"
266
267 #Read in header to determine SNP positions
268 infile= open(filename1 , ’r’)
269 firstline=infile.readline ()
270 head=firstline.split()
271 infile.close ()
272 header=np.array(head)
273
274 infile= open(filename3 , ’r’)
275 firstline=infile.readline ()
276 summ_head=firstline.split ()
277
278 #Find beta and maf locations in summ data
279 for i in range(len(summ_head )):
280 if str(summ_head[i])==" BETA":
281 beta_loc=i
282 if str(summ_head[i])==" MAF":
283 maf_loc=i
284
285 fs=open(filename3 , ’r’)
286 beta =[]
287 maf=[]
288 row=0
289 for line in fs:
290 if row >0:
291 beta.append(line.split ()[ beta_loc ])
292 maf.append(line.split ()[ maf_loc ])
293 row=row+1
294 fs.close()
295
296 beta=np.asmatrix(beta , dtype=float)
297 maf=np.array(maf , dtype=float)
298
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299 f=open(filename2 , ’r’)
300 data =[]
301 for line in f:
302 datalist =[]
303 testlist=line.split ()
304 for j in range(len(testlist )):
305 datalist.append(testlist[j])
306 loc=[i for i, x in enumerate(datalist) if x == "NA"]
307 for i in range(len(loc)):
308 datalist[loc[i]]=2* float(maf[loc[i]-6])
309 data.append(datalist)
310 f.close ()
311
312 data=pd.DataFrame(data)
313
314 filename4 ="data_" + str(output_filename) + "/" + \
315 str(input_filename )+ "_chr" + str(chr) + \
316 "_nomiss_nohead.raw"
317 data.to_csv(filename4 , header=None , index=None , sep=’ ’)
318
319 unigene_chr=unigene[unigene.CHR==str(chr)]
320
321
322 a= int(math.floor(len(unigene_chr )/size))
323 b=int(len(unigene_chr )-(a*size))
324
325 if ((rank +1)<=b):
326 start_gene =(( rank)*a)+ (rank +1)
327 end_gene= start_gene + a
328 elif ((rank +1)==(b+1)):
329 start_gene= ((rank)*a)+( rank +1)
330 end_gene= start_gene + a - 1
331 else:
332 start_gene= (b*a) + (b+1) + ((rank -b)*(a-1)) + (rank -b)
333 end_gene= start_gene + a - 1
334
335 MPI.COMM_WORLD.Barrier ()
336
337 if rank ==0:
338 results=np.empty ([Nind ,len(unigene_chr )], \
339 dtype=np.float64)
340
341 else:
342 results=np.empty ([Nind ,end_gene -start_gene +1], \
343 dtype=np.float64)
344
345 genename =[]
346
347 for gene in range(start_gene -1, end_gene ):
348
349 # Find SNPs in gene #
350 gene_snp=annot[annot.GENE== unigene_chr.iloc[gene][’GENE ’]]
351
352 gene_snp=gene_snp.sort_values ([’BP ’])
353
354 #Output gene chromosome
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355 gene_chr=gene_snp.iloc [0][’CHR ’]
356
357 filename1 ="data_" + str(output_filename) + "/" + \
358 str(input_filename )+ "_head_chr" + str(gene_chr)
359 filename2 ="data_" + str(output_filename) + "/" + \
360 str(input_filename )+ "_chr" + str(gene_chr) + \
361 "_nomiss_nohead.raw"
362 filename3 ="summ/" + str(output_filename )+ "_chr" + \
363 str(gene_chr) + ".summ"
364
365 #Read in header to determine SNP positions
366 infile= open(filename1 , ’r’)
367 firstline=infile.readline ()
368 head=firstline.split()
369 infile.close ()
370 header=np.array(head)
371
372 snp_loc =[]
373 #Find SNP locations in .raw data
374 for i in range(len(gene_snp.index )):
375 for j in range(6,len(header )):
376 if str(gene_snp.iloc[i][’SNP ’])== str(header[j]):
377 snp_loc.append(j)
378
379 snp_loc= np.unique(snp_loc)
380
381 gene_name=str(unigene_chr.iloc[gene][’GENE ’]) + \
382 "_" + str(len(snp_loc ))
383
384 if len(snp_loc) != 0:
385
386 infile= open(filename3 , ’r’)
387 firstline=infile.readline ()
388 summ_head=firstline.split ()
389
390 #Find beta and maf locations in summ data
391 for i in range(len(summ_head )):
392 if str(summ_head[i])==" BETA":
393 beta_loc=i
394 if str(summ_head[i])==" MAF":
395 maf_loc=i
396
397 fs=open(filename3 , ’r’)
398 beta =[]
399 maf=[]
400 row=-1
401 for line in fs:
402 if (row +6) in snp_loc:
403 beta.append(line.split ()[ beta_loc ])
404 maf.append(line.split ()[ maf_loc ])
405 row=row+1
406 fs.close()
407
408 beta=np.asmatrix(beta , dtype=float)
409 maf=np.array(maf , dtype=float)
410
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411 f=open(filename2 , ’r’)
412 data =[]
413 for line in f:
414 datalist =[]
415 testlist=line.split ()
416 for j in range(len(snp_loc )):
417 datalist.append(testlist[snp_loc[j]])
418 data.append(datalist)
419 f.close()
420
421 data=np.array(data)
422 data=np.asmatrix(data , dtype=float)
423
424
425 if len(snp_loc )==1:
426
427 score= data * beta
428
429 else:
430
431 corr_mat=np.corrcoef(data , rowvar =0)
432
433 eval , evect=LA.eig(corr_mat)
434
435 idx = eval.argsort ()[:: -1]
436 eval = eval[idx]
437 evect = evect[:,idx]
438
439 pc_snp=beta * evect
440
441 pc_wgt=evect
442 for i in range(len(eval )):
443 pc_wgt[:,i] *= \
444 math.sqrt ((1+(1/ math.sqrt(Nind )))/( eval[i]+ \
445 (1/ math.sqrt(Nind ))))
446
447 Bi= pc_wgt * pc_snp.transpose ()
448
449 score= data * Bi
450
451 gene_score=pd.DataFrame(score , columns=[’GeneName ’])
452
453 if rank ==0:
454 results[:,gene:gene +1]=np.array(score)
455 else:
456 results[:,gene -start_gene +1:gene -start_gene +2]= \
457 np.array(score)
458
459 genename.append(gene_name)
460
461 MPI.COMM_WORLD.Barrier ()
462
463 if rank ==0:
464
465 a= int(math.floor(len(unigene_chr )/size))
466 b=int(len(unigene_chr )-(a*size))
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467
468 for proc in range(1,size):
469 if ((proc +1)<=b):
470 start_gene =(( proc)*a)+ (proc +1)
471 end_gene= start_gene + a
472 elif ((proc +1)==(b+1)):
473 start_gene= ((proc)*a)+( proc +1)
474 end_gene= start_gene + a - 1
475 else:
476 start_gene= (b*a) + (b+1) + ((proc -b)*(a-1)) + \
477 (proc -b)
478 end_gene= start_gene + a - 1
479
480 ncol=(end_gene -start_gene +1)
481
482 local_a = np.zeros ([Nind ,ncol], dtype=np.float64)
483
484 MPI.COMM_WORLD.Recv(local_a , source=proc)
485
486 results[:,start_gene -1: end_gene ]= local_a
487
488 del local_a
489
490 else:
491
492 MPI.COMM_WORLD.Send(results [:,:], dest =0)
493
494 MPI.COMM_WORLD.Barrier ()
495
496 if rank ==0:
497
498 for proc in range(1,size):
499
500 local_b=MPI.COMM_WORLD.recv(source=proc)
501
502 genename.extend(local_b)
503
504 #print (genename)
505
506 del local_b
507
508 else:
509 MPI.COMM_WORLD.send(genename , dest =0)
510
511 MPI.COMM_WORLD.Barrier ()
512
513 if rank ==0:
514
515 results=pd.DataFrame(results)
516
517 #print(results)
518
519 results.columns=genename
520
521 final_results=pd.concat ([fam , results], axis =1)
522
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523 #print(final_results)
524
525 filename= "results /" + str(output_filename) + \
526 "_chr" + str(chr) + ". polaris"
527
528 final_results.to_csv(filename , header=True , \
529 index=None , sep=’\t’)
530
531 MPI.COMM_WORLD.Barrier ()
532
533 if rank ==0:
534
535 filename= "results /" + str(output_filename) + "_chr1.polaris"
536 data=pd.read_table(filename)
537
538 for chr in range (1 ,22):
539 chr=chr+1
540 filename= "results /" + str(output_filename) + \
541 "_chr" + str(chr) + ". polaris"
542 test=pd.read_table(filename)
543
544 num_genes=len(test.columns)-3
545
546 if num_genes >0:
547
548 data=pd.concat ([data , test[:, 3:len(test.columns )]])
549
550 filename= "results /" + str(output_filename) + ". polaris"
551
552 data.to_csv(filename , header=True , index=None , sep=’\t’)
553
554 MPI.COMM_WORLD.Barrier ()
555
556 ##################
557 # Logit Function #
558 ##################
559
560 def logit(input_filename , output_filename , covar_filename ):
561
562 size = MPI.COMM_WORLD.Get_size ()
563 rank = MPI.COMM_WORLD.Get_rank ()
564
565 log_filename= "log_" + str(output_filename)
566
567 # Read in Unique Gene file #
568 unigene_names =[" GENE"]
569 unique_filename =" unique_genes_" + str(output_filename)
570 unigene=pd.read_table(unique_filename , names=unigene_names)
571
572 filename= "results /" + str(output_filename) + ". polaris"
573
574 a= int(math.floor(len(unigene )/size))
575 b=int(len(unigene)-(a*size))
576
577 if ((rank +1)<=b):
578 start_gene =(( rank)*a)+ (rank +1)
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579 end_gene= start_gene + a
580 elif ((rank +1)==(b+1)):
581 start_gene= ((rank)*a)+( rank +1)
582 end_gene= start_gene + a - 1
583 else:
584 start_gene= (b*a) + (b+1) + ((rank -b)*(a-1)) + (rank -b)
585 end_gene= start_gene + a - 1
586
587 # Read in POLARIS results file #
588 f=open(filename , ’r’)
589 iddata =[]
590 for line in f:
591 datalist =[]
592 testlist=line.split ()
593 for j in range (3):
594 datalist.append(testlist[j])
595 iddata.append(datalist)
596 f.close ()
597
598 iddata=np.asmatrix(iddata)
599 iddata=pd.DataFrame(iddata)
600
601 new_header=iddata.iloc [0]
602 iddata=iddata [1:]
603 iddata=iddata.rename(columns = new_header)
604
605 iddata[’PHENOTYPE ’] = iddata[’PHENOTYPE ’]. astype(float)
606 iddata[’IID ’] = iddata[’IID ’]. astype(int)
607
608 f=open(filename , ’r’)
609 prs =[]
610 for line in f:
611 datalist =[]
612 testlist=line.split ()
613 for j in range(start_gene ,end_gene +1):
614 datalist.append(testlist[j+2])
615 prs.append(datalist)
616 f.close ()
617
618 prs=np.asmatrix(prs)
619 prs=pd.DataFrame(prs)
620
621 new_header=prs.iloc [0]
622 prs=prs [1:]
623 prs=prs.rename(columns = new_header)
624
625 prs=prs.astype(float)
626
627 prs_norm =(prs -prs.mean ())/( prs.std())
628 prs_norm=prs_norm.dropna(axis=1, how=’all ’)
629 no_genes=len(prs_norm.columns)
630
631 prs_norm=pd.concat ([iddata ,prs_norm], axis =1)
632
633 covar=pd.read_table(covar_filename)
634
228
635 no_covar=len(covar.columns)-2
636
637 data=prs_norm.merge(covar , how=’left ’, on=[’FID ’, ’IID ’])
638
639 data[’Intercept ’]=1.0
640
641 MPI.COMM_WORLD.Barrier ()
642
643 results=pd.DataFrame(index=range(no_genes), columns=range (8))
644
645 for gene in range(no_genes ):
646
647 text=data.columns[gene +3]
648
649 #Extract gene info from column header
650 results.set_value ((gene),0,text.split(’_ ’)[0])
651 results.set_value ((gene),1,text.split(’_ ’)[1])
652 results.set_value ((gene),2,text.split(’_ ’)[2])
653 results.set_value ((gene),3,text.split(’_ ’)[3])
654 results.set_value ((gene),4,text.split(’_ ’)[4])
655
656
657 #Logit regression model
658 pos =[]
659 pos.append(gene +3)
660
661 for i in range(no_genes+3, len(data.columns )):
662 pos.append(i)
663
664 train_cols=data.columns [[pos]]
665
666 logit=sm.Logit ((data[’PHENOTYPE ’]-1), \
667 data[train_cols], missing=’drop ’)
668
669
670 log_reg=logit.fit()
671
672 results.set_value ((gene),5, log_reg.params [0])
673 results.set_value ((gene),6, log_reg.bse [0])
674 results.set_value ((gene),7, log_reg.pvalues [0])
675
676 results_list=results.values.tolist ()
677
678 del results
679
680 MPI.COMM_WORLD.Barrier ()
681
682 if rank ==0:
683
684 for proc in range(1,size):
685
686 local_a=MPI.COMM_WORLD.recv(source=proc)
687
688 results_list.extend(local_a)
689
690 del local_a
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691 else:
692
693 MPI.COMM_WORLD.send(results_list , dest =0)
694
695 MPI.COMM_WORLD.Barrier ()
696
697
698 if rank ==0:
699
700 results=pd.DataFrame(results_list)
701
702 filename= "results /" + str(output_filename) + \
703 ". polaris.logit"
704
705 results.columns= \
706 [’GENE ’, ’CHR ’, ’BP_START ’, ’BP_END ’, ’NoSNPs ’, ’BETA ’, ’SE’, ’P’]
707
708 results=results.sort_values(’P’)
709
710 results.to_csv(filename , header=True , index=None , sep=’\t’)
711
712
713 ############################
714 # If on the main processor #
715 ############################
716
717 if __name__==’__main__ ’:
718
719 annotation ()
720
721 allele_match ()
722
723 polaris ()
724
725 logit ()
230
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